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Abstract 
 
 
A typical workflow for current liquid chromatography coupled to mass spectrometry (LC-MS) 
based proteomics employs the mass, charge and peptide fragmentation pattern for peptide/protein 
identification. In this thesis I employ this technique for profiling of cellular proteomes applied here 
to the analysis of glioblastoma stem cells and neuronal stem cells to gain insight into the cancer 
signature in the former cell type. At the same time, I explore improvements for proteomic 
workflows by better exploiting experimental parameters produced in proteomic experiments. 
Specifically, peptide isotope patterns are not routinely used in the current proteomics workflows, 
yet they are available in any mass spectrum that is generated. Therefore, we explorered the use of 
isotope patterns in MS1 mass spectra to support peptide identification. We demonstrated that the 
relative isotope abundance (RIA) error is 4-5%, and that this is only modestly influenced by spectral 
intensity, resolution and the number of MS1 scans. The current RIA accuracy has limited 
discriminatory power at a proteome-wide scale. At the same time, the analysis was hampered by the 
difficulty in calculating FDRs, particularly in constructing proper decoy databases that are similar in 
size as the target database, yet different in molecular composition for all peptides considered. 
Alternative strategies to calculate FDRs will be required to address this issue for complex 
proteomes. Regardless, the utility of RIA may become relevant with future instrument 
developments, considering that even a relatively modest decrease in RIA error down to <1% 
strongly improves discriminatory power. Alternatively, at increased mass accuracy even current RIA 
accuracy levels may be sufficient to fit isotope patterns as a constraint in the peptide identification 
process as a parameter that comes for free in any MS-based proteomic experiment. 
 Glioblastma is the most severe form of brain tumour and there has been strong evidence that 
brain cancers arise from a small population of cells known as cancer stem cells (CSCs) within the 
tumour that exhibit normal stem cell characteristics, i.e., long-term self-renewal, longevity and 
capacity to differentiate into adult cells. To reveal the difference in global protein expression 
between malignant neural stem cells derived from adult gliomas (GNSs) and untransformed, 
karyotypically normal foetal neural stem cells [1], we performed mass spectrometric analyses of 
both total cell proteome and secreted proteome of these cells. This resulted in a total of ~7500 and 
~2000 quantified proteins and 446 differentially expressed proteins (152 up-regulation, 294 down-
regulation in GNSs) and 167 differentially expressed proteins (144 up-regulation, 23 down-
regulation), respectively. After data analyses, several candidate proteins for surface markers that 
could distinguish between NSs and GNSs were experimentally validated using 
immunocytochemistry. Next, candidate GNS-secreted factors that could mediate tumourigenic 
transformation of NSs were evaluated using time-lapse imaging and colony-forming assays. Both of 
these experiments produced some positive results, demonstrating the power of proteomics. More 
experiments are, however, necessary to solidify these findings. 
 
Zusammenfassung 
 
 
Der derzeit klassische Ablauf einer Peptid/Protein Identifikation mittels 
Flüssigkeitschromatography mit gekoppeltem Massenspektrometer (LC-MS) beruht auf Masse, 
Ladung und Fragmentierung der Peptide. In dieser Doktorarbeit wende ich diese Technik zur 
Charakterisierung von zellulären Proteomen an, um Gliomstammzellen und neuronale Stammzellen 
zu analysieren um so Einblicke in die Krebssignatur der frühen Zellarten zu erhalten. Parallel 
untersuche ich in proteomischen Arbeitsabläufen Verbesserungen durch bessere Ausnutzung von 
experimentellen Parametern, die in proteomischen Experimenten auftreten. Besonders die 
Isotopenverteilungen von Peptiden wird generell nicht in proteomischen Methoden verwendet, 
obwohl sie in jedem akquirierten Spektrum enthalen sind. Daher untersuchten wir die Verwendung 
von Isotopenmustern in MS1 Massenspektren, um die Peptididentifikation zu unterstützen. Wir 
belegten, dass der relative Isotopenhäufigkeits (RIA)-Fehler 4-5% beträgt und dieser nur gering von 
Spektrumintensität, Auflösung und Anzahl an MS1 Spektren abhängt. In kompletten 
Proteomanalysen hat die derzeitige RIA-Genauigkeit eine limitierende Trennschärfe. Mit 
einherging, dass die Analyse durch die Schwierigkeit der FDR Berechnung beeinträchtigt wurde, 
insbesonders bei der Erstellung richtiger Zufallsdatenbanken, die ähnlich in der Größe aber 
unterschiedlich in der molekularen Zusammensetzung aller enthaltener Peptide der Zieldatenbank 
sind. Alternative Strategien zur Berechnung der FDR werden vonnöten sein um dieses Problem in 
komplexen Proteomanalysen Herr zu werden. Trotzdem wird die Nützlichkeit von RIA  mit 
künftigen instrumentellen Entwicklungen vielleicht relevant werden, wenn berücksichtigt wird dass 
eine nur geringe Senkung des RIA-Fehlers unter 1% eine starke Verbesserung der Trennschärfe 
bewirkt. Alternativ wäre mit Zunahme der Massengenauigkeit vielleicht sogar der derzeitige RIA 
Genauigkeitslevel ausreichend, um Isotopenmustern als Nebenbedingung in Peptididentifikationen 
einzubinden, da sie als Parameter „umsonst“ in jedem MS-basierden proteomischen Experiment 
vorhanden sind.  
 Das Glioblastom ist der häufigste bösartigste Gehirntumor und es gibt starke Hinweise, dass 
Gehirntumore aus einer geringen Population von Zellen, bekannt als Krebsstammzellen (CSCs) 
erstehen. Der Tumor weist normale Stammzell-Charakteristika auf, wie langfristige 
Selbsterneuerung, Langlebigkeit und die Fähigkeit sich in adulte Zellen zu differenzieren. Um die 
Unterschiede der globalen Proteinexpression zwischen bösartigen neuralen Stammzellen, die aus 
adulten Gliomen (GNSs) entstehen und unveränderten, karyotypischen normalen fötalen neuronalen 
Stammzellen [1] zu lüften, erbrachten wir massenspektrometrische Analysen von beidem, dem 
totalen Zellproteom und dem sekretierten Proteom dieser Zellen. Dies resultierte in ~7500 und 
~2000 quantifizierten Proteinen und 446 unterschiedlich exprimierten Proteinen (152 hoch- und 294 
herunterreguliert in GNSs) beziehungsweise 167 unterschiedlich exprimierten Proteinen (144 hoch- 
und 23 herunterreguliert). Nach der Datenanalyse konnten mehrere Proteinkandidaten als 
Oberflächenmarker zwischen NSs und GNSs unterschieden und mittels Immunozytochemie 
validiert werden. Weiterhin wurden Kandidaten der GNS-sekretierten Faktoren, die eine 
tumorgenetische Veränderung der NSs vermitteln können, mittels Zeitraffer Aufnahmen und 
koloniebildende Assays evaluiert. Beide Experimente lieferten positive Ergebnisse, die die 
Bedeutung der Protoemics demonstiert. Allerdings sind weitere Experimente nötig, um diese 
Resultate zu festigen. 
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OPC oligodendrocyte progenitor cell
pSILAC pulsed SILAC
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Chapter 1   
 
1  Introduction 
 
 
Cellular homoeostasis is regulated by genes, which encode RNAs, or transcripts, which are then 
translated into proteins. RNAs/proteins intricately associate with each other and rarely function in 
isolation. Protein-protein interactions can mediate cellular signalling and formation of protein 
complexes with diverse functionality. Protein-DNA/RNA interactions regulate 
transcriptional/transnational regulations of protein expression. For this reason, simultaneous 
identification/quantification of RNAs/proteins is crucial for the understanding of how these 
molecules collectively execute biological functions. Quantification is important since protein 
functions are governed by their concentrations in the cell and some proteins, such as transcription 
factors, can affect a phenotype even at very low concentrations and by subtle changes in 
concentration.   
 Microarray/RNA-seq and mass spectrometry (MS) are widely used for transcriptomics and 
proteomics, respectively, which can allow for identification and quantification of thousands of 
transcripts/proteins in a single sample. While transcriptomics is able to quantify a complete set of 
RNAs, MS-based proteomics is unable to identify a complete set of proteins of higher eukaryotes, 
such as human, in a reasonable time frame, due to high complexity and dynamic range of protein 
abundance within a cell. To make things worse, proteins are often “decorated” with post-
translational modifications (PTMs), such as phosphorylation and ubiquitination, and confidently 
identifying these PTMs requires additional steps for sample preparation, fractionation and data 
analysis. A typical workflow for current MS-based proteomics consists of peptide separation by 
high-performance liquid chromatography (HPLC), peptide ionization, acquisition of a full mass 
spectrum (MS1), followed by fragmentation of selected precursor ions and acquisition of MS/MS 
spectra (MS2). These MS/MS spectra are then compared to masses generated in silico from 
candidate peptides derived from a target protein sequence database. Currently, however, about 50 % 
of all acquired MS2 spectra are not confidently identified due to poor spectral quality. Furthermore, 
even if peptides are detected by mass spectrometer, the majority of those peptides are not targeted 
for tandem MS and therefore remain unidentified [2]. A typical workflow for current LC-MS based 
proteomics employs the mass, charge and peptide fragmentation pattern for peptide/protein 
identification. However, LC-MS-based proteomics generates other parameters such as LC retention 
time and peptide isotope patterns, which are not routinely used in the current proteomics workflow.   
 Chapter 2 explores the use of isotope patterns in mass spectra for peptide identification. 
Because the isotope pattern are determined by the atomic composition of a peptide, it could be used 
as a signature of its sequence. To this end, first, the instrument accuracy of relative isotope 
abundance (RIA) measurement obtained from various proteomic datasets was examined. Then we 
set up a strategy to expore how the isotope patterns could aid in peptide identification either using 
RIA alone or by combining RIA and MS2-based database searches using E. coli, S. cerevisiae and 
human samples as model systems of various complexities. Furthermore, a theoretical framework 
describing the combined contributions of mass accuracy and RIA for confident peptide 
identification was investigated. The utility of RIA may become relevant with future instrument 
developments. Alternatively, at increased mass accuracy even current RIA accuracy levels may be 
sufficient for improving peptide identification. 
 Despite its limitation to the number of protein identification, MS-based proteomics has some 
advantages over transcriptomics. For example, the mRNA abundance does not always correlate with 
that of proteins due to post-transcriptional regulations. Since proteins are the core executors of 
biological processes, phenotypes should be more accurately inferred from proteins than from 
mRNAs. In addition, secreted proteins can only be accurately quantified on the protein level. 
Therefore, Chapter 3 describes a quantitative proteomic study to characterize cells that initiate a 
tumour, by comparing glioblastoma-derived stem cells to neural stem cells. This project is a 
collaboration with Dr. Steven Pollard (UCL) and Dr. Paul Bertone (EBI). 
 Glioblastma is the most severe form of brain tumour according to the World Health 
Organization. There is strong evidence that brain cancers arise from a small population of cells 
within the tumour that exhibit normal stem cell characteristics, i.e., long-term self-renewal, 
longevity and capacity to differentiate into adult cells. These cells are called cancer stem cells 
(CSCs), or tumour initiating cells, and unless these cells are eradicated, tumour will rise again. 
Since CSCs exist in a small population, in vitro culture techniques are required to study biological 
properties of these cells, and to design strategies for anti-cancer therapy. However, culturing these 
cells in conventional serum-containing media causes loss of multipotency and induction of 
differentiation [3]. In addition, repetitive passaging will lead to accumulation of de novo mutations 
that may not have any relevance to the original tumour [3]. To overcome these problems and keep 
cells in the multipotent state, Pollard et al [4] developed a protocol for culturing human glioma 
neural stem cells (GNSs), in a very homogeneous fashion without losing their tumourigenic 
capacity. To identify key proteins/pathways that are the hallmarks of malignant GNSs, here we aim 
to globally characterise the protein expression of these malignant GNSs by having normal, 
untransformed foetal neural stem cells [1] as the control. Both total cell- and secreted proteomics 
analyses are performed in order to identify key proteins/pathways in the cell and secreted auto-
/paracrine factors mediating tumourigenesis. Since the gene expression of individual gliomas differ 
considerably from one another [5], we used four NS lines and four GNS lines from different 
individuals, so as to minimize the effect of inter-individual variability. Furthermore, we obtained 
tag-seq data on the NS and GNS lines from Dr. Paul Bertone and glioma tissue microarray data 
from public databases and combined them with the proteomics data to gain further insight into the 
biology. Following the data analyses, we selected candidate proteins for markers for malignant 
phenotypes and conducted immunocytochemistry for validation. We also selected candidate 
proteins for auto/paracrine factors for mediating tumourigenesis by adding these proteins to the 
culturing media and observing phenotypic changes over time. Colony-forming assays were also 
made with addition of these candidate proteins to the media and the number of colonies was 
counted as a readout for proliferation. Finally, the prospects of the candidate proteins as well as the 
global picture of protein expression between the NSs and GNSs is discussed.    
 In Chapter 4 I discuss the two projects in more general terms and conclude by mentioning 
the outlook and future plan for the projects and potential implications of the projects for future 
research in general.   
 
Chapter 2 
 
2  Properties of isotope patterns and their utility for peptide 
identification in large-scale proteomic experiments  
 
2.1  Introduction 
 
2.1.1  Peptide isotope patterns are not used in the standard proteomics workflow 
Mass spectrometry (MS) is widely used in proteomics to identify and quantify proteins in biological 
samples. A typical workflow for current MS-based proteomics consists of peptide separation by 
high-performance liquid chromatography (HPLC), peptide ionization, acquisition of a full mass 
spectrum (MS1), followed by fragmentation of selected precursor ions and acquisition of MS/MS 
spectra (MS2) [6]. These MS/MS spectra are then compared to masses generated in silico from 
candidate peptides derived from a target protein sequence database. Several search engines and 
scoring algorithms have been developed for this task [7]
 
such as SEQUEST [8], Mascot [9], 
OMSSA [10], X!Tandem [11] and Andromeda [12]. Although search engines have been the gold 
standard in MS-based proteomics, additional parameters independent of MS2 information have 
been used to support peptide identification, such as peptide retention time, isoelectric point and 
accurate mass. Retention time prediction calculates the expected elution time for a peptide of a 
given sequence and for particular chromatographic conditions [13-17] to narrow down the number 
of peptide candidates expected in a retention time window. Similarly, when isoelectric focusing is 
used for first-dimension peptide separation, the predicted versus observed isoelectric point can be 
used to increase confidence in peptide identification [18]. In modern mass spectrometers, especially 
using TOF, Orbitrap and FT-ICR detectors, the mass of intact peptides can be determined with high 
accuracy in MS1, greatly restricting the number of peptides that need to be considered and 
contributing to low false discovery rates (FDR) in large-scale proteomics [19]. 
 A parameter that has not been considered extensively for peptide identification, but one that 
is readily available in any high-resolution mass spectrometric experiment is the isotope pattern in 
MS1 spectra. The isotope pattern is determined by the atomic composition of the peptide (or any 
compound) which is reflected in the relative intensities of isotope peaks (with contributions mainly 
from 
13
C, 
15
N, 
18
O). Therefore, this is a compound-specific parameter that can be calculated from 
any given elemental composition. Isotope patterns have been used for various purposes such as 
charge state assignment [20], determination of monoisotopic mass and deisotoping [21], filtering of 
non-peptide features [22], estimation of protein turnover rate [23], and detection of peptides 
containing particular atoms such as mercury [24]. However, their use as a general constraint for 
peptide identification is largely unexplored. This is somewhat different in metabolomics where 
isotope patterns are employed routinely to compute possible atomic compositions, thereby reducing 
the number of candidate compounds [25-30]. A similar approach may become helpful in proteomics 
where it may serve as a parameter to support peptide identification. The primary challenge in the 
implementation of RIA as a constraint pertains to the complexity of the proteome, where it needs to 
be demonstrated that experimentally determined isotope patterns have the discriminatory power to 
distinguish closely related peptides. Therefore, in this study we have investigated the accuracy of 
relative isotope abundance in large-scale proteomic datasets and its dependence on various mass 
spectrometric parameters. In addition, we explored various strategies to quantify the discriminatory 
power of isotope patterns in the context of proteome analyses of various complexities (E. coli, 
Saccharomyces cerevisiae, and human cells). Finally, we provide a theoretical framework 
describing the combined contributions of mass accuracy and relative isotope abundance for 
confident peptide identification. 
 
 
2.2  Materials and methods 
 
2.2.1  Sample preparation for mass spectrometry  
E. coli and yeast were grown under standard conditions, lysed, and homogenized in 50 mM 
ammonium bicarbonate. HeLa cells were grown overnight in Dulbecco's Modified Eagle's Medium 
(DMEM) supplemented with 10% fetal calf serum. The lysates were concentrated using Amicon 
Ultra Centrifugal Filters (0.5 ml, 3 kDa cutoff) (Millipore). Disulphide bonds were reduced with 
100 mM dithiothreitol (DTT) and cysteine residues were alkylated with 200 mM iodoacetamide 
(IAA) followed by protein digestion with sequencing grade modified trypsin (Promega) overnight at 
37°C. Peptides were acidified and desalted with C18 Stagetips (Empore 3M) [31] and then dried 
down by vacuum centrifugation. Human peptides were fractionated into 12 fractions on an Agilent 
3100 OFFGEL Fractionator (settings as described by the manufacturer) using Immobiline DryStrips 
(ph 3-10 NL, 13 cm, GE Healthcare). Dried samples were resuspended in 360 ml H2O and diluted 
into 1.44 ml 1.25 x IEF stock solution (6% glycerol, 2% Ampholytes pH 3-10 (1:50)). Focusing was 
performed at a constant current of 50 mA with a maximum voltage of 8,000 V until 20 kVh. After 
IEF, peptides were acidified, desalted, and dried as described above, and then reconstituted with 4% 
acetonitrile in 0.1% formic acid. 
 
2.2.2  Liquid chromatography coupled to mass spectrometry (LC-MS/MS)  
Peptides were analyzed by nanoflow LC coupled to an LTQ Orbitrap Velos (Thermo Fisher 
Scientific) using a Proxeon nanospray source. Reverse phase chromatography was performed with a 
nanoACQUITY UltraPerformance LC system (Waters) fitted with a trapping column (nanoAcquity 
Symmetry C18, 5 μm, 180 μm x 20 mm) and an analytical column (nanoAcquity BEH C18, 1.7 μm, 
75 μm x 200 mm) directly coupled to the ion source. The mobile phases for LC separation were 
0.1% (v/v) formic acid in LC-MS grade water (solvent A) and 0.1% (v/v) formic acid in ACN 
(solvent B). Peptides were separated at a constant flow rate of 300 nl/min with a 3 to 40% solvent B 
gradient (120 min for E. coli and yeast, 145 min for IEF fractions of HeLa cells). The MS1 scan 
was acquired in the Orbitrap from m/z 300 to 1,700 at a maximum filling time of 500 ms and10
6
 
ions. The resolution was set to 30,000 (at m/z 400) unless stated otherwise. Fragmentation was 
performed in the LTQ by collision induced dissociation, selecting up to 15 most intense ions (top15) 
at an isolation window of 2 Da, unless stated otherwise. Target ions previously selected for 
fragmentation were dynamically excluded for 30s with relative mass window of 10 ppm. A lock 
mass correction was applied using a background ion (m/z 445.12003).  
 
2.2.3  Feature extraction  
Raw data files were converted into mzXML files in centroid mode with MM file Conversion Tool 
available at http://sourceforge.net/projects/massmatrix/files/MM_File_Conversion.zip/download. 
We also tested the profile mode, however, this did not change the result. All raw mz- and intensity 
values were extracted from mzXML files with the mzR R package 
(http://www.bioconductor.org/packages/2.9/bioc/html/mzR.html) and processed with a C++ 
programme written in-house. The source codes (as well as those for the scripts described below) are 
available upon request. For each MS/MS spectrum, the corresponding MS1 chromatographic 
feature was extracted from all the scans in a window +/- 0.3 min relative to the time of the MS/MS 
event. Isotopic peaks were extracted based on the theoretical distance calculated from the charge, 
(i.e., 0.5 Th for a +2 ion) with 10 ppm mass accuracy. Only the first three isotopic peaks were 
extracted since the 4
th
 and 5
th
 peaks were often missing. Scans that had a missing value in the first 
three isotopic peaks were discarded.  
 
2.2.4  Decoy database construction 
To use the FDR approach [32] for MS/MS sequence search, the decoy database was obtained by the 
“decoy.pl” script from (http://www.matrixscience.com/help/decoy_help.html) with the standard 
reverse mode and “random” mode. The latter generates random sequences with the same average 
amino acid composition as the input database.  
 
2.2.5  Peptide identification and mass recalibration 
Mascot generic files were generated with MM File Conversion Tool from the raw file and peptide 
identification was carried out with Mascot (version 2.2.06). The precursor mass tolerance was set to 
5 ppm, fragment ion mass tolerance was 0.6 Da, cystein-carbamidomethylation as a fixed 
modification and methionine-oxidation as a variable modification. The number of missed cleavages 
was set to 1. The FDR was computed as the number of decoy Mascot top hits over the number of 
target Mascot top hits. Based on this FDR, the q-value was assigned to each Mascot top hit. This q-
value function was interpolated for Mascot runner-up hits. Each peptide spectrum match (PSM) was 
matched back to the corresponding MS1 chromatographic feature, indicated as a feature with 
peptide spectrum match (FWP). Mass recalibration was performed based on top Mascot hits with a 
robust linear regression function in the R package MASS. 
 
2.2.6  Relative isotope abundance (RIA) measurement error calculation 
For each FWP, only MS1 scans having an intensity value above 50% of the top intensity of that 
FWP were extracted and averaged. The theoretical isotope pattern of the identified peptide 
(including fixed cysteine-carbamidomethylation and variable methionine-oxidation) was generated 
with an R programme written in-house. The RIA measurement error for each isotopic peak was 
calculated  
as:   -   ) 
 
where     and  
 
with E being the experimental isotope abundance (intensity) of the three isotopic peaks, T the 
theoretical RIA, and j  indicating the isotopic peak index. Each isotopic peak was normalized by 
the Euclidian norm of the three isotopic peaks and this difference between the experimental- and 
theoretical isotope patterns was converted into the percentage. 
 
T = (
i1
i2)
i3
E = (
I1
I2)
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2.2.7  Assessing discriminating power of RIA 
To examine the power of RIA to discriminate between target and decoy hits upon a Mascot search, 
the ratio of the RIA error was computed as mean(E – T1) / mean(T1 - D1), where E is the vector of 
the experimental isotope pattern, T1 is the vector of the theoretical isotope pattern of the 
corresponding top target hit, and D1 is the vector of the theoretical isotope pattern of the decoy hit 
that is most similar to that of the target hit. Therefore, the scalars both in the nominator and 
numerator indicate the mean RIA error of the first three isotope peaks. Only if the ratio mean(E - 
T1) / mean(T1 - D1) is < 1, the experimental isotope pattern can discriminate the target hit from the 
closest decoy hit. 
 Similarly, to test the power of RIA to discriminate between candidate peptides in a Mascot 
search for each top Mascot hit–runner-up hit combination, the RIA error was computed and the 
minimum RIA error was taken as mean(T1 – Tr), where T1 is the isotope pattern of the top Mascot 
hit and Tr is the isotope pattern of the runner-up hit that minimizes mean(T1 - Tr). Only if the ratio 
mean(E -T1) / mean(T1 - Tr) is < 1, the experimental isotope pattern can discriminate the top 
Mascot hit from the closest runner-up hit.  
 
2.2.8  In silico digestion of proteomes 
The E. coli and human proteomes were obtained from SwissProt 
(http://www.uniprot.org/downloads), the yeast proteome from the Saccharomyces Genome 
Database (http://www.yeastgenome.org/). In silico digestion of these proteomes was done with the 
proteogest.pl script from (http://www.utoronto.ca/emililab/proteogest.htm) allowing 1 missed 
cleavage, while cysteine carbamidomethylation and methionine-oxidation were used as a fixed and 
variable modification, respectively.  
 
2.2.9  Reclassification of target and decoy hits 
The RIA error was scored as the mean of residuals by fitting the first three isotopic peaks to the 
theoretical isotope patterns using the “lm” linear regression function in R. LDA and QDA were 
perfomed using the R package MASS. SVM was performed using the R package e1071. The 
posterior probability was used for scoring re-classified peptides. 
 
2.2.10  Generation of theoretical isotopic fine structures and RIA error calculation 
The theoretical isotopic fine structures were generated using the most abundant peaks, namely 
C12H1N14O16, C12H1N15O16, C13H1N14O16, C13H1N15O16, C14H1N14O16 and 
C12H1N14O16S34 (if sulphur is absent this value is 0). The summed RIA difference, rather than 
the mean RIA difference, over the peaks was calculated in this analysis in order to compare the RIA 
differences conferred by different numbers of peaks (i.e., three for normal isotope patterns and six 
for isotopic fine structures) with the same RIA accuracy.  
 
 
2.3  Result and discussion 
 
2.3.1  Accuracy of RIA in proteomic data  
If isotope patterns are to be used as a constraint in peptide identification, one of the defining 
features is the accuracy in the measurement of relative isotope abundance (RIA). Since it is 
unknown what RIA accuracy can be obtained from a typical proteome analysis, we analyzed a 
proteomic dataset collected using routine conditions. We used a yeast digest as a model system, 
analyzed by LC-MS/MS on an LTQ-Orbitrap Velos using a top15 method (i.e. 1 MS1 scan followed 
by up to 15 MS2 scans). To generate a reference list of confidently identified peptides, MS2 spectra 
were submitted to a Mascot database search only retaining the hits with q-value <=0.01. Matching 
the experimental to the corresponding theoretical isotope patterns of these peptides, the mean RIA 
error was 3.7%, 4.1% and 4.8% for the mono-isotopic, first and second isotope peak, respectively. 
This error depended on intensity to a limited extent (Figure 2-1 B), e.g. for the mono-isotopic peak 
ranging from 1.6% (± 2.5%) for the highest intensity bin (10
7
) to 5.0% (± 5.4%) for the lower 
intensity bin (10
4.5
). The better concordance for high-abundant ions was reported previously for 
Orbitrap [30] and FT-ICR [29], and is unlikely to be caused by wrong Mascot identifications since 
there was only a slight positive correlation between the precursor intensity and Mascot score 
(Figure 2-1 C). In order to evaluate the potential effect of chromatographic peak interference on 
RIA error, we calculated the RIA error from a digest of single protein (BSA) analyzed by LCMSMS 
over a 30 min gradient, thereby minimizing peak overlap. This resulted in 4-5 % RIA error (Figure 
2-2), thus being very similar to the values obtained for complex proteomes (Table 2-1), indicating 
that RIA is minimally affected by sample complexity. We observed a tendency for underestimation 
of the intensity of the monoisotopic peak but an overestimation of the 2
nd
 isotopic peak (Figure 2-1 
B). This was also observed for both E. coli and human samples (not shown), and for the BSA digest 
(Figure 2-2). The underestimation of ion intensities of compounds of similar mass was reported 
before as a result of isotopic beat effects in FT-ICR [33], however, the overestimation is, to our 
knowledge, previously unreported. Nevertheless, overall there seems to be a limited effect on the 
measured isotope distribution, since the RIA error is symmetrically distributed (Figure 2-1 D) with 
only a small sign of divergence for a minority of cases (Figure 2-1 D, inset).  
 
 
Figure 2-1.  (A) Error in the relative isotope abundance (RIA) as a function of ion intensity, for the mono-
isotopic peak and the first 2 isotope peaks across all features detected in a total yeast digest. Red lines 
indicate standard deviation of RIA error. (B) Mascot score as a function of ion intensity. The blue and red 
lines indicate the mean and median Mascot score, respectively, indicating that Mascot score is largely 
independent of peak intensity. (C)  Distribution of the isotope ratio divergence comparing the experimental 
intensities of the mono-isotopic and 2nd isotope peaks to their theoretical values. The divergence is defined 
as (I0/I2)theory / (I0/I2)experimental, where I0 and I2 are the intensities of the mono-isotopic and second 
isotope peak, respectively, within a peptide isotope pattern. The distribution of these values shows a normal 
distribution with only a slight tailing to higher values (see inset).  
 
 
 
 
 
 
 
 
 
 
Figure 2-2. Error in the relative isotope abundance (RIA) as a function of ion intensity, for the mono-
isotopic peak and the first 2 isotopic peaks across all features detected in a BSA digest. 
 
2.3.2  Effect of mass resolution on RIA measurement 
We next aimed to investigate in more detail how other experimental parameters impact the accuracy 
of the RIA measurement, including mass resolution. Reasoning that the scan time, and thus the 
resolution, of MS1 spectra may influence RIA accuracy, a yeast digest was analyzed at resolution 
7,500, 15,000, 30,000, 60,000 and 100,000 (corresponding to MS1 scan times of 270, 360, 560, 950 
and 1,710 milliseconds, respectively). The difference in RIA error between these conditions was 
relatively small (Table 2-1; Figure 2-3), although the error was the highest at the highest resolution 
(100,000). This is consistent with recent studies [26, 29, 30] showing a larger RIA error at high 
resolution in Oribtrap and FT-ICR. 
 The increased scan time for higher resolution inevitably decreases the number of both MS1 
and MS2 spectra, peptide spectrum matches (PSMs), features with PSM (FWPs), and peptide and 
protein identifications (Table 2-1). Decreasing the resolution from 30,000 to 15,000 or 7,500 
resulted in an increased number of spectra but the numbers of PSMs and FWPs were worse than at 
30,000. Taken together, with this yeast data set the highest number of peptide identification was 
achieved at resolution 30,000 in LTQ-Orbitrap Velos with a mean RIA error of 4.2%. 
 
Table 2-1. Evaluation of the error in relative isotope abundance and other mass spectrometric parameters 
across a range of resolutions. Applied to the analysis of a complete yeast digest by LC-MS/MS.  
Resolution Total spectra 
(features) 
Peptides 
with 
spectrum 
match 
(PSM) 
Features with 
PSM (FWP) 
RIA 
error 
(%) 
Unique peptide 
identificaitons 
Unique protein 
identifications 
7500 30388 12345 10627 4.45 5649 1212 
15000 27609 12618 11877 4.16 6219 1330 
30000 23559 13271 12758 4.17 6284 1311 
60000 21118 12184 11808 4.30 5788 1233 
100000 17203 9519 8794 5.56 4461 999 
 
2.3.3  Correlation between RIA error and number of MS1 scans 
Considering that chromatographic features almost always consist of multiple scans, we investigated 
the effect of the number of MS1 scans on the RIA error by varying the number of MS2 scans 
between MS1 scans from 3 (top3, resulting in a larger number of MS1 scans across a 
chromatographic peak) to 50 (top50, resulting in a fewer scans per peak) (Figure 2-4). As before, 
only yeast peptide identifications with q-value below 0.01 were used for the RIA error calculation. 
The results (Figure 2-4) indicate that the mean RIA error of 4.2% obtained in the top15 method can 
be modestly improved to 3% by increasing the number of MS1 scans from 7 to 22 in the top 3 
method. Conversely, a decreased number of MS1 spectra per peak (in the top 30 and top 50 
methods) slightly increased RIA error to 4.5% and 4.7%, respectively. In addition and as expected, 
increasing the number of MS1 scans comes at the cost of a reduced number of MS2 scans and thus 
peptide identifications (Figure 2-4).  
 
Figure 2-3.  (A) RIA error as a function of ion intensity at different resolutions ranging from 7,500 to 
100,000. Coloured lines indicate 95 percentiles of all isotope distributions, plotted in grey in the background. 
(B) RIA error at different resolutions across all intensities, showing that on average RIA error increases with 
increasing resolution. Inset: zoom-out of the same data, showing highly similar distribution of outliers. 
 
 
Figure 2-4.  RIA error as a function of the number of MS1 scans per detected peptide feature. A yeast digest 
was analyzed at resolution 30,000 with different MS2 methods: (A) top3, having MS1 scans separated by 3 
MS2 scans (B) top15, (C) top30, (D) top50. Numbers in the insets in each panel indicate that increasing the 
number of MS1 scans decreases the RIA error, but offsets the number of peptide identifications. 
2.3.4  Use of isotope patterns as an independent scoring scheme 
Aiming to explore several potential approaches to assess if isotope patterns may be used as a 
constraint for peptide identification, we first considered an ideal scenario where RIA is to be used as 
the sole parameter to identify a peptide. This requires that a given proteome do not contain peptides 
with identical atomic composition since these cannot be distinguished by isotope patterns. To 
determine the number of unique peptides that can be expected in proteomes of various complexities, 
we in silico digested the entire E. coli, yeast and human proteomes allowing one missed cleavage 
and methionine oxidation as a variable modification. E. coli had 262,722 unique peptide sequences, 
252,032 of which were unique in their atomic composition (95.9%). For yeast these numbers were 
480,317 and 362,885 (75.6%), and for the human proteome 1,692,023 and 1,030,190 (60.9%). The 
relatively high proportion of unique atomic compositions indicates that in principle a large 
proportion of these proteomes are accessible for analysis by isotope patterns, most notable for the 
less complex organisms. Therefore, we investigated if a global FDR approach was possible by using 
isotope patterns as the sole 'search engine'. For this to happen, there should not be common atomic 
compositions between the target and decoy databases. Table 2-2 shows that in 30-50% of the 
reverse database and 10-20% of the randomized database, atomic compositions were common to the 
target database. Therefore, it is clear that isotope patterns alone cannot be used to uniquely identify 
peptides in complex proteomes. 
 
2.3.5  Difference in RIA error between Mascot target hits and decoy hits 
We then investigated if isotope patterns may be used in conjunction with a classical peptide 
identification based on MS2-spectra. Specifically, we tested if RIA may help in reducing the 
number of decoy hits in a Mascot search, thereby improving FDR. We analyzed the proteomes of E. 
coli, yeast and HeLa cells by LC-MS/MS, performing Mascot searches against the respective target-
randomized databases for these species. This procedure significantly reduced the number of decoy-
to-target hit ratio in the peptide set compared to the full proteome analysis above. Among the 
confident Mascot top hits (q-value <= 0.01), decoy hits with identical atomic composition to a 
target hit were excluded. This resulted in 1,219 target hits and 9 decoy hits with unique atomic 
composition in E. coli; 5,885 target and 53 decoy hits in yeast, and 20,391 target and 180 decoy hits 
in HeLa cells. Based on these numbers, E. coli was excluded from the subsequent analysis since the 
number of decoy hits was insufficient for the proper FDR calculation. The RIA error distribution 
(Figure 2-5 A, B) showed no separation between the target and decoy hits in both yeast and HeLa 
cells, suggesting that an FDR approach on this Mascot result is not possible with the current RIA 
accuracy (4-5%). We also attempted to generate a decoy database without common atomic 
compositions with the target database. However, we did not succeed evidenced from the strong bias 
towards the target hits upon Mascot search (Figure 2-6), making the proper FDR calculation 
unrealistic. 
 
Table 2-2. Number of tryptic sequences in E. coli, yeast and human proteome target databases, and the 
proportion of molecular compositions shared with reverse and randomized decoy databases.  
E. coli Reverse Randomized 
Total sequences 3,030,939 3,137,134 
Total common atomic compositions with target 1,582,388 889,570 
Unique sequences 257,084 1,101,606 
Unique common atomic compositions with 
target 
137,138 117,854 
Fraction of unique common atomic 
compositions (%) 
53.3 10.7 
Yeast Reverse Randomized 
Total sequences 1,299,076 1,368,272 
Total common atomic compositions with target 818,914 565,478 
Unique sequences 470,012 521,331 
Unique common atomic compositions with 
target 
208,328 116,457 
Fraction of unique common atomic 
compositions (%) 
44.3 22.3 
Human Reverse Randomized 
Total sequences 4,669,151 4,953,655 
Total common atomic compositions with target 3,208,613 2,603,995 
Unique sequences 1,663,003 1,851,902 
Unique common atomic compositions with 
target 
595,296 380,153 
Fraction of unique common atomic 
compositions (%) 
35.8 20.5 
 
 We therefore examined the RIA accuracy that would be required to confidently discriminate 
between target and decoy hits upon a Mascot search. Figure 2-5 C shows that in about 80% (yeast) 
and 70% (human) of cases the experimental isotope patterns can discriminate the top target hits 
from the decoy hits (normalized RIA error <1). From the same plot, it can be estimated that to do so 
in 95% of cases would require four times higher RIA accuracy in yeast and about 15 times in human 
samples, i.e. corresponding to a tolerable RIA error of 1.25% and 0.35%, respectively.  
 
Figure 2-5.  RIA error distribution of target and decoy hits in (A) yeast, and (B) HeLa cells. (C) Fraction of 
cases where experimental isotope pattern can distinguish between the top target hit and the closest decoy hit. 
The normalized RIA error is defined as RIA error(E – T1) to RIA / RIA error (T1 - D1), where E, T1 and D1 
are experimental isotope pattern, the theoretical isotope pattern of its top target hit, and the theoretical 
isotope pattern of the closest decoy hit, respectively.  The dashed line indicates 95% confidence. 
 Figure 2-6. We also attempted to generate a decoy database without common atomic compositions with the 
target database. However, in order to make the number of peptides in the decoy database similar to that of the 
target database, the same atomic compositions had to be used repeatedly in the decoy database, resulting in a 
strong bias towards the target hits upon Mascot search, making the FDR unrealistic Mascot search bias 
towards a target or decoy database. (A) Reversed sequences. (B) Randomized sequences.(C) Decoy database 
with minimum atomic composition overlap with the target. 
 
2.3.6  RIA error difference between top Mascot hits and runner-up hits 
In an alternative approach, we investigated to what extent isotope patterns can discriminate between 
top Mascot hits and their runner-up hits, identified from the same MS1 feature with a lower Mascot 
score. We only retained the FWPs where runner-up hits had a different atomic composition than the 
top hit (373, 606 and 1217 in E. coli, yeast and human samples, respectively). The result, split into 
five intensity bins (Figure 2-7), indicates that in about 95% of the cases isotope patterns can 
distinguish between the top hits and runner-up hits (normalized RIA error <1) within the higher 
intensity bins, down to around 70% in the lowest intensity bin. This is unlikely due to incorrect 
Mascot identification since there was little difference in the Mascot score distribution among the 
intensity bins (Figure 2-8). Thus, with the current experimental procedure and instrument it was 
possible to a large degree to discriminate between top Mascot hits and runner-up hits by their 
isotope patterns especially when the intensity is high. However, in order to do so in at least 95% of 
the cases across all intensities, Figure 2-7 A-C indicate that the RIA accuracy has to be 4-5 times 
higher than the current level.   
 In proteomics it is common practice to assume that the top Mascot target hit for a particular 
spectrum is the “correct” peptide without considering lower scoring alternatives. However, it would 
be interesting to use isotope patterns for ranking hit sequences especially when the Mascot score is 
similar between the top hit and runner-up hit. To investigate this, we first composed a reference set 
of very confident Mascot identifications (Mascot score >= 70), and estimated the RIA error rate of 
experimental isotope patterns by interpolating the mean RIA error as a function of intensity. This 
subset covered the entire intensity range observed in the entire data set (Figure 2-9). Then the ratio 
of this RIA error rate to half the theoretical RIA difference between the top hit and 1st runner-up hit 
(T – Tr) was taken (i.e., RIA error rate / (T -Tr)/2). Note that halving was necessary since the RIA 
error needs to be taken into account for both top hit and runner-up hit. If this ratio is < 1, the RIA 
error rate is small enough to tell the top hit and runner-up hit apart by the isotope pattern. Taking the 
FWPs mentioned above where a runner-up hit was found (i.e. 373 (E. coli), 606 (yeast) and 1,217 
peptides (HeLa cells), Figure 2-7 D shows the fraction of the cases where these could be 
discriminated based on isotope patterns. This was the case for about 30% of E. coli cases and <10 % 
in yeast and HeLa cells, indicating that the RIA accuracy was insufficient to tell them apart. 
Figure 2-7.  (A) Fraction of cases in E. coli where experimental isotope pattern can distinguish between the 
top target hit and the closest decoy runner-up hit as a function of the normalized RIA error. The normalized 
RIA error is defined as RIA error(E – T1) / RIA error(T1 - Tr), where E, T1 and Tr are the experimental 
isotope pattern, the theoretical isotope pattern of its top target, and the theoretical isotope pattern of the 
closest runner-up hit, respectively. The entire dataset was split by intensity into five bins. (B) Same as panel 
A, but for yeast. (C) Same as panel A, but for human.  
 Figure 2-8. Mascot score distribution of the top Mascot target hits in different intensity bins in the proteome 
analysis of (A) E. coli, (B) yeast, and (C) human. Intensity bins for the respective organisms correspond with 
those indicated in Figure 1-6. 
 Figure 2-9.  RIA error as a function of ion intensity of yeast sample, only considering peptides that were 
identified with very high confidence (Mascot score >=70). The mean RIA error over the three isotopic peaks 
was taken. 
 
2.3.7  Re-classifying target and decoy hits using RIA did not improve peptide identification 
Next, we investigated whether the RIA could contribute to improving peptide identification when 
combined with other parameters. The first three isotopic peaks to the theoretical isotope patterns 
were fitted with a linear model and the mean of the absolute value of the residuals was used as a 
score for how similar the experimental- and theoretical isotope patterns were to each other. Then 
this mean absolute residuals and the Mascot score were used to re-classify target and decoy hits by 
LDA, QDA and SVM (Figure 2-10 A, B, C, respectively). The posterior error probability was used 
as the score after re-classification. The number of target hits as a function of FDR is plotted in 
(Figure 2-10 D). The result showed that QDA and SVM performed much worse than the Mascot 
score alone and LDA was almost identical to the Mascot score, suggesting that increasing 
confidence in peptide identification in this two-dimensional space is difficult.  
 
2.3.8  Required accuracy in mass and RIA for theoretical digest peptide isotope patterns 
Since our data indicated that RIA accuracy is generally insufficient to be helpful in peptide 
identification at a proteomic scale, we took a theoretical approach to estimate the RIA accuracy that 
would be required to uniquely identify peptides in a given proteome. Therefore, the E. coli, yeast 
and human proteomes were in silico digested in order to calculate the atomic compositions and 
isotope distributions of the resulting peptides. We generated a representative dataset by selecting all 
peptides from 24 mass windows, each 1 Th-wide and 50 Th apart, ranging from 300-301 Th to 
1450-1451 Th. This resulted in 7304, 10838 and 27087 peptides from E. coli, yeast, and human 
proteomes, respectively. Figure 2-11 A-C show that without considering RIA (i.e. RIA > 0.15), a 
larger proportion of peptides can be uniquely identified with increasing mass accuracy in the three 
organisms. For instance, at 3 ppm mass accuracy less than 20% of the peptides in E. coli can be 
uniquely identified (Figure 2-11 A), increasing to 40% and 65% at mass accuracies 1 and 0.5 ppm, 
respectively. In order to achieve more than 90% of unique peptide identification by mass alone, 0.1 
ppm mass accuracy would be necessary for E. coli and yeast, and 0.05 ppm for human peptides.  
 
A       B 
C       D 
 
Figure 2-10.  Target and decoy hits re-classified by Mascot score and mean absolute residual using (A) 
linear discriminant analysis (LDA), (B) quadratic discriminant analysis and (C) support vector machine 
(parameters). (D) Number of target hits false discovery rate (FDR) using Mascot socre and comibined score 
after re-classification by LDA, QDA and SVM. X-axis range from 0 to 0,1. 
  When the RIA is used as an additional filter, the number of unique identifications showed a 
modest increase between the RIA errors 5% and 10%, but increased sharply at RIA error below 2% 
(Figure 2-11 A-C). To achieve 95% unique peptide identification in E. coli, at 1 ppm mass accuracy 
about 0.5% RIA accuracy would be required (Figure 2-11 D), and even a better RIA in yeast (Figure 
2-11 E) and human (Figure 2-11 F). The required RIA accuracy sharply decreases at 0.1 ppm to 
around 8%, 2%, and 1.5% in E. coli, yeast and human, respectively. It should be noted, however, 
that at this mass accuracy more than 90% of the peptides were already uniquely identified by mass 
alone in E. coli and yeast (Figure 2-11 A, B), and 80% in human (Figure 2-11 C). With a mass 
accuracy of 1-3 ppm, the RIA accuracy would need to be ~0.2%, i.e. 20-30 times higher than the 
current level (4-5%) in order to uniquely identify atomic compositions proteome-wide, independent 
of MS2. Conversely, with the current RIA accuracy, the mass accuracy would have to be at least 
better than 0.05 ppm (20-60 times better than our current accuracy). This analysis illustrates the 
combined contribution of mass and RIA accuracy to confidently identify peptides with unique 
atomic composition.  
 
2.3.9  Required accuracy in mass and RIA for the isotopic fine structures of theoretical digest 
peptide  
So far we have considered only the most dominant isotopic peaks assuming that these peaks consist 
of a mixture of different atomic elements (e.g. C, N, O, S). However, it has been known that a 
sufficiently high mass resolution could resolve contributions from these different elements known 
as isotopic fine structures produced by the slight differences in mass increase of isotopes of C, N, O 
and S [34, 35]. Miladinovic et al [36] were able to resolve isotopic fine structures of a few peptides 
using FT-ICR with resolving power 1,500,000 at m/z 1061. This resolution cannot be achieved by 
the current Orbitrap technology, and its maximum resolution (100,000) is insufficient to resolve 
isotopic fine structures. Therefore, we performed a theoretical study to assess whether isotopic fine 
structures may be more informative than normal isotope patterns to elucidate peptide identity. The 
result (Figure 2-12) indicates that in order to achieve 95% unique atomic composition identification, 
isotopic fine structures could relax the RIA accuracy requirement by 1.5 – 2 fold in comparison to 
the normal isotope patterns in all the three organisms. A similar trend was observed for the 99% 
unique identification rate (Figure 2-12), suggesting that resolving isotopic fine structures is in 
principle another constraint that could aid in peptide identification. 
 
 Figure 2-11. (A) The theoretical identification rate for unique atomic composition as a function of the RIA 
accuracy at different mass accuracies (coloured lines) in the E. coli proteome, (B) the yeast proteome and (C) 
the human proteome. (D) The RIA accuracy necessary for uniquely identifying 95% (red line) and 99% (blue 
line) of atomic composition at different mass accuracies in the E. coli proteome, (E) yeast proteome, and (F) 
human proteome. 
 Figure 2-12.  Required RIA performance to achieve 95% (A, B, C) and 99% (D, E, F) peptide identification 
rate comparing normal isotope patterns (green line) and isotopic fine structures (purple line) as a function of 
mass accuracy, applied to in silico digested proteomes of E. coli (A, D), yeast (B, E) and human (C, F). Note, 
the y-axis is the RIA accuracy (%) for the summed RIA difference over isotopic peaks, not the mean, since 
here the RIA difference conferred by different numbers of isotopic peaks (i.e., isotope patterns or isotopic 
fine structures) is evaluated. 
 
2.4  Conclusion 
 
In this study we have quantitatively examined the accuracy of RIA obtained from proteomic 
datasets. We demonstrate that the RIA error is 4-5%, and that this is only modestly influenced by 
spectral intensity, resolution and the number of MS1 scans. To assess the utility of isotope patterns 
as a discriminatory feature in peptide identification, we have tested a number of potential 
applications, either using RIA alone or in combination with MS2-based database searches, applied 
to proteomes of various complexities. The current RIA accuracy has limited discriminatory power at 
a proteome-wide scale. At the same time, it should be stated that this analysis was hampered by the 
difficulty in calculating FDRs, particularly in constructing proper decoy databases that are similar in 
size as the target database, yet different in molecular composition for all peptides considered. 
Alternative strategies to calculate FDRs will be required to address this issue for complex 
proteomes. Regardless, our analyses have shown that the limited utility of RIA in Orbitrap data is 
primarily due to the fact that it cannot compete with the strong discriminatory power of mass 
accuracy. The utility of RIA may become relevant with future instrument developments, considering 
that even a relatively modest decrease in RIA error down to <1% strongly improves discriminatory 
power (Figure 6). Alternatively, at increased mass accuracy even current RIA accuracy levels may 
be sufficient to fit isotope patterns as a constraint in the peptide identification process as a 
parameter that comes for free in any MS-based proteomic experiment. 
 
 
Chapter 3 
 
3  A comparative proteomics study between neural stem cells [1] and 
glioma neural stem cells (GNSs) 
 
3.1  Introduction 
 
3.1.1  Epigenetic models of tumour development 
Knudson [37] was the first to propose the clonal genetic model of cancer, in which tumour 
development begins with genetic alterations in a single founding cell which then evolves and 
becomes a dominant population by undergoing clonal selection. However, epigenetic changes 
regulated by DNA methylation and non-coding RNAs can stably influence gene transcription and 
are often observed at the earliest stages of neoplasia within the altered tissue stem/progenitor cells. 
To take these epigenetics into account, Feinberg et al [38] postulated the epigenetic progenitor 
model of cancer development, which proposes that malignant transformation takes place in three 
steps. First, essential epigenetic disruptions of stem/progenitor cells make them epigenetically 
permissive to tumourigenesis. Second, genetic alterations occur in a tumour suppressor gene or an 
oncogene. Third, genetic and epigenetic changes occur, which enhance their ability to stably evolve 
the tumour phenotype. A major difference to the clonal genetic model is that the epigenetic events 
occur prior to genetic alterations, and are necessary for creating a polyclonal population that 
subsequently undergoes genetic alterations and transformation. It remains unclear whether 
epigenetic changes are necessary and sufficient for initiating and/or sustaining the malignancy. Teng 
et al. [39] showed that methylating the tumour suppressor genes RASSF1A and HIC1 in human 
mesenchymal stem cells by recruiting DNMTs to these loci resulted in the formation of stem-like 
cells that started malignant transformation. The resulting cells showed genome-wide changes in 
DNA methylation and altered TP53 function and DNMT inhibitors were able to reverse this 
phenotype. Thus, this is a direct demonstration that aberrant DNA methylation can directly lead to 
tumourigenesis. It is, however, still unknown if the DNA methylation, or other epigenetic 
mechanisms, is indeed employed for initiating tumours in vivo as the majority of experimental 
evidence is correlative in nature. 
 
3.1.2  Glioblastoma multiform consists of heterogeneous cell types 
Among primary adult brain tumours, glioblastoma multiform (GBM) (grade IV astrocytoma) is the 
most common and severe form [40] with a median survival time of only 15 months [41]. Efforts 
have been made to characterise GBM and the genetic aberrations and disrupted signalling pathways 
have been identified [42, 43]. However, individual tumours contain varying proportions of different 
cell types including both differentiated cells and ill-defined anaplastic cells. Thus, it is uncertain 
how these findings operate in different cell types. It also remains unclear how tumours are initiated 
and maintained.   
 
3.1.3  Cancer stem cells are stem-like cells within tumour that can initiate a tumour 
Among various cell types, a small population (0.01-1%) of stem-like cells within the tumour that 
exhibit self-renewing and differentiation capacity are called cancer stem cells (CSCs). The cancer 
stem cell hypothesis proposes that a tumour arises from these CSCs, as demonstrated for leukemia 
[44] for the first time. Analogous to normal stem cells differentiating into various committed cells, 
these stem-like cells are thought to give rise to a heterogeneous population of cells that constitute 
hierarchy of tumorigenic stem-like cells and their differentiated non-tumorigenic progeny. 
Therefore, CSCs are also called tumour initiating cells. CSCs in brain cancer were first isolated 
from adult- and child brain tumours using an NS marker CD133 [45, 46] and they were able to 
reproduce the brain tumour upon xenotransplantation [47]. The origin of brain tumour stem cells is 
unclear, and requires more investigations. They may arise via transformation of bone fide adult stem 
cells, committed progenitors or through de-differentiation of mature cells [48]. Since both normal 
stem cells and CSCs have the ability to differentiate into functional cells, terminally differentiating 
CSCs may suppress tumour development and malignant properties which often arise in later stages 
of cancer, possibly driven by epigenetic mechanisms [49]. Regardless of the cell of origin of the 
tumour initiating cells, it is imperative that we understand their biology in order to selectively target 
them. Thus, it is now an important goal in the field to identify proteins that are easily accessible for 
external stimuli, such as in the plasma membrane or extracellular matrix, as these are tractable 
therapeutic targets compared to intrinsic regulators such as transcription factors. 
 
3.1.4  Serum culture and neurosphere culture for CSCs have been widely used but have some 
limitations 
Since CSCs drive tumour growths, it is more accurate to study specifically these cells rather than 
the entire heterogeneous population of a primary tumour. Because CSCs often represent a 
subpopulation of the tumour bulk, screening studies such as compound screening and omics 
analyses necessitate efficient derivation and propagation of these cells. Historically, investigators 
have made use of serum culture media to try and propagate GBMs in derivation of ‘classic’ cell 
lines such as U87. However, these cellular models do not provide a realistic model of the disease, 
primarily because serum irreversibly differentiates CSCs and resultant cells no longer have the 
capacity to form a tumour again when transplanted into immunosuppressed mice [3, 50]. In 
addition, repetitive passaging results in accumulation of extensive in vitro acquired de novo 
mutations [3]. It is likely the high levels of BMPs within serum are what drive differentiation of 
primary tumour cultures and restrict their expansion. To circumvent these problems, the serum-free 
neural stem cell culture conditions, such as the neurosphere culture methods, have been used for 
enrichment of brain tumour stem cells [45, 46, 50-52]. Neural stem/progenitor cells float in 
suspension culture in a serum-free media containing necessary growth factors, namely EGF and 
FGF. Though neurosphere culture has been successful in maintaining tumourigenic capacity of the 
tumour stem cells, there are some important limitations. The cultured cells can contain not only true 
stem cells but also partially-committed progenitor cells and even differentiated cells due to 
spontaneous differentiation and apoptosis [53-55]. The resultant sphere aggregation of different cell 
types provides a hurdle for meaningful population level analyses such as monitoring of stem cell 
behaviour and marker expression and omics studies. Furthermore, the cells in these spheres are 
unequally exposed to agents applied to the cells (growth factors, drugs, transfection reagents, etc.), 
limiting the rigorousness of these experiments.  
 
3.1.5  Adherent monolayer culture enables expansion of pure normal- and glioma stem cells 
To overcome these shortcomings of neurosphere culture, Pollard et al. [4] using the ‘NS cell’ 
culturing methodology reported in [56-58] derived a panel of adherent monolayer cell cultures of 
human glioma cells that display stem cell characteristics, which they termed the glioma neural stem 
(GNS) cells. Adherent monolayer culture employs laminin to attach stem cells to the surface of the 
flask, thereby reducing aggregation and detachment, facilitating expansion and propagation of a 
highly homogeneous stem cell populations. It also allows cells' uniform access to media, restricting 
the spontaneous differentiation and cell death that accompany the three dimension culture of 
neurospheres. The NSs were derived from human foetuses since adult NSs are difficult to obtain for 
ethical reasons, while the GNSs were derived from adult patients. The GNSs are tumour initiating 
upon intracranial transplantation into immunocompromised mice (NOD/SCID) using as few as 100 
cells, whereas NSs never generated tumours even using 100,000 cells [4]. Furthermore, different 
GNS cell lines fall into different phenotypic classes which expressed different molecular markers of 
distinct stem and progenitor subtypes and correlate with cell-of-origin (personal communication 
with S.P.).  
 
3.1.6  Auto-/Paracrine factors in microenvironment regulate stem- and cancer cells 
It has been recognized that stem cells of various tissues are tightly regulated by the immediate 
microenvironment, or stem cell niche [59]. Though stem cell niches manifest themselves in diverse 
forms, their critical function is to provide extrinsic cues that sustain stem cell self-renewal. This can 
either be specific growth factors or signalling molecules, but also specific forms of extracelluar 
matrix (ECM). For instance, GBM secretome has been demonstrated to aid in the invasiveness of 
this tumour [61]. Glioma stem cells have been shown to secrete VEGF that directly supports the 
development of the local vasculature [60, 62]. It has recently been prposed that glioma stem cells 
can also directly contribute to the microvasculature through their transdifferentiation into vascular 
cells [63, 64], although the efficiency with which this occurs is low. Furthermore, endothelial cells 
secrete nitric oxide that induces Notch signalling in glioma cells [65] and only glioma stem cells, 
but not glioma non-stem cells, were dependent on nitric oxide synthase-2 [66]. Thus, glioblastoma 
stem cells are known to be regulated by factors secreted by the surrounding microenvironment, 
however, whether secreted factors from glioma cells could help normal cells turn into a malignant 
state remains elusive. Venugopal et al [67] showed using the neurosphere culture that GBM 
secretome was able to transiently enhance proliferation of normal neural progenitor cells (NPCs) 
and these NPCs acquired glioblastoma stem cell-like properties such as increased CD133, ALDH 
and IGFBP7 expressions and decreased differentiation. Growth factors such as EGF, VEGF and 
PDGF and their cognate receptors were also found to be up-regulated in these GBM secretome-
treated NPCs. However, their mass spectrometry analysis of the GBM secretome could not 
definitively identify critical signalling factors. When these GBM secretome-treated NPCs were 
reverted back to normal conditions for seven days, their neoplastic properties disappeared. Thus, it 
is still uncertain whether prolonged exposure to GBM-secretome can epigenetically reset NS cells 
to acquire tumour specific disruptions that subsequently enable transformation. 
 
3.1.7  Objectives 
In the current study we have three objectives. First, we aim to globally characterize the differences 
in protein expression of both total cell proteome and secreted proteome between untransformed 
foetal NSs and malignant adult GNSs. By using genetically normal NSs as the reference control, we 
aim to derive a cancer signature present in GNSs as possible causes for tumourigenesis by 
eliminating the properties related to stem cells present in both NS and GNSs. Second, we aim to 
identify surface markers that distinguish between NSs and GNSs, since proteins outside the plasma 
membrane can be more effectively targeted with drugs than those inside the cell. It is of particular 
interest to try and define cell surface molecules unique to the GNS cells, as these may be used in 
antibody based therapeutic approaches. Third, we investigate the effects of GNS-secreted factors on 
NSs. NSs can most likely be vulnerable to transformation due to their longevity and self-renewal 
capacity, the properties that GNSs also share. Three TGF-alpha family growth factors, EGF, VEGF 
and PDGF, have been shown to be over-expressed in glioma-conditioned media [67]. EGF is a 
growth factor we use to proliferate NSs in culture and VEGF has a role in angiogenesis [62]. 
However, it is still unclear whether these are the only auto-/paracrine factors mediating the entire 
process of tumourigenesis in vivo. In previous drug screening EGFR pathway inhibitors did not 
efficiently kill our GNSs, indicating that other pathways may be operating and that GNS secreted 
factors, other than EGF, VEGF and PDGF, may be involved in this process.  
 
 
 
 
 
3.2  Materials and methods 
 
3.2.1  Cell lines 
1. Total cell analysis 
The NS lines (CB660, CB192, CB152 and CTX985) were derived from human foetuses. GNS lines 
(G144, G166, G179 and G25) were derived from adult patients following local ethical board 
approval. The details on the GNS derivation is described in [4]. Briefly, tumours were dissociated 
into single cells with Accutase (Sigma) or an enzyme cocktail for 15–20 min at 37°C. For those 
tumours with excess debris, cells were initially allowed to form spheres/aggregates in suspension 
culture, and these were then transferred to a fresh laminin-coated flask.   
 
2. Secretome analysis 
For the secretome experiment, CB660, U5 and CB11130 NS lines, and G179, G144 and G7 GNS 
lines were used. 
 
3. Mouse cells 
The mouse NS line ANS4 was derived from adult mouse. The GNS line IENS was obtained from 
the NS line by removing the Ink4a/Arf locus (-/-) followed by virus over-expression of EGFRViii.  
 
3.2.2  Cell culturing 
1. Total cell analysis 
Both NS cells and GNSs cells were cultured in serum-free, Dulbecco's modified Eagle's medium 
supplemented with bovine serum albumin (Invitrogen), penicillin/streptomycin (PAA), N2 (PAA), 
B27 (PAA), EGF (Peprotech), FGF (Peprotech) and laminin (Sigma), as described previously [4, 
58]. Medium was replaced every 3–5 days. Cells were grown to 60-70 % confluency harvested and 
pelleted down. The passage numbers are 20 for CB660, 27 for CB192, 15 for CB152, 10 for 
CTX985, 28 for G144, 18 for G166, 18 for G179 and 26 for G25.  
 
2. Secretome analysis 
For stable isotope-labelled amino acid labelling (SILAC) and AHA-labelling, cells were grown to 
60-70% confluence. Then the cells were grown either in intermediate media containing 1ul/ml Lys-
4, Arg-6 and 0.2 ul/ml AHA, or in heavy media containing 1ul/ml Lys-6, Arg-10 and 0.2 ul/ml 
AHA. Supernatant was collected after 24 hours and centrifuged at 4000 RPM for 10 min and the 
supernatant was collected for LS-MS/MS. The viability of the cells after AHA incorporation was 
assessed with ViCellar. The passage numbers are 10 for CB660, 10 for U5, 14 for CB11130, 40 for 
G144, 31 for G166 and 30 for G7.  
 
3. Colony forming assay 
For NS/GNS cell colony-forming assays, 1000 cells were plated on a 10 cm dish filled with 10 ml 
of culturing media. Factors of interest were added to the media at the same time. When conditioned 
media was added, 5 ml of the culturing media and 5 ml of the conditioned media were mixed to 
make the dilution 1:1. The number of colonies was counted 7-10 days later, depending on the 
growth speed. The colony count was normalized to the +EGF/FGF control. The number of cells 
within each colony was not taken into account. 
 
3.2.3  Peptide sample preparation 
1. Total cell 
The cell pellets were homogenized in RapiGest (Waters) followed by reduction of disulphide bonds 
using 100 mM dithiothreitol (DTT), alkylation using 100 mM iodoacetic acid (IAA) and protein 
digestion using sequencing grade modified trypsine (Promega) overnight at 37°C. Peptides were 
stable isotope-labelled via reductive dimethylation, as described in [69]. All NS lines were 
combined to form a common reference, to which each individual GNS cell line was compared. 
These samples are named NSpool-G166, NSpool-G144, NSpool-G25 and NSpool-G179. A 
common GNS cell line pool was also made and compared to the NS pool (NSpool-GNSpool). This 
sample was only used for increasing peptide identifications during the “match between runs” 
process in MaxQuant (see below). Reverse labelling was performed on an aliquot of each of these 
samples. Peptides fractionated into 12 fractions on Agilent 3100 OFFGEL Fractionator (settings as 
described by the manufacturer) using Immobiline DryStrips (pH 3‐10 NL, 13 cm, GE Healthcare). 
Dried samples were resuspended in 360 ml H2O and diluted into 1.44 ml 1.25 x IEF stock solution 
(6% glycerol, 2% Ampholytes pH 3‐10 (1:50)). Focusing was performed at a constant current of 
50 mA with a maximum voltage of 8,000 V until 20 kVh. Then peptides were acidified, desalted 
with C18 StageTips (Empore 3M) [31], and reconstituted with 4% acetonitrile in 0.1% formic acid.  
 
2. Secretome analysis 
8 ml of each cell supernatant was filtered using Amicon Ultra Centrifugal Filters (3-kDa cutoff) to 
the end volume of ~250 µL. The proteins in this concentrated media were enriched using the Click-
iT Protein Enrichment Kit (Invitrogen C10416) and applying the vendor’s protocol with slight 
modifications; 100 µl of agarose resin slurry was used and the volume of all the reagents was 
halved. After washing the resin with 900 µL water, the concentrated media was diluted in 250 µL 
urea buffer, to which the catalyst solution was added and incubated for 16–20 h at room 
temperatures. Then the resin was washed with 900 µL water, and 0.5 mL SDS buffer and 0.5 µL 1 
M dithiothreitol (DTT) (Bio-Rad) were added to the resin and vortexed at 70 °C for 15 min. The 
supernatant was aspirated and 3.7 mg iodoacetamide (IAA) (Bio-Rad) was added and incubated for 
30 min in the dark. The resin was transferred to a spin column and washed with 20 mL of SDS 
buffer, 20 mL of 8 M urea in 100 mM Tris pH 8, 20 mL 20% isopropanol and 20 mL 20% 
acetonitrile. After dissolving the resin in the digestion buffer (100 mM Tris, pH 8, 2 mM CaCl2 and 
10% acetonitrile), 0.5 µg trypsin (Promega) was added and incubated overnight at 37 °C. The 
peptide solution was collected and the resin was washed with 500 µL water. Both solutions were 
combined and acidified with 20 µL 10% CF3COOH. Peptides fractionated into 12 fractions on 
Agilent 3100 OFFGEL Fractionator was performed, as described above (Section 1). IEF fractions 1 
and 3, 4 and 5, 6 and 9, 7, 8 and 12, 10 and 11 were combined prior to LS-MS/MS. 
 
3.2.4  Liquid chromatography-tandem MS (LC-MS/MS) 
Peptides were analysed by LC coupled to an LTQ Orbitrap Velos (Thermo Fisher Scientific) using a 
Proxeon nanospray source. Reverse phase chromatography was performed with a nanoACQUITY 
UltraPerformance LC system (Waters) fitted with a trapping column (nanoAcquity Symmetry C18, 
5 μm, 180 μm x 20 mm) and an analytical column (nanoAcquity BEH C18, 1.7 μm, 75 μm x 200 
mm) directly coupled to the ion source. The mobile phases for LC separation were 0.1% (v/v) 
formic acid in LC-MS grade water (solvent A) and 0.1% (v/v) formic acid in can (solvent B). 
Peptides were separated at a constant flow rate of 300 nl/min with a 3 to 40% solvent B gradient for 
145 min for each IEF fraction. The MS1 scan was acquired in the Orbitrap from m/z 300 to 1,700 at 
a maximum filling time of 500 ms and 106 ions. The resolution was set to 30,000. Fragmentation 
was performed in the LTQ by collision induced dissociation, selecting up to 15 most intense ions 
(top15) at an isolation window of 2 Da, unless stated otherwise. Target ions previously selected for 
fragmentation were dynamically excluded for 30s with relative mass window of 10 ppm. MS/MS 
selection threshold was set to 2,000 ion counts. A lock mass correction was applied using a 
background ion (m/z 445.12003).  
 
3.2.5  Data processing  
Raw files were processed with MaxQuant [22] version (1.2.0.17) and the Andromeda search engine 
[12]. The MS/MS spectra were searched against the database containing the forward and reverse 
Human SwissProt databases and common contaminants. The precursor mass tolerance was set to 20 
ppm for the first pass and 6 ppm for the 2
nd
 pass. The fragment mass tolerance was 0.5 Da. 
Quantification was done by DimethylLys0 + DimethylNter0 for the light labelling and 
DimethylLys4 + DimethylNter4 for the intermediate labelling. Unique- and razor peptides were 
used for quantification, using only unmodified peptides without discarding unmodified counterpart 
peptides. Cysteine-carbamidomethylation and methionine-oxidation were set for the fixed 
modification and variable modification, respectively. The minimum peptide length was set to 6, the 
maximum allowed miss-cleavage was 2 and the false discovery rate (FDR) was set to 0.01 for both 
peptide and protein identifications. Re-quantification, match between runs, and intensity based 
absolute quantification (iBAQ) were also performed. After MaxQuant processing, reverse and 
contaminant proteins and proteins with only one peptide identification were discarded. MaxQuant-
computed raw protein ratios were normalized with median and median absolute deviation (MAD) 
using the following scheme: 
     
X j  = 
X j− median
MAD  
where 
X j  is a raw protein ratio.  
 
3.2.6  Significance test for differential expression (DE) 
Significance test for DE protein groups was performed using the limma R package [70]. As limma 
assumes independent sample variances, the NSpool-GNSpool sample was not used for this analysis. 
Since the dependence of ratio variance on the intensity was observed, data was split into intensity 
bins with each containing 300 protein groups and significance test was applied to each bin. Multiple 
hypothesis testing correction was done with Benjamini-Hochberg FDR threshold of 0.05. 
Subsequently, protein groups with expression value less than 2-fold were discarded. For the 
secretome analysis, the fold-change filter was not applied. 
 Cell line-specific DE protein groups were defined as 1) those that were quantified at least in 
three out of the four cell lines including the cell line in question, and 2) those that had expression 
values less than +-2-fold in the cell line in question but more than 4-fold in the other three cell lines, 
or those that had expression values more than +-4-fold in the cell line in question but less than 2-
fold in the other three cell lines  in the reverse expression direction. 
 
3.2.7  Prediction of secreted proteins 
Computational prediction of secreted proteins was performed using SignalP 
(http://www.cbs.dtu.dk/services/SignalP/), UniProt keywords (http://www.uniprot.org/) “Signal”, 
“Secreted” and “Extracellular space”. If a protein is positive at least in one of these four criteria, 
that protein is considered secreted. 
 
3.2.8  Gene set enrichment analysis 
In each of the two experiments the DE proteins were subjected to a Fisher's exact test for 
chromosomes, Panther pathway [71], OMIM (http://omim.org/), CORUM [72], Gene Ontology 
Biological Processes (GO.BP) (http://www.geneontology.org/), Reactome Pathway [73], embryonic 
stem (ES) cell-signature gene sets [74], Signalling Pathway Impact Analysis [75] and Molecular 
signature database [76]. Multiple test correction was done with Benjamini-Hochberg correction.  
 
3.2.9  Transcriptome data 
The tag-seq data was obtained from [77] and processed the same way. Glioblastoma microarray 
data, survival information and other related metadata were retrieved from The Cancer Genome 
Atlas (TCGA) and processed as described in [77].  
 
3.2.10  Transcription factor annotation and their target genes 
The “transcription factor” annotation was retrieved from Panther, MetaCore and UniProtKB. 
Transcription targets were retrieved from MetaCore (by Thomson Reuters) using “search for genes 
that transcriptionally directly interact downstream with the protein of interest” in Meta search 
programme.  
 
3.2.11  Immunocytochemistry 
Cells were fixed in 4% paraformaldehye (PFA) for 8 min and then washed/permeabilised using 
wash buffer (1× PBS+0.1% Triton-X 100). Blocking was carried out for 1 h using a blocking 
solution (wash buffer plus 3% goat serum and 1% BSA). Primary antibodies were incubated 
overnight at 4 °C at the appropriate dilution in blocking solution. Excess primary antibody was 
washed for 5 min (2 times) and then 15 min (2 times) and secondary antibodies were incubated for 
at least 1 h at room temperatures before another round of washing. Images were taken using an 
Olympus IX50 inverted fluorescent microscope with a DP-50 camera. DAPI was used as a nuclear 
counterstain. Primary antibodies used were: Tenascin-C (1:100, Sigma), Galectin-3 (1:100, abcam), 
THY1 (1:100, Millipore), CD9 (1:100, Millipore), TES (1:100, SigmaAb1), mouse Nestin (1:10, 
DSHB), human Nestin (1:500, R&D) and KI67 (1:1000, Labvision). Species-specific or Ig-subtype 
specific goat secondary antibodies were used throughout with either Alexa488 or Alexa594 
fluorophores (Molecular Probes/Invitrogen).  
 
3.2.12  Time lapse imaging and growth factor screening 
For time-lapse imaging and generation of growth curves, we used the Incucyte system (Essen 
Instruments, USA). Cells were plated at 5%–30% confluence on 12-well plates (Falcon) in the 
standard culturing media, incubated for 1 day and then factors were added to the wells. Confluence 
readings were obtained at each time point. CellProfiler (http://www.cellprofiler.org/) was used to 
count the number of cells. The parameters used were; typical diameter of objects between 13 and 70 
pixels, the three-class Otsu-Adaptive threshold method, clumped objects distinguished by shape and 
divided by intensity. The default settings were used for the other parameters. For cell tracking 
analysis, we processed image stacks using ImageJ and analyzed cell tracks using the MTrackJ 
Plugin (http://rsb.info.nih.gov/ij/). The factors used for screening were; Tenascin-C (Millipore), 
Midkine (PeproTech), CNTF (PeproTech), APOE3 (PeproTech), IGFBP3 (PeproTech), IGFBP4 
(PeproTech) and CSF1 (PeproTech).  
 
 
3.3  Results 
 
3.3.1  446 protein groups were differentially expressed in total cell proteomes of GNS and NS 
cells 
The total proteomes of four GNS lines (G166, G144, G25 and G179) were compared to the 
reference pool of NS cells (containing CB660, CB192, CB152 and CTX985) in a total of 120 LC-
MS/MS runs. 7476 protein groups were quantified across the five total cell samples with two label-
swapped technical replicates, each with a complete overlap of 6492 proteins (Table 3-1). The mean 
number of unique peptide identifications for each protein group was 11, and the mean sequence 
coverage was 17%. The mean sample correlation coefficient based on protein groups present in all 
the samples was 0.38. A significance test yielded 743 DE proteins, 719 of which were present in all 
the four GNS samples. The proteins with less than 2-fold change were discarded, leaving 464 DE 
protein groups, 446 proteins of which were found in all the four samples. 152 of the 446 proteins 
were up-regulated and 294 were down-regulated (Figure 3-1). These DE proteins were used in the 
subsequent analyses.  
 
Table 3-1. Number of quantified protein groups in total cell experiment. Differential expression was defined 
as adjusted p-value <=0.05 and absolute log2(mean fold change) >= 1 (Up1 and Down1), and as adjusted p-
value <=0.05 and absolute log2(fold change of each sample) >= 1 (Up2 and Down2). Complete overlap 
indicates number of proteins quantified in all the four samples. *NSpool-GNSpool was not used for the 
significance test since its variance is not independent of the other samples.   
 
 
 
 
 
 
 
Sample Quantified DE Up1 Down1 Up2 Down2
*CBall – Gall 7064    - - - - -
CBall – G166 6765 461 167 294 166 292
CBall – G144 7215 455 161 294 161 291
CBall – G25 6891 459 164 295 164 295
CBall – G179 7068 463 168 295 168 292
Complete overlap 6290 446 155 294 155 294
Total 7476 464 166 295 166 295
  
 
 
 
 
 
 
 
 
 
 
Figure 3-1. Volcano plot of protein ratios of total cell experiments. Red dots are DE proteins.   
 
3.3.2  Galectin-3, Galectin-3-binding protein, L1CAM, GFAP were over-expressed, while 
integrin α6 and ALDH2 were under-expressed in our GNSs 
Several glioma stem cell markers have been identified and used previously, the expression of which 
we examined across the four GNS cell lines used here. Candidate markers include CD133 
(Prominin 1), CD44, CD15, L1CAM, A2B5, SSEA-1, Nestin, SOX2, MELK, CXCR4, Olig2, 
LGALS3 (galectin-3), LGALS3BP (galectin-3-binding protein), Musahi-1, BMI-1, ITGA6 (integrin 
α6), podoplanin, ALDH2 [78, 79]. The expression of TBR2, DLX2 as markers for transiently-
amplifying cells and GFAP as a marker for astrocytes was also checked. The result showed that 
LGALS3, LGALS3BP, L1CAM and GFAP were differentially over-expressed, while ITGA6 and 
ALDH2 were under-expressed in GNSs (Figure 3-2). All the others were either not DE or not 
identified in this analysis. The pluripotency factors Nanog, OCT4 and KLF4 were not identified and 
SOX2 was not DE. None of the epithelial (CDH1) and mesenchymal markers (CDH3, VIM, FN1, 
Zeb2, FOXC2, SNAIL1, SNAIL2, TWIST1 and TWIST2) were DE (data not shown). 
 LGALS3 is an adult astrocyte stem cell marker [80] known to have many functions; one of 
them may promote cell migration that was induced by CSPG4 via α3β1 integrin [81]. Wei et al [82] 
found that the GBM-initiating cells markedly inhibited T-cell proliferation and activation, induced 
regulatory T cells and triggered T-cell apoptosis that was mediated by B7H1 (CD274?) and soluble 
LGALS3. These immunosuppressive properties were diminished on altering the differentiation of 
the GBM-initiating cells, suggesting the role of LGALS3 in immunosurveillance evasion. 
LGALS3BP was also up-regulated in our GNSs. It is an ECM protein that can bind to LGALS3 and 
several other proteins [83] and may promote cell adhesion [84]. L1CAM (neural cell adhesion 
molecule L1) is a neuronal cell adhesion molecule. Cheng et al. [85] has shown that the DNA 
damage checkpoint response and radioresistance of GNSs is regulated in part by L1CAM through 
the activation of the ATM kinase pathway. The L1CAM expression patterns was similar to a stem 
cell marker CD133 [86-90], and was required for maintaining the growth and survival of CD133+ 
glioma cells both in vitro and in vivo [91]. CD133 is a five transmembrane glycoprotein whose 
function is still largely unknown. Although it has been used to isolate brain tumour stem cells from 
different brain tumours [46, 47], it was identified only in our G166 and G179 lines and not DE 
when compared to the NSs and also not on the mRNA level [77], suggesting that this marker may 
not be reliable in separating between NSs and GNSs. The absence of CD133 expression in glioma 
stem cells was also observed in Beier et al. [92] and Pollard et al. [4]. GFAP (glial fibrillary acidic 
protein) is an astrocyte marker but was also expressed in some GNS cell line [4]. Since the GFAP 
isoforms do not seem to be annotated in the uniprot database we used for the protein identification, 
it is uncertain whether GFAP α or δ/ε were over-expressed. ITGA6 (Integrin α6) is a receptor for the 
ECM protein laminin and its mRNA was highly expressed in embryonic-, neural- and 
heamatopoietic stem cells [93]. Lathia et al. [94] showed that ITGA6 was differentially up-
regulated in CD133+ glioma stem cells in comparison to CD133- glioma stem cells, and regulated 
the CD133+ population. However, in our data ITGA6 was under-expressed in GNSs. A more 
discussion about integrins is found in section (3.3.3 and 3.3.4). ALDH2 (mitochondrial aldehyde 
dehydrogenase) was also down-regulated in our GNSs. It is a detoxifying enzyme that can oxidise 
intracellular aldehydes [95] and was identified as a CSC marker in hepatocytes [96], leukemia [97], 
lung [98], head and neck [99], pancreas [100] and ovary [101]. Chute et al. [102] showed that 
inhibition of ALDH promoted heamatopoietic stem cell self-renewal via reduction of retinoic acid 
activity, implying that down-regulation of ALDH in our GNSs may be contributing to their 
increased proliferation. Indeed, a positive correlation between ALDH expression and patient 
survival was observed in many cancers [103]. In summary, several known glioma stem cell markers 
were DE between NSs and GNSs, which could be used for distinguishing both cell types. However, 
heterogeneity between GNSs cells may compromise general applicability of some markers.  
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-2  Heatmap of known NS/GNS marker expression. Colours indicate log2(fold change) of protein 
ratios. 
 
3.3.3  Gene set enrichment analysis and signalling pathway impact analysis captured known 
chromosomal aberrations and putative tumour-associated processes   
The 446 DE proteins completely overlapping across all the four comparisons were subjected to the 
GSEA and signalling pathway impact analysis [75] [75]. The result is summarized in Table 3-2. The 
over-representation of the glioma pathway (KEGG) reassures the quality of our data, as this 
pathway was expected to be disregulated and was also over-represented in the transcriptome study 
[77]. Over-representation of chromosomes 7 and 15 and under-representation of chromosome X 
were observed. Consistent with the GSEA, the protein expression of chromosome 7 appeared higher 
than the average, whereas that of chromosome 15 appeared lower in each of the cell lines (Figure 3-
3). The gain of chromosome 7 and loss of 15 were previously reported [4, 77] and the under-
representation of X is most likely due to the sample genders, where three out of the four GNS 
samples are male whereas NS samples are half male and half female. These findings suggest that 
* 
* 
* 
 
* 
* 
 
* 
chromosomal aberrations influence not only mRNA- but also protein expression levels. The over-
representation of Gene Ontology Biological Processes (GO.BP) “cell differentiation”  and “neuron 
differentiation” is in line with the hypothesis that tumourigenesis starts with a block of 
differentiation and concomitant mitotic arrest followed by uncontrolled proliferation. Although 
many DE proteins bearing “cell proliferation” categories were found in our data, the GSEA did not 
result in cell proliferation-related categories, presumably because both NS and GNS cells were 
cultured in the proliferating conditions. Enrichment in GNSs of cell motility-related categories such 
as regulation of cell migration (GO.BP), cell junction organization (Reactome Pathway) and gap 
junction (KEGG) could be explained by the increased cell motility and invasive property of GNSs. 
Several integrin-related categories such as integrin signalling pathway (GO.BP, PantherPathway), 
cell-cell adhesion mediated by integrin (GO.BP), integrin-mediated cell adhesion (WikiPathway), 
integrin cell surface interactions (Reactome Pathway) were enriched. In addition, many integrin-
related protein complexes were over-represented in CORUM and Reactome Complex. Integrins are 
heterodimer cell surface receptors that consist of α and β subunits, through which the extracellular 
matrix (ECM) modulates cell behaviour including cellular shape, motility and cell cycle progression 
[104]. Interactions between the extracellular matrix and the actin cytoskeleton commonly take place 
at focal adhesions on the cell surface that contain localized concentrations of integrins, signalling 
molecules and cytoskeletal elements (http://www.biocarta.com/pathfiles/h_integrinpathway.asp). In 
agreement with this, focal adhesion (WikiPathway, SPIA), ECM-receptor interaction (KEGG), 
ECM organization (GO.BP) and cell-ECM interactions (Reactome Pathway), and several 
cytoskeleton related processes such as cytoskeletal regulation by Rho GTPase, regulation of 
cytoskeletal remodelling and cell spreading by IPP complex components (Reactome Pathway) and 
regulation of actin cytoskeleton (WikiPathway, KEGG) were over-represented, suggesting the 
importance of ECM re-organization for tumourigenesis, a property that apparently is maintained 
even in cultured cells. Among ECM interactions, the L1CAM interactions (Reactome Pathway) was 
also over-represented. Apart from the integrin signalling pathway, several signalling pathways also 
appeared in the analysis, including MAPK signalling pathway (KEGG), ERK1 activation 
(Reactome Pathway) Negative regulation of TGF-beta receptor signalling pathway (GO.BP), 
positive regulation of calcium-mediated signalling (GO.BP), response to elevated platelet cytosolic 
Ca2+ (Reactome Pathway), signalling of hepatocyte growth factor receptor (WikiPathway), GnRH 
signalling pathway (KEGG). This indicates that disregulation of these signalling pathways could be 
associated with tumouriginicity. However, the expression levels alone do not tell if these pathways 
are activated or inhibited since signalling cascades also depend on post-translational modifications 
of proteins such as phosphorylation, sub-cellular locations of the molecular players and mutations 
on amino acid residues that could disrupt protein-protein interactions. The categories such as blood 
vessel development (GO.BP), platelet activation, signalling and aggregation (Reactome Pathway) 
and VEGF signalling pathway (KEGG) strongly indicates the role of angiogensis in our GNS-
mediated tumourigenesis. Endocytosis (GO.BP) is known to digest ECM components such as 
Cadherins and its over-representation in our GNSs may suggest an enhanced microvesicle transport 
of RNA and proteins, which was previously reported in glioma cells [105]. 
Taken together, our enrichment analyses captured known chromosomal aberrations and 
many biological pathways and processes that could be responsible for the malignancy. However, it 
is hard to tell from an enrichment analysis which of these enriched categories are the actual 
“drivers” for the tumouriginicity and which are just “bystanders”. It should also be noted that a 
single protein may be present in multiple processes and it is difficult to distinguish between the 
effects of that particular protein on different pathways. Thus, we looked into further details on the 
DE proteins.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-3.  log2(Protein ratios) (blue dots) as a function of chromosomal locations. Solid black line is a 
moving average of 10 ratios. Chromosome number is indicated on top. 
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Table 3-2 A  Selected categories enriched by DE proteins in chromosomes, OMIM, Gene Ontology, Panther 
Pathway, Reactome, WikiPathway, InterPro and CORUM. Annotation: total number of genes in category, DE 
genes: number of differentially expressed genes, oddsRatio: measure of over-representation (> 1 is over-
representation, < 1 is under-representation), padj: Fisher's exact test p-value adjusted with Benjamini 
Hochberg correction.  
 
 
Annotation DE genes oddsRatio padj
A. Chromosome
15 225 27 2.1 0.011
7 366 36 1.7 0.035
X 269 6 0.4 0.043
B. OMIM
 ESOPHAGEAL CANCER 3 3 16.8 0.023
F. GO.BP
cell differentiation 1001 97 1.8 0.000
endocytosis 176 29 2.9 0.000
neuron differentiation 444 53 2.1 0.000
response to chemical stimulus 1103 100 1.7 0.001
integrin-mediated signaling pathway 31 9 4.9 0.004
NAD metabolic process 18 7 6.6 0.004
blood vessel development 187 24 2.2 0.011
isocitrate metabolic process 6 4 11.2 0.014
regulation of cell migration 146 20 2.4 0.015
multicellular organismal signaling 242 28 2.0 0.015
response to metal ion 108 16 2.5 0.019
cell-cell adhesion mediated by integrin 7 4 9.6 0.020
negative regulation of transforming growth factor beta receptor signaling pathway 17 5 5.0 0.040
positive regulation of calcium-mediated signaling 5 3 10.1 0.045
extracellular matrix organization 65 10 2.6 0.049
C. Panther pathway
Integrin signalling pathway 113 26 4.0 0.000
Cytoskeletal regulation by Rho GTPase 45 9 3.4 0.023
D. Reactome pathway
Cell-extracellular matrix interactions 11 10 15.5 0.000
Cell junction organization 34 13 6.6 0.000
L1CAM interactions 70 16 3.9 0.000
Regulation of cytoskeletal remodeling and cell spreading by IPP complex components 5 5 16.9 0.002
Response to elevated platelet cytosolic Ca2+ 38 10 4.5 0.003
Localization of the PINCH-ILK-PARVIN complex to focal adhesions 3 4 22.5 0.004
Platelet activation, signaling and aggregation 101 16 2.7 0.008
Integrin cell surface interactions 45 10 3.8 0.009
Sema4D in semaphorin signaling 22 7 5.4 0.009
c-src mediated regulation of Cx43 function and closure of gap junctions 3 3 16.8 0.023
ERK1 activation 3 3 16.8 0.023
Phase 1 - Functionalization of compounds 11 4 6.1 0.046
E. Wikipathway
Focal Adhesion 117 18 2.6 0.006
Integrin-mediated cell adhesion 70 12 2.9 0.017
Regulation of Actin Cytoskeleton 92 14 2.6 0.020
Signaling of Hepatocyte Growth Factor Receptor 27 7 4.4 0.020
G. GO.MF
actinin binding 8 7 14.8 0.000
integrin binding 43 13 5.2 0.000
calmodulin binding 85 15 3.0 0.005
isocitrate dehydrogenase activity 5 4 13.5 0.010
DNA binding 817 29 0.6 0.021
Differentially expressed
(446 proteins)
Table 3-2 A  (continued) 
 
 
Table 3-2 B  Selected KEGG pathways from Signalling Pathway Impact Analysis of DE proteins. 
Annotation: total number of genes in category, DE genes: number of differentially expressed genes, padj: p-
value from Signalling Pathway Impact Analysis [75].  
 
Annotation DE genes oddsRatio padj
H. InterPro
Znf_LIM 40 15 6.5 1.50535991460478e-05
CH-domain 54 11 3.5 0.009
EF_HAND_2 88 14 2.7 0.015
Spectrin/alpha-actinin 19 6 5.3 0.018
Isocitrate_DH_NAD 3 3 16.8 0.023
Myosin_head_motor_dom 21 6 4.8 0.024
EF_hand_Ca-bd 57 10 3.0 0.028
ZU5 4 3 12.6 0.035
EPS15_homology 10 4 6.7 0.039
I. CORUM
40S ribosomal subunit, cytoplasmic 29 10 5.9 0.001
LRP-1-Alpha-2-M-annexin VI complex 3 4 22.5 0.004
40S ribosomal subunit, cytoplasmic 140 21 2.6 0.004
Polycystin-1 multiprotein complex (ACTN1, CDH1, SRC, JUP, VCL, CTNNB1, PXN, BCAR1, PKD1, PTK2, TLN1)9 5 9.4 0.008
ITGAV-ITGB3-COL4A3 complex 5 4 13.5 0.010
ITGAV-ITGB5-SPP1 complex 5 4 13.5 0.010
ITGAV-ITGB6 complex 3 3 16.8 0.023
ITGA11-ITGB1 complex 3 3 16.8 0.023
ITGAV-ITGB3-SPP1 complex 4 3 12.6 0.035
ITGAV-ITGB3-ADAM15 complex 5 3 10.1 0.045
ITGA9-ITGB1-FIGF complex 1 2 33.6 0.050
J. Reactome complex
Alpha 11 beta 1 integrin: Collagen type-I:Mg++ complex [plasma membrane] 4 4 16.9 0.006
L1:Integrin complex [plasma membrane] 4 4 16.9 0.006
Integrin alpha2beta1:Collagen I:Mg++ [plasma membrane] 4 4 16.9 0.006
Cx43:ZO-1:c-src hemi-channel [plasma membrane] 3 3 16.8 0.023
phospho-Y265 Cx43:ZO-1 gap junction [plasma membrane] 3 3 16.8 0.023
Cx43:ZO-1:c-src gap junction [plasma membrane] 3 3 16.8 0.023
PINCH-ILK-parvin complex [cytosol] 3 3 16.8 0.023
IDH3 complex [mitochondrial matrix] 3 3 16.8 0.023
Docked Cx43-containing transport vesicles [plasma membrane] 10 4 6.7 0.039
connexons in Golgi transport vesicle docked to microtubules [cytosol] 10 4 6.7 0.039
Calcium Bound Sarcomere Protein Complex [cytosol] 10 4 6.7 0.039
ADP:Calcium Bound Sarcomere Protein Complex [cytosol] 10 4 6.7 0.039
Inactive Sarcomere Protein Complex [cytosol] 10 4 6.7 0.039
ATP:Calcium Bound Sarcomere Protein Complex [cytosol] 10 4 6.7 0.039
Differentially expressed
(446 proteins)
Pathway Annotation DE genes padj Predicted status in GNS lines
Focal adhesion 130 24 0.000 Inhibited
Gap junction 53 14 0.001 Inhibited
Regulation of actin cytoskeleton 132 23 0.001 Inhibited
MAPK signaling pathway 127 15 0.017 Inhibited
Leukocyte transendothelial migration 52 9 0.043 Activated
GnRH signaling pathway 52 8 0.044 Inhibited
Glutamatergic synapse 53 7 0.044 Inhibited
VEGF signaling pathway 43 7 0.045 Inhibited
ECM-receptor interaction 52 9 0.066 Activated
Glioma 44 6 0.080 Inhibited
Dopaminergic synapse 69 11 0.080 Inhibited
Long-term potentiation 42 8 0.086 Inhibited
3.3.4  Differentially expressed proteins in Gene Ontology Biological Process “neuron 
differentiation” physically and transcriptionally interact with each other and some of them have 
no prior association with glioma 
Given the hypothesis that a disrupted balance between self-renewal and differentiation initiates 
tumourigenesis, we more closely looked at the DE proteins in Gene Ontology Biological Process 
(GO.BP) neuron differentiation. The direct interaction (physical interaction and transcriptional 
regulation) among these DE proteins retrieved from MetaCore displayed a highly interconnected 
network (Figure 3-4), underlying the importance of this process to GNS malignancy. We 
investigated their prior tumour associations to tumour development (Table 3-3). Several integrins 
(αV, α6, β1) were present among these DE proteins belonging to GO.BP neuron differentiation. 
Since integrins are obligate heterodimers, these integrins likely form a complex and play a role in 
distinguishing between normal NSs and GNSs. In breast cancer integrin α6β1 and neuropilin-2 
regulate the formation of focal adhesions [106]. Integrin α6 was discussed in section (3.3.2). 
Integrin beta-1 (ITGB1) is a heterodimeric receptor involved in cell-matrix and cell-cell adhesion, 
and has been implicated to play a crucial role in the maintenance of stemness by controlling the 
angle of cell division by interacting with astral microtubules that regulate centrosome positioning. 
Since the loss of asymmetric division could over-amplify the stem cell pool, disrupted integrin beta-
1 functionality is thought to lead to tumourigenesis [107]. In fact, many structural proteins such as 
myosins (MRCK, MYO6, MYH9, MYH11, MYH14, MYRL2), tubulins (TUBB1, TUBB2, 
TUBB3), collagens (COL1A1, COL1A2, COL1A3), GJA1, Dystrophin and SPTBN2, were also 
among the DE proteins in the GO.BP neuron differentiation category, illustrating the possible roles 
in tumourigenesis played by these proteins. Disregulated signalling pathways are likely involved in 
this process, as indicated by the presence of kinases/phosphatases (ILK, LIMK1, MAP2Ks, 
MAPKs, SRC). Other connected components include Tenascin-C (TNC) is an ECM glycoprotein 
that is abundantly expressed in foetal NSs and vanishes as the organism matures and is absent in 
normal adult brains [108] but re-expressed upon injury or neoplasia. This agrees with our data 
where TNC was over-expressed in our GNSs. Tnc is thought to enhance the sensitivity of mouse 
embryonic NSs to EGF by increasing EGFR expression [109]. It also has putative EGFR binding 
domains [110]. Mouse oligodendrocyte progenitor cells (OPCs) proliferate less but migrate faster 
within the optic nerves of Tnc-deficient mice [111] and that cultured OPCs from Tnc-deficient mice 
display higher maturation rates [112]. Thus, up-regulation of TNC may contribute to sustained 
proliferation. THY1 (CD90) is a GPI-anchored, plasmamembrane protein localized to lipid rafts 
expressed on human fibroblasts, neurons, blood stem cells, endothelial cells and murine T cells 
[113, 114]. It is also a common marker for mesenchymal stem cells, multipotent mesenchymal 
stromal cells [115] and early stages of iPS reprogramming [116]. THY1 expression correlated with 
the tumourigenic potential of hepatocellular carcinoma cell lines and was suggested as a putative 
liver CSC marker [117]. Furthermore, CD133+ glioblastoma CSCs from primary cultures showed 
high levels of THY1 mRNA and were resistant to several chemotherapeutic agents [118]. It has no 
reported association with glioma and the over-expression of THY1 in our GNSs makes it a potential 
marker for GNS cells but not for normal NSs. LZTS1 (Leucine zipper putative tumour suppressor 
1) has been shown be ubiquitously expressed in normal tissues and in uveal melanomas. The 
expression of this protein is silenced in rapidly metastasizing and metastatic tumour cells but has 
normal expression in slowly metastasizing or non-metastasizing tumour cells (RefSeq, Nov 2009). 
LZTS1 was shown to inhibit cancer cell growth through mitosis by activating CDK1 [119]. It is 
somewhat contradictory that this protein was over-expressed in GNSs, while CDK1 was under-
expressed, however, this could be due to difference in the expression of other proteins between 
somatic cancer cells and cancer stem cells as well as between different tissue types. Alternatively, 
LZTS1 might have loss-of-function mutations and constitutively activated. EPHB2 (Ephrin type-B 
receptor 2) has been implicated in many cancers and in intestinal CSCs [120]. NCAM1 (neural cell 
adhesion molecule 1) is involved in neuron-neuron adhesion, neurite fasciculation and outgrowth of 
neurites but is also known to be dis-regulated in cancers including glioma. FKBP4 (Peptidyl-prolyl 
cis-trans isomerase) belongs to the immunophilin protein family, and is involved in 
immunoregulation and protein folding and trafficking. To our knowledge, no prior association with 
glioma has been reported.  
 Other “non-connected” components include CD166 antigen (ALCAM), which belongs to 
the Single-pass type 1 membrane protein that was shown to regulate long-term HSCs [121]. It is a 
plasma membrane protein that interacts homophilically and heterophilically with L1/NgCAM and 
CD6 [122-125]. ALCAM has been shown to be involved in neuronal cell adhesion [122], axon 
growth and navigation [125], migration [126] and differentiation [127]. ALCAM is selectively 
present on neurons carrying an axon and not found on neuroblasts or non-neuronal cells, however, 
its down-regulation in our GNSs may indicate an ALCAM's role in tumourigenesis. Taken together, 
DE proteins in GO.BP neuron differentiation appear to directly/transcriptionally interact with each 
other to a large degree, suggesting that these DE proteins are likely disrupting the neuron 
differentiation in our GNSs. In addition, we highlighted those that have known associations with 
glioma and those that do not. The latter can be novel candidates for glioma tumourigenesis.  
 
Table 3-3  Differentially expressed proteins belonging to GO.BP neuron differentiation. Mean ratio: mean 
ratios over four protein samples. 'Association with glioma'  and 'Association with other cancer' columns 
indicate PubMed IDs for pertinent reference. 'many' is put when > 5 references were found.  
 
Chromosome Gene name Log2(mean ratio)
Association 
with glioma
Association with 
other cancer
3 ALCAM -1.5 18941255 many
4 ANK2 -2.4 - 21042036
1 CAP1 -1.0 - -
6 CAP2 -1.6 - -
16 CBFB -0.9 - 23160462, 22160378
10 CDK1 -1.4 many many
17 COL1A1 -3.7 21072323 many
7 COL1A2 1.3 21325292, 18664619 many
2 COL3A1 -4.0 - -
X DMD -1.8 many many
10 DOCK1 -2.0
22323579, 22080864, 
17671188 many
7 EGFR -1.3 many many
1 EPHB2 -2.7 many many
10 FGFR2 -2.6 many many
12 FKBP4 1.3 - many
17 GFAP 4.8 many many
6 GJA1 -2.1
22230665, 22131169, 
20512920 many
2 GPC1 1.5 18417614
21996748, 18064304, 
17016645, 18064304
5 GPRIN1 2.4 - -
11 ILK -1.6 many many
2 ITGA6 -1.0 many many
2 ITGAV -1.3 many many
10 ITGB1 -1.0 many many
X L1CAM 2.8 many many
7 LIMK1 1.8 - many
8 LZTS1 2.5 - many
15 MAP2K1 -1.5 many many
19 MAP2K2 -0.4 many many
22 MAPK1 -0.7 many many
16 MAPK3 -1.2 many many
16 MYH11 -2.1 - many
19 MYH14 -2.6 - -
22 MYH9 -1.9 - many
20 MYL9 -4.8 -
22898599, 21139803, 
20818426, 20551518, 
19198601, 17341888
6 MYO6 -1.5 - 20353999, 18543251
11 NCAM1 1.5 many many
15 NEDD4 -1.6
22217575, 20332230, 
18539596 many
15 NPTN -1.5 - 22586443, 18568347
2 NRXN1 -2.4 - 23236287
4 PDLIM5 -2.1 16549780 22392539, 22454401
1 PHGDH -1.4 19089318, 23229761 many
11 PICALM -1.3 - many
1 PPT1 1.1 - many
13 RAP2A -1.4 23093786, 23093778 many
19 RRAS -1.2 - many
2 SERPINE2 -3.3
8940166, 10037469, 
11814314 many
Table 3-3  (continued) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-4. Differentially expressed (DE) proteins belonging to GO.BP neuron differentiation in MetaCore 
direct interaction. 
 
3.3.5  Among 36 DE transcription factors/regulators, several had little prior associations with 
glioma and could be novel genes for further study   
In our data we identified 36 transcription factors that were differentially expressed between GNS 
and NS cells, 19 of which were up-regulated and 17 down-regulated (Figure 3-5). 16 of them are 
known to have direct transcriptional target genes, ranging from many hundreds for TP53 and NFIC 
Chromosome Gene Symbol log2(mean ratio)
Association 
with glioma
Association 
with neoplasia
5 SLC1A3 -1.8 many many
11 SPTBN2 1.3 - -
20 SRC many many
1 SRGAP2 -2.0 - -
11 THY1 2.5 16354539 many
9 TNC 1.1 many many
20 TUBB1 21807073 many
6 TUBB2A -1.0 21807073 many
16 TUBB3 1.1 21807073 many
1 UBE4B -1.3 - many
to a few dozens or less for most of the others (Table 3-4). Furthermore, eight of them have been 
implicated in glioma while others have been associated with other cancers. FOXO3 (Forkhead box 
protein O3) was up-regulated in GNSs and had 238 known targets. It is a transcriptional activator 
that is known to trigger apoptosis in the absence of survival factors such as IGF1 [128-130] by 
causing oxidative stress in neuronal cells [131]. Notably, it is regulated by FOXG1 [132] and TP53 
[133]. FOXG1 is a key transcription factor that is expressed in non-quiescent forebrain progenitor 
cells during development and into adulthood [134, 135], involved in the regulation of self-renewal 
[136] and a reprogramming factor from MEF to NPCs [137]. FOXG1 was over-expressed in GNSs 
on the mRNA level [77] (not identified in our proteomics data), suggesting that these two proteins 
may play important roles in maintenance of tumourigenicity. TP53 is a well-known tumour-
suppressor gene (TSG) with numerous target genes. Its up-regulation in our GNSs may seem 
contradictory, although it is not uncommon that this protein undergoes loss-of-function mutations 
resulting in constitutive activation. So we assume, without proof, that this protein is probably not 
functioning in our GNSs. NFIC (nuclear factor 1 C-type) was up-regulated in GNSs and had 621 
known direct transcriptional targets. Being a member of nuclear factor (NF) proteins, it is involved 
in driving astrocyte identity/differentiation (personal communication with S.P.). Thus, the observed 
up-regulation might be because the GNSs originated from astrocytes that de-differentiated and this 
protein was not silenced afterwards. SATB2 is a nuclear matrix attachment region (MAR) protein 
that can induce local chromatin-loop remodelling that is expressed in adult brain and to a lesser 
extent in foetal brain [138]. Our GNSs more highly expressed this protein than the NSs, due 
presumably to the difference between adult and foetal brains in our samples. HMGA2 is expressed 
predominantly during embryogenesis and was down-regulated in our GNSs and this was also the 
case on the mRNA level [77]. Low or absent mRNA expressions has also been observed in 
glioblastoma tissue in comparison to low-grade gliomas [139] and HMGA2 polymorphisms have 
been associated with mRNA-based survival time in glioblastoma [140]. Among those without 
known targets identified in our data, IGHMBP2 (immunoglobulin mu-binding protein 2) has been 
shown to be expressed in neuronal body and axon [141, 142], implicated as a ribosome-associated 
helicase [142] and was most highly expressed in our GNSs. This is in favour with the notion that 
mature neurons de-differentiated into GNSs. LZTS1 is a putative transcription factor with a leucine 
zipper domain present in the interaction network in GO.BP neuron differentiation discussed above 
(Figure 3-4). Although LZTS1 was shown to activate CDK1 by physically binding to it, it has no 
known transcriptional targets as well as no prior association with glioma (Table 3-3), suggesting 
that this protein is a novel gene for further studies in relation to glioma. Two over-expressed zinc 
finger proteins ZNF121 and ZNRF2 may be involved in the tumourigenicity but their functions are 
not well-studied. Finally, STAT3 was not among the 446 DE proteins since it did not pass our cut-
off criteria. Yet, it was consistently under-expressed in all the four GNS cell lines (average log2 fold 
change -0.98). STAT3 was implicated in maintenance of tumourigenic capacity of colon cancer 
stem cells [143] and in maintaining the stemness of glioma stem cells [144]. Since it was down-
regulated in comparison to the normal NSs, STAT3 may play a role specifically in tumourigenesis, 
rather than stem cell-related properties, in GNSs. In summary, we identified 36 transcription 
factors/regulators, eight of which have been implicated in glioma and the others are either 
associated with other cancers or without any known association.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5  Heatmap of DE transcription factors. Column names indicate GNS line. Colours indicate 
log2(fold change) of protein ratios. 
 
 
 
 
 
Table 3-4  Number of direct transcriptional target genes of 36 DE transcription factors and their associations 
with glioma and other cancer types. 'Target gene number' indicates number of known targets present in 
MetaCore. 'Identified target gene number' indicates number of targets identified in our data. 'Association 
with glioma' and 'Association with other cancer' columns indicate PubMed IDs for pertinent reference. 
'many' is put when > 5 references were found.  
 
3.3.6  The four cell lines exhibit heterogeneous protein expression patterns 
Since 1186 out of 7476 proteins were not identified in all the four samples, we investigated the 
difference among the cell lines by examining completely overlapping, DE proteins in each line (see 
Materials and methods for the definition of DE proteins in this analysis). There were 136, 110, 59 
Gene names
Target gene 
number
Identified target 
gene number
Association 
with glioma
Association with 
other cancer
IGHMBP2 2 0 - 16752224
ZNF121 0 0 - -
FOXO3 238 114 23197693, 22782899 many
SATB2 18 3 - many
LZTS1 0 0 - many
SP140L 0 0 - 20056315
TP53 1423 600 many many
TFCP2 216 96 - many
LIMD1 0 0 - many
IFI16 4 1 23387973 many
ZNRF2 0 0 - -
TSC22D4 0 0 - 23307490
NFIC 621 260 19540848 many
RABEPK 0 0 - many
SAFB2 0 0 -
19077293, 14587024, 
12660241
SUB1 4 1 - 19086899
MKL2 3 0 -
22139079, 20607705, 
1717086
AHCTF1 0 0 - -
GTF3C4 0 0 - -
CHTOP 1 0 - -
CAND1 0 0 - 23019411, 17823919
C14orf166 0 0 - 19775290, 19152423
PURA 23 9
18927497, 15517862, 
11748591 many
BTF3L4 0 0 - -
BZW1 0 0 - 19446954
PLEKHF2 0 0 - -
FHL3 0 0 - many
RQCD1 0 0 - 20878056, 19724902
MYEF2 3 0 - -
YAP1 19 9
21666501, 21267586, 
19952108, 17114655 many
DPY30 19 5 - 23508102
LMCD1 0 0 - 21996735
HMGA2 18 6
22572881, 21360625, 
20368557 many
SDPR 0 0 - 18422756, 17878531
PRKCB 0 0 10417813 many
HIC2 1 0 - 19420922, 17475218
and 79, DE proteins in G166, G144, G25 and G179 lines, respectively (Figure 3-6), showing the 
heterogeneity among them. The interpretation of this heterogeneity, however, is multitudes, ranging 
from genotypes to environmental effects.  
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Figure 3-6.  Heatmap of cell line specific DE proteins in (A) G166, (B) G144, (C) G25 and (D) G179. 
Colours indicate log2(fold change) of protein ratios. 
 
 
3.3.7  Comparison with a study by Thirant et al. [145] shows proteins whose expression patterns 
are consistent with ours 
Our data was also compared to the data by Thirant et al. [145], in which a proteomics analysis was 
conducted on four of their glioma stem cell (GSC) lines, tumour tissues (TTs) and normal NSs 
using 2D-gel electrophoresis followed by LC-MS/MS. They identified 108 proteins, 18 were over-
expressed in the GSCs, 23 in the NSs and 19 were common to the GSCs and TTs. The overlap 
between these proteins and our 446 DE proteins was evaluated; four out of 18 proteins up-regulated 
in their GSCs were overlapped, two (NNMT, YWHAG) of which were also up-regulated in our 
GNSs. Similarly, eight out of 23 proteins up-regulated in their NSs were overlapped and five 
(FABP7 (BLBP), ACTR1A, PPP2R1A, CASP3, PEA15) of them were also up-regulated in our 
NSs. Finally, seven out of 23 proteins up-regulated in their GSCs and TTs were overlapped, two 
(GANAB, TPI1) of which were also up-regulated in our GNSs. These consistently overlapping 
proteins could be good markers for distinguishing between GNSs and NSs. 
 
3.3.8  Comparison of proteomics data with transcriptome data increases the confidence of some 
DE proteins 
Since a similar comparison between GNS and NS cells was performed recently by tag-seq data [77], 
we compared this to our proteomics data. The tag-count of genes without protein identification was 
overall lower than that of genes with protein identification (Figure 3-7 A), suggesting, as expected, 
that our proteomics data is biased against low abundance proteins. By superimposing the data 
(Figure 3-7 B), 41 proteins were DE on both levels (blue dots), 207 proteins were DE only on the 
mRNA level (red dots) and 405 proteins were DE only on the protein level (green dots). This 
relatively poor overlap of DE genes may be due partly to posttranscriptional regulation of protein 
expression but perhaps also to a slightly different set of cell lines used in the two experiments. Next, 
these overlapping DE genes/proteins were further classified into six categories; 1) up-regulated on 
both levels (Figure 3-8 A), 2) down-regulated on both levels (Figure 3-8 B), 3) down-regulated on 
the protein level and up-regulated on the mRNA level (Figure 3-8 C), 4) up-regulated on the protein 
level and down-regulated on the mRNA level (Figure 3-8 D), 5) DE on the protein level and not DE 
on the mRNA level (Figure 3-8 E) and 6) DE on the mRNA level and not DE on the protein level 
(Figure 3-8 F). There were 15, 19, 5, 2, 405 and 207 proteins in these categories, resepctively. 
GFAP, THY1, NCAM1, LGALS3 and TNC fall in category 1 and HMGA2 and TES in category 2; 
these were already discussed above. NNMT (category 1) is related to radio-resistance of CSCs 
[146] and possibly conferring radio-resistance to our GNSs too. CD9 (category 1) is a tetraspanin 
found in exosomes and has been shown to be able to modulate cell migration and tumour metastasis 
[147]. TAGLN (category 2) is an actin-binding protein of the calporin family, and has been 
characterised as a tumour suppressor gene in non-brain tissues [148]. It is reasonable to assume that 
if a protein is DE both on mRNA and protein levels in the same direction, then the confidence that 
the differential expression of that protein and its influence on the cell is strong. Therefore, we 
selected LGALS3, CD9 and TES as unique candidates from this analysis for further follow-up 
studies (discussed below). Finally, since categories 5 and 6 each contained many proteins, they were 
subjected to a GSEA (Table 3-5). Several ECM and signalling-related processes were enriched 
among the proteins, whereas immunity-related categories were enriched among the mRNAs.  
 
Table 3-5.  Selected categories of GSEA on (A). genes DE in only proteins (category 5), and (B) genes DE 
in only mRNAs (category 6). 
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3.3.9  136 DE proteins were significantly related to patient survival based on public microarray 
data on glioma tissues  
A patient survival analysis was performed on the publicly available GBM and HGG data sets. 5579 
out of 20768 genes were significantly (adjusted p-value <= 0.05) associated with the patient 
survival in HGG and GBM datasets. 136 out of 5579 genes were also among the 446 DE proteins. 
This proportion was not statistically significant (p-value = 0.199). The GSEA was done on these 
139 proteins but no process was enriched. 
 
DE in only mRNA
Interferon-gamma-mediated signaling pathway
reactive oxygen species  metabolic process
antigen processing and presentation of peptide or polysaccharide antigen via MHC class II
lymphocyte activation
response to vitamin D
Ionotropic glutamate receptor pathway
Cadherin signaling pathway
MHC Class II bearing antigen peptide [plasma membrane]
Cytokine Signaling in Immune system
TCR signaling
DE in only protein
Chromosome 15
ITGAV-ITGB3 complexes
actin filament-based process
Platelet activation, signaling and aggregation
integrin-mediated signaling pathway
vesicle-mediated transport
aerobic respiration
Cell-extracellular matrix interactions
Signaling of Hepatocyte Growth Factor Receptor
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A       B 
Figure 3-7.  (A) Density distribution of tag-seq intensity of genes with corresponding protein identification 
(red) and without identification (blue). (B) Scatter plot of mRNAs (tag-seq) and protein log2 fold change.  
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Figure 3-8.  Heatmap of DE (adjusted p-value <= 0.05, mean log2(absolute fold-change) >= 1). proteins and 
mRNAs. The first four columns are protein expression on each GNS line and the last column (log2fc) is 
mean mRNA expression. Proteins and mRNAs were (A) both over-expressed, (B) both under-expressed, (C) 
under-expressed and over-expressed, respectively, and (D) over-expressed and under-expressed. (E) Proteins 
differentially expressed only on the protein level, and (F) genes differentially expressed only on mRNA 
level. 
3.3.10  167 protein groups were DE in secretome 
The secreted proteome analysis the reference NS sample (containing CB660, U5 and CB11130) and 
each GNS line (G166, G144 and G7) resulted in a total of 36 LC-MS/MS runs. The median number 
of unique peptide identifications for each protein was 5 and the median sequence coverage was 14.8 
%. The mean sample correlation coefficient based on protein groups present in all samples was 0.6. 
1718 protein groups were quantified across the three sample pairs and 595 of them were DE, and 
389 of them were predicted to be secreted based on SignalP, UniProt keywords “Signal”, “Secreted” 
and “Extracellular space” (see Materials and methods) (Table 3-6). Among the 389 protein groups 
that were predicted to be secreted, 167 were DE, 144 of them were up-regulated and 23 of them 
were down-regulated. The volcano plot also shows a bias of DE proteins towards over-expression 
(Figure 3-9), suggesting that GNSs secrete more proteins than NSs.  
 
Table 3-6. Number of quantified protein groups in total cell. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-9. Volcano plot of DE secreted proteins. 
 
Sample Quantified DE Up Down
NSall - G166 1931 666 383 283
NSall - G144 1939 673 391 282
NSal - G7 1926 679 398 281
Complete overlap 1718 595 319 276
Complete overlap, predicted secreted 389 167 144 23
Total 2093 731 448 283
3.3.11  Total cell- and secretome experiments resulted in disparate sets of DE proteins 
The overlap of quantified protein groups between the two experiments is presented in (Figure 3-10 
A). 9 % of the secretome protein groups (182) was unique to the secretome analysis. However, if 
only the DE proteins in both datasets were considered that were predicted to be secreted, the 
overlap was small (Figure 3-10 B) with only 12 protein groups in common. The overlap between 
the 182 proteins and 155 DE proteins from the secretome experiment that were predicted to be 
secreted (Figure 3-10 C) resulted in relatively a poor overlap (28 proteins). The possible reasons for 
this are that quantification of secreted proteins was not accurate in the total cell experiment, or due 
to the slightly different cell lines used between the two experiments, or due to the pulsed-SILAC 
methodology used in the secretome experiment which captures newly synthesized proteins, or the 
combination of these reasons. The Pearson correlation coefficient of the ratios of 1893 overlapping 
protein groups between total cell and secretome exepriments was 0.28 (Figure 3-10 D). The ratios 
of the 12 DE overlapping proteins appear to have a good correlation. 
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Figure 3-10.  Venn diagram showing overlap between two experiments; (A) quantified protein groups and 
(B) DE total cell protein groups and DE secretome protein groups that were predicted to be secreted. (C) 
Overlap between 182 proteins unique to secretome experiment and 167 DE secretome proteins predicted to 
be secreted. (D) Scatter plot of ratios of 1893 overlapping protein groups between total cell and secretome 
exepriments. Large red dots are 12 DE overlapping protein groups. 
3.3.12  Classification of DE secretory proteins revealed diverse functional categories including 
growth factors and cytokines and many of them did not have prior associations with glioma 
64 and 167 DE protein groups that were predicted to be secreted in the total cell experiment and in 
the secretome experiments, respectively, were functionally categorized using UniProt keywords 
(Figure 3-11). In addition, their prior associations with glioma and neural stem cells were 
investigated by PubMed search (Table 3-7). In the secretome experiment the majority of the DE 
proteins were over-expressed, whereas in the total cell experiment the categories with abundant 
proteins tended to have more under-expressed ones and more over-expressed proteins were found in 
categories with a few proteins. The four most abundant terms were the same between the two 
experiments; Receptor / membrane protein, Disease mutation, Collagen, (Extracellular matrix) and 
Cell adhesion. The high abundance of receptor / membrane proteins suggests that many of these 
proteins are shed to the extracellular space. It is also noteworthy and expected that there were 18 
proteases in the secretome experiment, while there was only three in the total cell experiment. This 
proportional discrepancy was observed only in this category. 21 proteins in total were proteases; 
A2M, APLP2, ADAM10, CTSD, LGMN, CPXM1, DPP7, TIMP1, TIMP2, CTSA, ERAP1, 
PEBP1, PLAT, CST3, C1S and C1R (over-expressed), SERP, IDE, PCSK9 and NRD1 (under-
expressed), many of them are metalloproteinases and cathepsins. ADAM10 is a metalloproteinase, 
TIMP1 and TIMP2 are metalloproteinase inhibitors, and CTSD and CTSA are cathepsins. 
Metalloproteinases and cathepsins were also found to be up-regulated in U87 glioma conditioned 
media in relation to that of other glioma cell lines LN18 and U118 [61]. CST3 (cystatin-C) is an 
inhibitor of cysteine protease, and has been shown to regulate neural stem cells [1] and glial 
development [149] and to mediate differentiation of ESs into neural stem cells [150] and into 
neuronal cell [151]. It has also been implicated in glioma [152, 153], and was over-expressed in our 
GNSs, suggesting that regulation of cysteine proteases is a factor that can differentiate between NSs 
and GNSs. Many other proteases do not have any known associations with glioma and/or neural 
stem cells (Table 3-7). There were in total 10 proteins belonging to growth factor/growth factor 
binding; MDK, PRNP, CSF1, VEGFA, IGFBP4, NOV, LTBP4 (over-expression), IGFBP3 and 
IGFBP5 (under-expression), and two cytokines; CSF1 (also a growth factor) and GRN (over-
expression). These will be further discussed below. No cadherin was differentially expressed. 
 
 
 
 
 
 
A                B 
 
Figure 3-11  UniProtKB functional annotation of DE proteins predicted to be secreted. (A) Total cell 
experiment. (B) Secretome experiment. 
 
3.3.13  Interaction between DE secreted proteins and receptors identified candidate factors 
Next, all known interactions between our DE secretory proteins (from both total cell and secretome 
experiments) and identified receptors were retrieved from MetaCore (Table 3-8). We hypothesized 
that if either a secreted protein and/or its plasma membrane receptor is DE, they may have a 
functional significance to the cell. We further narrow the list down by focusing only on those that 
belonged to UniProt keywords “Growth factor”, “Growth factor binding”, “Cytokine” and 
“Transport”. Every interaction was manually checked if they were experimentally validated via 
corresponding literatures, which resulted in APOE, GRN, IGFBP3, IGFBP4, IGFBP5, MDK, NOV, 
PRNP and VEGFA as prime candidates for further studies and discussed below. The direct 
interactions between DE secretome and GO.BP neuron differentiation was also investigated, 
however, no new interaction was identified (data now shown).  
Table 3-7  Log2(mean ratio), log10(intensity) and prior associations with glioma, neural stem cells and 
cancer of 167 DE proteins from secretome experiment that were predicted to be secreted. 'Association with 
glioma', 'Association with neural stem cell' and 'Association with other cancer' columns indicate PubMed IDs 
for pertinent references. 'many' is put when > 5 references were found.  
 
Chromosome Gene name log2(ratio) log10(intensity)
GBM survival 
Padj
Association with 
glioma
Association with 
neural stem cell
Association with 
cancer
15 ADAM10 1.13 7 0.032 many
21878106, 22466506, 
23262104 many
1 AGT 2.67 9.45 0.813 many - many
15 ANXA2 1.64 8.56 0.54
16640645, 19351187, 
21033036, 23082878, 
23195957 19351187 many
19 APLP1 1.67 8.34 0.073 - 20049903 many
11 APLP2 1.09 8.5 NA 7616233
11987239, 18717733, 
20049903 many
1 APOA1BP 1.04 7 0.533 - - 18277965
19 APOE 1.93 8.17 0.627 many 21352230 many
6 ARG1 0.83 7.16 0.631 3016193 - many
22 ARSA 1.51 6.27 0.06 15494095
16871228, 17080190, 
18667806 many
8 ASAH1 1.28 7.63 0.079 15088070 - many
20 ATRN 1.71 7.84 0.4 17085642 - many
15 B2M 1.44 8.27 0.347 10378372 20716364, 23317542 many
19 BCAM 2.57 7.63 0.327 - - many
3 BCHE 2.05 7.68 0.18 20641589 17459421 many
3 BTD 1.21 7.77 0.651 11792359 - many
12 C12orf10 -0.9 7.88 0.241 - - 20811708
17 C1QL1 2.16 7.21 0.144 - - -
12 C1R 2.12 8.12 NA - - 15988036
12 C1S 2.1 7.95 0.714 - - 15988036
8 CA2 0.98 6.8 0.437 many - many
11 CADM1 0.71 8.07 0.873 - 20871982, 21672091 many
5 CANX 1.39 7.33 0.577 17545629, 17878160 - many
HSCHR6_MHC_DBB CDSN 0.91 6.75 0.807 - - -
11 CHID1 1.43 7.83 0.185 - - -
13 CLN5 1.14 7.13 0.014 - 21235444 16955048, 19345705
1 CLSTN1 1.47 9.61 0.35 - - many
12 CLSTN3 1.8 8.45 0.091 - - 18489135
1 COL11A1 1.68 7.97 0.842 19351187, 22537279 - many
1 COPA -0.54 8.34 0.305 21365010 - many
20 CPXM1 1.5 7.21 0.009 - - -
5 CRHBP -1.64 8.28 0.452 - - -
1 CSF1 2.31 8.03 0.622 2038877 - many
20 CST3 1.88 9.06 0.716 12483523, 16153465
21417836, 1659563, 
11144350 some
20 CTSA 1.72 8.08 0.647 - - many
11 CTSD 1.36 8.58 0.068 many
7020877, 18346466, 
23365100 many
3 DAG1 1.26 8.39 0.092 many many many
11 DCHS1 0.79 6.57 NA - - -
HSCHR6_MHC_DBB DDR1 -0.6 6.82 NA
11126911, 15750623, 
16234985, 16652150, 
22879068 22008533 many
11 DKK3 1.43 9.05 0.341
18443132, 19847810, 
18033687 - many
3 DNAJB11 1.19 7.61 0.279 - - 20418907
7 DNAJB9 1.14 6.67 0.401 - - many
19 DNASE2 2.05 7.81 0.266 - - -
9 DPP7 1.53 7.25 0.079 - - 20817072
18 DSC1 0.92 7.67 0.669 16521483 - many
18 DSG1 1.03 7.96 0.342 - - many
7 EPDR1 1.53 7.61 0.126 - - 18374504, 22252855
5 ERAP1 1.79 7.54 NA - - many
12 ERP29 1.62 7.39 0.982 21667264 - many
7 FAM3C 1.44 7.83 0.133 - - many
4 FAT1 1.19 8.56 0.609 22986533 16865240 many
11 FAT3 1.47 7.62 0.715 - 21903076 many
22 FBLN1 1.25 8.95 0.964 - - many
2 FBLN7 2.28 6.43 NA - - -
20 FLRT3 2.12 7.89 0.925 - - 17091452, 17450523, 
Table 3-7 (continued 1) 
 
Chromosome Gene name log2(ratio) log10(intensity)
GBM survival 
Padj
Association with 
glioma
Association with neural 
stem cell
Association with 
cancer
13 FREM2 2.62 9 0.233 22538188 -
22538188, 20629094, 
16087869
6 FUCA2 1.37 8.03 0.047 - - 19666478
17 GAA 1.73 6.26 0.007 15170390 - many
18 GALNT1 0.85 6.9 0.033 - - many
10 GFRA1 -1.35 7.28 0.836 many many many
8 GGH 1.77 9.01 0.971 - - many
X GLA 1.51 6.9 0.737 22740420, 2540282 - many
16 GLG1 0.9 7.79 0.785 - - many
12 GNS 1.18 7.77 0.357 - - 12932876
13 GPC6 1.08 6.92 0.855 - - many
17 GRN 1.43 7.69 0.111 10728698 17179653 many
15 HEXA 1.29 8.03 0.468 - - many
5 HEXB 1.41 8.46 0.611 -
19591217, 22367451, 
23383290 many
13 HMGB1 -0.64 8.34 NA many 21527633, 23137544, many
4 HMGB2 -1.13 8.41 0.028 19240692 - many
22 HMOX1 -1.26 7.42 0.893 many many many
21 HSPA13 1.22 7.82 0.357 - - -
HG299_PATCH HYOU1 1.12 7.92 0.252 - - many
X IDS 1.56 8.12 0.997 - - many
6 IGF2R 1.55 7.82 0.511 16582634, 18562769
16037066, 21047779, 
23525019 many
7 IGFBP3 -1.84 8.73 0.603 many 21136151 many
17 IGFBP4 2.73 7.49 0.021
7683520, 12937144, 
16586492 16809006 many
2 IGFBP5 -1.05 8.55 0.629 many 19772911, 20604680 many
3 IL1RAP 1.31 7.64 0.666 - - many
20 JAG1 1.34 8.19 0.522 2229617 many many
11 JAM3 1.32 7.54 0.634 19795504 22114908 many
16 KARS -0.64 7.89 NA - - many
X L1CAM 1.36 7.32 0.027 many many many
20 LAMA5 0.92 8.61 0.028 - - 18506748
3 LAMB2 1.21 8.17 0.733 - - many
19 LDLR 1.21 8.14 0.945
17052361, 16679074, 
22586629, 22059152 10375696 many
1 LEPRE1 1.18 6.5 0.439 - - 22724020, 22955849
22 LGALS1 -1.67 8.49 0.745 many many many
14 LGALS3 1.8 7.71 0.854 many 21587270, 21693585 many
17 LGALS3BP 1.44 8.64 0.003 - - many
14 LGMN 1.46 7.73 0.968 - - 16702559, 21237226
5 LMAN2 1.3 8.12 0.638 - - 23161554
5 LOX -1.92 8.48 0.923 17931358 - many
2 LOXL3 2.1 8.17 0.381 - - many
1 LPHN2 -2.46 7.65 0.424 - - many
4 LPHN3 1.24 8.01 0.197 - - 20668451, 3317273
1 LRP8 1.21 7.12 0.433 - 22407947
15615770, 22614235, 
23142051
11 LTBP3 0.98 7.68 0.025 - - many
19 LTBP4 1.97 7.95 0.078 - - many
4 MANBA 1.77 7.87 0.654 - - 17899454
22 MAPK1 -0.55 8.37 0.024 many many many
8 MATN2 1.45 8.03 0.222 16401863 - many
11 MCAM 1.42 7.83 0.506 8616875 - many
16 METRN -1.07 7.03 0.094 -
15085178, 19130216, 
22044868 many
15 MFAP1 -1.34 7.54 0.813 - - 19377877
15 MFGE8 1.85 8.01 0.052 11085522 - many
22 MIF 0.55 8.43 0.199 many many many
1 NFASC 1.58 7.76 0.94 - - 8812479, 8921253
1 NID1 1.16 7.92 0.895 - 17569787, 21283688 many
14 NID2 2.6 8.12 0.837 21349332 - many
16 NOMO2 1.54 8.12 0.008 - - -
8 NOV 2.07 6.67 0.959
18784988, 18004727, 
17340618, 15213231, 
11577170 19286457 many
Table 3-7 (continued 2) 
 
 
 
 
 
 
 
 
 
 
 
Chromosome Gene name log2(ratio) log10(intensity)
GBM survival 
Padj
Association with 
glioma
Association with neural 
stem cell
Association with 
cancer
1 NRD1 -1.01 7.68 0.231 - - 21769958, 22653443
2 NRXN1 -1.14 7.89 0.979 - 23536886
20113834, 2323628, 
23474816
19 NUCB1 0.96 8.84 0.023 - - -
11 NUCB2 1.37 7.75 0.942 - -
12087473, 19351608, 
21988594
11 OAF 1.43 6.95 0.018 - - -
12 OS9 1.98 7.93 0.744 - - some
5 PAM 0.82 8.27 0.385 9778036 - many
13 PCDH17 1.32 7.96 0.564 - - many
13 PCDH9 1.68 7.42 0.028 2230079, 18828157 - 22150124
1 PCSK9 -1.17 7 0.3 - - many
12 PEBP1 1.82 8.93 0.943 22292035 17146836 many
8 PLAT 1.86 8.29 0.955 many many many
7 PLOD3 1.7 8.79 0.491 - -
20687567, 22559327, 
16322899
22 PLXNB2 1.2 7.27 0.392 - - -
15 PPIB 1.15 8.48 0.204 - - many
19 PRKCSH 2.06 7.51 0.001 - - many
20 PRNP 1.39 7.61 0.938 15274317, 17390034 many many
3 PROS1 2.22 8.09 0.467 - - some
1 PTGFRN 1.55 7.97 0.925 - - many
1 PTPRF -1.02 7.31 NA - - many
3 PTPRG 0.78 7.82 0.523 9795134 21969550 many
6 PTPRK 0.68 7.75 0.026 - 20212451 many
19 PTPRS 1.04 8.06 0.053 - 16784531 many
7 PTPRZ1 2.35 9.44 0.164 many 18308476 many
3 PTX3 1.62 8.41 0.676 2148922
10457011, 14732407, 
15135891, 17196845, 
18929554 many
19 PVR 1.73 7.6 0.264 many 22529845 many
11 PVRL1 0.74 7.28 0.008 - - many
19 PVRL2 1.56 7.14 0.163 - -
15254712, 16391793, 
17696193, 22122800, 
22997493
2 PXDN 0.73 8.35 NA 20063114 - 17330099, 20667089
1 QSOX1 1.83 8.89 0.023 - - many
11 RCN1 1.91 8.05 0.802 - - some
6 RNASET2 1.49 7.06 0.273 - - many
3 ROBO1 0.72 7.86 0.898
16636676, 17968499, 
20008733, 21113198 22244746, 22433866 many
1 SDF4 1.5 8.33 0.028 - - 16215274, 21949389
5 SEMA5A 1.27 7.25 0.908 20696765, 21706053 - many
11 SERPING1 -0.93 7.89 0.608 - - many
17 SEZ6 2.13 7.37 0.652 - - 16863507
11 SIAE 1.53 6.56 0.635 - - 21803834
15 SORD 1.3 6.33 0.35 2144507 - many
11 SORL1 1.5 7.29 0.291 1763461 - 22774576
1 SORT1 1.47 6.94 0.863 - - 16540638
5 SPARC 0.87 9.74 0.889 many many many
X SRPX 0.85 8.33 0.265 20964819 - many
3 TFRC 1.71 6.96 0.095 19386095 20373404 many
1 THBS3 0.6 8.33 0.906 - - 18452548, 17022822
X TIMP1 1.7 9.33 0.778
22995409, 21327941, 
20530493, 20332466 - many
17 TIMP2 1.75 8.82 0.764 many - many
3 TIMP4 3.31 6.71 0.976 19062176 - many
6 TNFRSF21 1.12 6.39 0.906 22802048 - many
9 TXN 2.29 8.46 0.802 many 11565801 many
6 TXNDC5 2.02 8 0.31 - - many
6 ULBP2 1.53 7.78 NA 16891318, 19089914 - many
5 VCAN 1.91 8.48 0.544 many many many
6 VEGFA 1.76 7.17 0.84 many many many
9 VLDLR 0.74 7.99 0.837 - 12586425, 16190894 many
1 YARS -1.22 8.35 0.671 - - 15577315
Table 3-8  DE secretome-receptor interactions retrieved from MetaCore. 'Symbol.from' is secretory proteins 
and 'Symbol.to' is recepors.  
 
Symbol.from Mechanism symbol.to Effect References
A2M Binding LRP1 Activation
9349534;10652313;10815129;12194978;15053742;15910735;16149055;
16725309;16982616;17288987
ADAM10 Cleavage HLA-A Unspecified 17150042
ADAM10 Cleavage PVRL1 Activation 20501653
ADAM10 Cleavage NGFR Unspecified 12843241;15701642
ADAM10 Cleavage LRP4 Unspecified 20383322
ADAM10 Cleavage PTPRK Activation 16648485
ADAM10 Cleavage PRNP Unspecified 11477090;15975064;16263114;16824663;18951988;19564338
ADAM10 Cleavage F11R Activation 19258599
ADAM10 Cleavage CLSTN1 Unspecified 19864413
ADAM10 Cleavage APLP2 Activation 16279945
ADAM10 Cleavage L1CAM Activation
12475894;15814625;16199880;18064447;18289051;18762209;
18951988;19260824;20594269;21195665;21346732;22586143
ADAM10 Cleavage CLSTN3 Unspecified 19864413
ADAM10 Cleavage LRP8 Unspecified 17913923
ADAM10 Cleavage EPHB2 Unspecified 17428795;18951988
ADAM10 Cleavage SORT1 Activation 12419319;21730062
ADAM10 Cleavage CDH2 Inhibition 21123580
APLP1 Binding HMOX1 Inhibition 11144356
APLP2 Binding HMOX1 Inhibition 11144356
APOE Binding LRP1 Activation
2266137;7615159;9124278;10815129;11421580;15863833;16401069;
17288987;17341585
APOE Binding LDLR Activation
10075730;10357834;10889196;11067868;11890675;12036962;16630895;
16725309;17234631;17923100
APOE Binding VLDLR Activation
11353330;11374859;11421580;11743951;11839845;12167620;12870663;
12966036;15319263;15863833;19116273
APOE Binding LRP8 Activation 8626535;11421580;12167620;12950167
APOE Binding SORL1 Activation 11557679;17326667
ASAH1 Transcription regulationNR0B1 Inhibition 22927646
B2M Binding HLA-A Activation
9162021;9427624;9605335;9774416;10064069;10428963;
10631933;11160214;16181333
B2M Binding FCGRT Activation
4758346;8702683;10933786;11336709;12006623;12023961;12144784;
12162790;12242328;16002696;20936779
BCAM Binding ITGA4 Activation 17158232
C1S Cleavage SERPING1 Unspecified 17709141
C1S Cleavage IGFBP5 Inhibition 18930415
CADM1 Binding JAM3 Activation 18055550
CANX Binding L1CAM Inhibition 22222883
CANX Binding HLA-A Activation
8006598;8943049;9551918;12788224;15494401;16181333;
17708944;18420789
COL18A1 Binding ITGA5 Inhibition 12682293;14973128;17597104;18006826;19542224
COL18A1 Binding GPC1 Activation 11336704;20936779
COL3A1 Binding ITGA2 Activation 16043429
COL3A1 Binding GPR56 Activation 21768377;22238662
COL3A1 Binding ITGA1 Activation 16043429
CTSD Cleavage COL18A1 Unspecified 11119712
CTSD Cleavage CTSD Activation 1812719;10508159
CTSD Cleavage SRI Unspecified 20627866
CTSD Cleavage IGFBP3 Inhibition 9275067
CTSD Cleavage IGF2R Inhibition 15258139;15518240;20541250;20936779
CTSD Cleavage IGFBP5 Unspecified 9275067
CTSD Cleavage CST3 Inhibition 2013314;22898924
CTSD Cleavage IGFBP4 Inhibition 9275067
DDR1 Phosphorylation DDR1 Activation 10681566;16440311
DDR1 Phosphorylation PTPN11 Unspecified 16337946;16611743;16626936;22057045
DNAJC3 Binding VCAM1 Activation 16923392
EGFR Phosphorylation PTPRJ Unspecified
EGFR Phosphorylation TLR3 Activation 22810896
EGFR Phosphorylation FAS Activation 12586732;15917250;16772302;17258167
Table 3-8 (continued 1) 
 
 
Symbol.from Mechanism symbol.to Effect References
EGFR Binding GRB2 Activation
1322798;7506413;7510700;7518560;7527043;7798267;7925272;7929151;
8305738;8316835;8386805;8479540;8479541;8524223;8577724;8626525;
8626530;8647858;8662998;8810325;8887653;8940013;9050991;9363897;
9685397;9715408;9765228;9886492;10026169;10085134;10090597;10490623;
10635327;11208164;11287756;11297548;11412040;11726515;11823423;11853876;
11960376;12577067;14498832;14679214;14743216;15194809;15352158;15635092;
15657067;15782189;15784896;15982853;16055672;16099987;16273093;16477079;
16729043;16799092;16889899;17242169;17372273;17548515;17671194;17715395;
17971399;18174162;18358509;18562239;18721752;18793634;19278030;19289468;
19531065;19836242;20067773;20124286;20462955;20473329;20945942;21185312;
21258366;21258655;21278786;21278788;21356361;21596750;21706016;23027125
EGFR Phosphorylation EPS8 Activation 7532203;7532293;8404850;11099046;12127568
EGFR Binding GRB10 Activation 7731717;9006901;9506989;15901248;18721752
EGFR Phosphorylation EGFR Activation
2543678;2552117;3138233;3494473;9335547;11894079;15708576;
16946702;17139251
EGFR Phosphorylation GAB1 Activation
8596638;9890893;10648629;10734310;11432805;11606067;11940581;12370245;
12628344;14668796;15231819;16185843;18046719;19359598;19651513;
21214269;21278788;23027125
EGFR Binding NCK1 Activation
1333047;8561895;8662998;9362449;10026169;11252954;
16273093;18721752
EPHB2 Binding GRB2 Activation 16298995
EPHB2 Phosphorylation L1CAM Activation 9089215
FBLN1 Binding ADAMTS1 Activation 16061471
FBN1 Binding ITGA5 Activation 12807887;17158881
GALNT1 Glycosylation DAG1 Unspecified 21937429
GALNT1 Glycosylation COL18A1 Unspecified 21937429
GFRA1 Binding NCAM1 Activation 12837245;12953054;17322291
GPC1 Binding VEGFA Activation 10196157
GRN Binding ADAMTS7 Inhibition 20506400
GRN Binding ADAMTS12 Inhibition 20506400
HMGB1 Binding NR3C1 Activation 9671457;12006575
HMGB1 Binding NR3C1 Activation 9033409;15808513
HSPG2 Binding ITGA2 Activation 15240572;16882656;17197432
HYOU1 Transport VEGFA Unspecified 11358846;11435455;11435456;11771177;12445237
IGF2BP1 Binding CD44 Activation 16541107;17101699
IGFBP3 Binding RXRA Inhibition 10874028;14715249;15935690;17644060;19324019
IGFBP3 Binding LRP1 Activation 9252371;10037769;14597676
IGFBP4 Binding LRP1 Activation 10037769
IGFBP4 Binding LRP6 Inhibition 18528331
IGFBP5 Binding PLAT Activation 16505491
IGFBP5 Binding LRP1 Activation 10037769
ITGAV Binding PLAUR Activation 8548872;12297505
ITGB1 Binding EGFR Activation 9822606;18247373;21217148
JAM3 Binding JAM3 Activation 11590146;11739175
L1CAM Binding ITGB1 Activation 12077189;16330023
L1CAM Binding ITGA3 Activation 16330023
L1CAM Binding CNTN1 Activation 7595520;18490510
L1CAM Binding PTPRZ1 Activation 7559574
L1CAM Binding L1CAM Activation 12084815
LAMA5 Binding ITGA6 Activation 12519075;17383963
LAMA5 Binding ITGA3 Activation 12519075;17383963
LAMA5 Binding ITGA6 Activation 12297042;12441134;15761669;16581764
LAMA5 Binding BCAM Activation
9642222;11133776;11319237;11507772;12244066;12921739;
17383963;17638854;20936779
LGALS3 Binding ITGA3 Activation 15181153;19755493
LGALS3 Binding EGFR Activation 17889671;19940114;21258405
LGALS3 Binding L1CAM Activation 20124415
LGALS3 Binding LGALS3BP Activation
1917996;8390986;8813152;9501082;11146440;14758079;16189514;
16393961;16518858;19060903;21031433
LRP1 Binding TIMP2 Inhibition 15489233
LRP1 Binding A2M Activation 1423505;2430968;2451858;7693397;10652313;12194978
Table 3-8 (continued 2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Symbol.from Mechanism symbol.to Effect References
LSAMP Binding LSAMP Activation 11984841
LTBP3 Binding ITGAV Activation 12358597
LTBP3 Binding ITGAV Activation 12358597
MDK Binding ITGA6 Activation 15466886
MDK Binding ITGA4 Activation 15466886
MDK Binding PTPRZ1 Inhibition 10212223;10706604;11340082;12573468;20936779
MDK Binding LRP1 Unspecified 10772929;12215536;12573468;17971413;20936779;21688265
MFGE8 Binding ITGAV Activation 14697347;16529932;17299048;17591687;21901532
MIF Binding CXCR4 Activation 17435771;18818421;19066630;20807568;20861157
NCAM1 Binding NCAM1 Activation 14527396
NCAM1 Binding PTPRZ1 Activation 7528221;7559574;9049255
NID1 Binding PLXDC1 Activation 16574105
NOV Binding ITGA5 Activation 12695522
NOV Binding ITGAV Activation 15611078
NRD1 Binding ADAM17 Activation 16923819;19005493;20184396
PCSK9 Cleavage LRP8 Inhibition 18039658;18675252
PCSK9 Cleavage LDLR Inhibition
17012247;17080197;17435765;17449864;17452316;18039658;18250299;18354137;
18675252;18753623;19196236;21692990;22081141
PCSK9 Cleavage VLDLR Inhibition 18039658;18675252
PDIA3 Transcription regulationA2M Unspecified 19995546
PDIA3 Covalent modificationITGB5 Unspecified 17170699;19887585
PDIA3 Covalent modificationADAM17 Unspecified 17170699;19887585
PDIA3 Covalent modificationITGB1 Unspecified 17170699;19887585
PDIA3 Covalent modificationADAM10 Unspecified 17170699;19887585
PDIA3 Binding PRNP Inhibition 15772339;19798432
PDIA3 Binding CANX Activation
8974399;9497314;9545232;10436013;11160214;12052826;14988724;15236594;
16181333;16467570;19054761;20936779
PDIA3 Binding HLA-A Activation 9545232;9637923;9637924;15494401;16467570
PLAT Binding EGFR Activation 17456763
PLAT Binding LRP1B Activation 11384978;16725309
PLAT Binding LRP1 Activation 1502153;1502154;10632583;16303771;17170123;20936779
PLAT Cleavage IGFBP3 Unspecified 22778398
PPIB Binding BSG Activation 11688976
PPIC Binding BSG Activation 17483319;17700972
PRNP Binding NGFR Activation 11489911;14625887
PRNP Binding NCAM1 Activation 11743735;14625887;15146195;15851519;17051207;19209230;19798432
PTPRF Dephosphorylation EPHB2 Inhibition 19047466
PTPRF Dephosphorylation PTPRF Unspecified 11158333
PTPRF Dephosphorylation EGFR Unspecified 1599438
PTPRK Dephosphorylation EGFR Inhibition 15899872;16263724
PTPRS Dephosphorylation CDH2 Activation 17060446
PTPRS Dephosphorylation EGFR Inhibition 10435588;10749673
PVR Binding PVRL3 Activation 12456712;12759359;16189514;16216929;16904340;17352739;21880730
ROBO1 Binding ROBO2 Activation 12504588;16226035
SERPINE2 Binding LRP1 Unspecified 12871303;17409116
SERPINE2 Binding PLAT Inhibition 15128599
SERPING1 Binding C1R Inhibition 3458172;6282262;11044372;20936779
SERPING1 Binding C1S Inhibition 3458172;3756141;6604523;9882449;11044372
SORL1 Binding PLAUR Activation 14764453
SORT1 Binding NGFR Activation 14985746;14985763;15626491
TIMP1 Binding ADAM10 Inhibition 10818225
TIMP2 Binding ADAM33 Inhibition 14676211;15949939
TIMP2 Binding ITGA3 Activation 12887919;12968163
TIMP4 Binding ADAM33 Inhibition 14676211;15949939
TIMP4 Binding ADAM17 Inhibition 15713681
TNC Binding ITGA7 Activation 14715956
TNC Binding EGFR Activation 11470832;16632194;17311283
TNC Binding ITGA9 Activation 7523411;8798654;10209034;16632194
TNC Binding PTPRZ1 Activation 7512960;7514167;7559574;16632194
TNC Binding ITGA8 Activation 7559467;9548928;16632194
TNC Binding ITGA2 Activation 7693733;16632194
Table 3-8 (continued 3) 
 
 
 
The major findings from our proteomics data are surmmarized in Figure 3-12. We selected several 
candidates for further studies from the different analyses (Figure 3-13) and these will be discussed 
in the next sections. 
 
 
 
Figure 3-12  Picture summarizing major findings from the proteomic study. 
 
Symbol.from Mechanism symbol.to Effect References
TXNDC5 Covalent modificationLAMB2 Unspecified 19887585
TXNDC5 Covalent modificationLDLR Unspecified 19887585
VCAN Binding EGFR Activation 16648628
VCAN Binding ITGB1 Activation 11805102;14978219;15126624;16045811;20936779
VCAN Binding CD44 Activation 10950950;11821431
VEGFA Binding ITGA9 Activation 17363377
 
Figure 3-13  Diagram showing proteins to be further studied experimentally. 
 
 
3.3.14  TNC and LGALS3 were expressed in both NSs and GNSs, whereas THY1 and CD9 were 
expressed only in GNSs and could be GNS-specific markers  
To validate our proteomics data and to identify potential surface markers that could distinguish 
between GNSs and NSs, we performed immunocytochemistry for TNC, LGALS3, THY1, CD9 and 
TES (Figure 3-14 , Figure 3-15, Figure 3-16, Figure 3-18, respectively). For this experiment, U7 
and CB660 lines were used for the NSs and G7 and G166 lines were used for the GNSs, since the 
other cell lines were not available. TNC is an ECM protein implicated in guidance of migrating 
axons during development and in neuronal regeneration. It is absent in normal adult brains but re-
expressed upon injury or neoplasia [109, 154]. Our proteomics data indicated that TNC was over-
expressed in GNSs and belonged to the GO.BP neuron differentiation. However, TNC is known to 
be expressed also in foetal NSs. Cultured mouse neural stem/progenitor cells express all Tnc 
receptors [154]. Indeed, it was difficult to see an appreciable difference between the NSs and GNSs 
in our immunostaining.  
 LGALS3 was over-expressed in GNSs both on the mRNA and protein levels. It was shown 
to be an adult astrocyte stem cell marker [80] likely functional in cell migration/motility [81]. Our 
immunostaining showed that LGALS3 was expressed in both NSs (CB660) and GNSs (G166) to a 
similar degree. This may be because G166 had a low level of LGALS3 expression (Figure 3-15 
Table). More immunostaining with the other GNS lines needs to be carried out to validate this. The 
expression was not confined to the cell surface but also within cells, which is consistent with the 
fact that LGALS3 is expressed also in the nucleus (http://www.uniprot.org/uniprot/P17931).  
A              B  
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Figure 3-14  Immunostaining for TNC (green). Nuclei were stained with DAPI (blue) (A) U7 (NS). (B) G7 
(GNS). (C) CB660 (NS). (D) G166 (GNS). Table shows log2(mean ratio) of TNC in each cell line from 
proteomics data. 
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Figure 3-15  Immunostaining for LGALS3 (green). Nuclei were stained with DAPI (blue). (A) CB660 (NS). 
(B) G166 (GNS). Table shows log2(mean ratio) of TNC in each cell line from proteomics data. 
 
GNS line G166 G144 G25 G179
log2 (TNC) 0.9 1.8 1.1 0.6
GNS line G166 G144 G25 G179
log2(LGALS3) 0.2 1.1 1.4 1.5
THY1 has been characterised as a marker for many cell types including heamatopoietic stem cells 
[113], glioma stem cells [155] and early stages of iPS reprogramming from MEF [116]. It belongs 
to GO.BP neuron differentiation, and was over-expressed in our GNS. Our immunostaining did not 
show any THY1 expression on the NSs (U7 and CB660), while being expressed in many GNSs (G7 
and G166), suggesting that it could be a reliable GNS-specific marker. We still need to validate this 
aspect by differentiating GNSs and examining THY1 expression on these cells. The observed 
expression could also be due to other reasons such as the age and patient background that is not 
related to glioma.  
 
A                B 
 
 
 
 
 
 
 
 
 
 
 
 
 
C                D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-16  Immunostaining for THY1 (green). Nuclei were stained with DAPI (blue). (A) U7 (NS). (B) 
G7 (GNS). (C) CB660 (NS). (D) G166 (GNS).  
 
 
CD9 is a tetraspanin (transmembrane 4) on the cell surface with four hydrophobic domains, and was 
over-expressed in our GNSs. It can modulate cell adhesion and migration and tumour metastasis, 
and also trigger platelet activation and aggregation [147]. Co-immunostaining was carried out for 
these two proteins. In accordance with our tag-seq and proteomics data, TES was more highly 
GNS line G166 G144 G25 G179
log2(THY1) 1.5 3.5 3.5 1.4
expressed in CB660 than in G7, whereas CD9 was totally absent in CB660 and weakly expressed in 
G7. Therefore, CD9 could be a marker only for GNSs but not for NSs, and vice versa for TES. 
More experiments are necessary to confirm this finding, as is the case for THY1.  
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Figure 3-17  Co-immunostaining for TES (green) for (A) CB660 (NS) and (B) G7 (GNS), and CD9 (red) for 
(C) CB660 (NS) and (D) G7 (GNS). Nuclei were stained with DAPI (blue). 
 
 
Taken together, THY1 and CD9 could be GNS-specific markers, however, the markers could be the 
remnants of the original cells (e.g. neuron, astrocytes) that de-differentiated into GNSs and not 
silenced afterwards. To rule out this possibility, we need to make sure these proteins disappear after 
differentiating GNSs into adult cells as well as to test more GNS lines. 
 
3.3.15  The IENS conditioned media could increase IENS cell proliferation but not ANS4 cells, 
and the ANS4 conditioned media did not proliferate either cell line 
In the 2
nd
 line of the follow-up experiment, we aimed to find GNS-secreted factors that could 
mediate tumourigenic transformation of NSs ex vivo. For this part of the project, ANS4 (mouse 
GNS line G166 G144 G25 G179
log2(CD9) 1.4 2.3 2.4 0.9
log2(TES) -7.3 -3.6 -5 -3.6
normal NSs) and IENS (mouse GNSs) cell lines were also used since human cells often grow too 
slowly. As a preliminary step, the effect of ANS4- and IENS conditioned media was investigated by 
growing each cell line in both ANS4 and IENS media. The hypothesis here is that IENS conditioned 
media contains enough concentrations of secreted factors that could transform ANS4 cells. The 
result showed that the ANS4 conditioned media did not increase proliferation of either cell line, 
whereas the IENS conditioned media promoted proliferation of the IENS cells but not ANS4 cells 
(Figure 3-18). The increase in both confluency and cell count of the IENS cells exposed to 
autologous conditioned media appeared later and weaker than that of the EGF/FGF treatment. It is 
difficult to say if this increase was due to EGF (or related factors) and/or other factors since we 
could not identify EGF in our proteomics data (Table 3-9). The cellular morphology of IENS 
conditioned media-treated IENS cells did not seem to be different from that of EGF/FGF-treated 
IENS cells (Figure 3-19).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-18  Confluency and cell count for cell line ANS4 and IENS treated with EGF/FGF (+EF) alone, 
ANS4 conditioned media without EGF/FGF (-EF+ANS4), and IENS conditioned media without EGF/FGF (-
EF+IENS). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-19  Phase-contrast images of ANS4 cell line at t = 144 h treated with EGF/FGF (+EF), without 
EGF/FGF +ANS4 conditioned media (-EF+ANS4), and without EGF/FGF +ANS4 conditioned media (-
EF+IENS). 
 
3.3.16  ANS4 cells stopped proliferating at EGF/FGF concentration below 0.1 ng/ml, whereas 
IENS cells continued proliferating in the absence of EGF/FGF  
We hypothesized that the observed increase in IENS cell proliferation, but not ANS4 cells, in the 
IENS conditioned media was due to the difference in cell sensitivity to the media composition. 
Therefore, the sensitivity of ANS4 and IENS cells to EGF/FGF was investigated by exposing them 
to a dilution series of these factors, since we already know how cells respond to them. The result 
(Figure 3-20) showed that the proliferation capability of ANS4 cells decreased at dilution factor 
10E7 (the standard dilution factor is 10E5 (10 ng/ml)) and proliferation was almost completely 
ceased at 10E8. On the other hand, IENS cells continued proliferating even in the absence of 
EGF/FGF. This was, however, somewhat contradictory to the earlier experiment, where IENS cells 
did not proliferate in the -EF+ANS4 conditioned media (Figure 3-19), implying that ANS4 cells 
might secrete anti-proliferation/pro-differentiation factors. Further experiments are necessary to 
confirm this.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-20  Confluency and cell count for cell lines ANS4 and IENS treated with EGF/FGF (+EF) at 
different doses. The standard dilution factor is 10E5. The dilution series was make up to 10E9.  
 
 
3.3.17  TNC, MDK, CNTF, APOE, IGFBP3, IGFBP4 and CSF1 were chosen as candidate 
secreted factors for proliferation/tumourigenesis 
Next, we aimed to test the effect of candidate secreted factors from our proteomics data. Venugopal 
et al. [67] observed using neurosphere culture that the expression of TGF-alpha family ligands, 
EGF, VEGF, PDGF and their cognate receptors, was higher than the control media, which suggests 
that these factors may be responsible for transient proliferation of their NSs. However, our 
proteomics analysis did not sufficiently identify these proteins (Table 3-9) and therefore their 
expression levels need to be quantified by experiments like ELISA. In a previous drug screen, 
EGFR pathway inhibitors did not efficiently kill GNSs, indicating that other pathways may be 
operating downstream and that GNS secreted factors, other than EGF, VEGF and PDGF, may 
induce/help tumourigenesis of NSs. In the Venugopal et al. [67] study, a mass spectrometry analysis 
of the GBM secretome did not definitively identify key secreted factors that may play a role in 
induction of transformation of NPCs. Here, we selected seven factors, which were DE in our total 
cell/secretome data, for testing their ability to transform NSs. 
 Tenascin-C (TNC) was one of the proteins in the GO.BP neuron differentiation category that 
is known to increase the sensitivity of embryonic NSs to EGF and FGF [109]. It was also shown to 
directly bind to EGFR [110]. So our question is whether TNC could induce an EGF-like effect, 
leading to increased proliferation. The 2
nd
 candidate, Midkine (MDK), is more than 4-fold up-
regulated in our GNSs. It is a pleiotrophin family growth factor that can activate anaplastic 
lymphoma kinase [58] and subsequent mitogen-activated protein kinase (MAPK) and PI3-kinase, 
which leads to cell proliferation and can be related to tumourigenesis 
(http://www.uniprot.org/uniprot/P21741). Care should be taken, however, since it is also involved in early 
foetal adrenal gland development and its differential expression could be due to the comparison 
between foetuses and adults. Networks of known interactions for the candidates were made in 
MetaCore. Although these networks consist of interactions identified in different cell types and 
conditions, they might give us some hint as to what could happen when the system is perturbed. The 
network for MDK (3-21 A) suggests that it could increase sensitivity to EGF by increasing EGFR 
expression. APOE3 is a secreted lipid transporter that binds to MEGF7, LRP1, APOER2, VLDLR, 
and can stimulate neurosphere formation via MAPK/ERK pathway. The network of known 
interactions (Figure 3-21 B) indicates that APOE might activate RBPJ and NOTCH1, which are 
known self-renewal regulators. APOE could also activate CNTF. Since CNTFR was up-regulated in 
our GNSs, CNTF was also chosen for the follow-up study. In the network CNTF could lead to the 
activation of JAK-STAT pathway. CNTF is also known to promote astrocyte differentiation and its 
receptor CNTFR was shown to be over-expressed in glioma stem cells by another study [156]. 
Since mutations were not found in its sequence, this receptor was apparently functional [156]. It is 
thus contradictory that proliferating GNSs express more receptors for a pro-differentiation factor 
and this question needs to be addressed. Since APOE is known to activate CNTF, we hypothesized 
that APOE could have a similar effect to that of CNTF. IFGBP3 and IFGBP4 can prolong the half-
life of insulin-like growth factors (IGFs), which has a growth promoting effect. Thus, our 
hypothesis is that IGFBP3 and IGFBP4 could increase the IGF effect, namely proliferation. The 
network analysis (Figure 3-21 C) suggests that these proteins could lead to activation of an 
oncogene c-Myc. CSF1 is a cytokine released from tumour cells and thought to stimulate 
macrophages to release EGF. It could activate VEGFR-3, whose signal could have a similar 
outcome as the EGFR signalling. Its putative network is shown in (Figure 3-21 D). 
 
Table 3-9  Expression level of EGF, EGFR, VEGF, VEGFR, PDGF and PDGFR. 
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G166 G144 G25 G179 G166.secre G144.secre
EGF - - - - - -
EGFR -0.99 -1.95 -0.71 -1.59 0.31 -0.42
VEGF(A) - - - - 2.36 0.78
VEGFR - - - - - -
PDGF - - - - - -
PDGFR(A) 2.38 -1.08 1.34 3.95 - -
PDGFR(B) -2.40 -0.98 0.78 -1.17 - -
 B 
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12475894;15814625;16199880;18064447;18289051;18762209; 
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Figure 3-21  Networks of known interactions reconstructed in MetaCore for (A) MDK, (B) APOE, (C) 
IGFBP3 and IGFBP4, and (D) CSF1. Each factor was used as a seed and MetaCore function 'Auto expand' 
was used with 50 maximum number of nodes. Resultant networks were pruned by removing nodes not 
connecting down to nucleus. Thick arrows indicate well-established, canonical pathways.  
 
 
3.3.18  Up to 100 ng/ml TNC, MDK and CNTF did not have any visible effect on mouse ANS4 
and IENS cells in the presence of EGF/FGF 
First, the effect of TNC, MDK and CNTF on cells at different doses (5, 10, 50 and 100 ng/ml) in the 
standard culturing conditions (i. e., in the presence of EGF/FGF) was evaluated. At the highest dose 
(100 ng/ml), these factors did not have a discernible effect on both ANS4 and IENS cells in terms of 
the confluency (Figure 3-22), cell count (Figure 3-22), morphology (Figure 3-23) and proliferation 
capacity (Figure 3-24). 5 ng/ml, 10 ng/ml and 50 ng/ml showed the same results (data not shown), 
suggesting that the factors were neither pro-proliferation, nor pro-differentiation, nor toxic to both 
NSs and GNSs in the presence of EGF/FGF. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-22  Confluency and number of cells counted every hour for 68 hours. ANS4 and IENS cells were 
treated with EGF/FGF (+EF) alone and in combination with 100 ng/ml TNC, 100 ng/ml MDK and 100 
ng/ml CNTF. 
 
 
 
 
 
 
 
 
 
Figure 3-23  Phase-contrast images of ANS4, IENS and 223 mouse lines at t = 48 hours. ANS4 and IENS 
cells were treated with EGF/FGF (+EF) alone and in combination with 100 ng/ml TNC, 100 ng/ml MDK and 
100 ng/ml CNTF. 
 
 
 
 
 
 
Figure 3-24  Immunocytochemistry for KI67 in cell lines ANS4 and IENS 72 hours post-treatment with 
EGF/FGF (+EF) alone and in combination with 100 ng/ml TNC, 100 ng/ml MDK and 100 ng/ml CNTF. 
 
3.3.19  Effect of TNC, MDK, CNTF, APOE3, IGFBP3, IGFBP4 and CSF1 on ANS4 and CB660 
cells in the absence of EGF/FGF 
The effect of each of the seven candidate factors (TNC, MDK, CNTF, APOE3, IGFBP3, IGFBP4 
and CSF1) on the ANS4 and CB660 cell lines was tested in the absence of EGF/FGF (-EF). The cell 
count, but not confluency, of ANS4 cells treated with MDK (-EF+MDK) increased at a similar rate 
to the +EF positive control up to time t = 80 h (Figure 3-25). Thus, the morphology of these ANS4 
cells was checked at t = 77 h (Figure 3-26). Cells, however, looked more similar to the -EF negative 
control, indicating that MDK might promote proliferation to a certain degree but the effect is 
transient and not as strong as EGF. This effect was not observed in CB660. More replicates with 
different lines are needed to confirm this. The confluency of CNTF-treated ANS4 cells looked a 
little larger than the others but the cell count remained the same (Figure 3-25). The morphological 
comparison between -EF, -EF+CNTF, +EF and +EF+CNTF at t = 144 h (Figure 3-27) showed that -
EF+CNTF cells appeared more roundish than the other three, contributing to the observed increased 
confluency. CNTF is known to induce astrocyte differentiation and EGF is probably a strong pro-
proliferation factor that can suppress the CNTF differentiation effect. This CNTF effect was, 
however, apparently not observed in CB660 and the morphology seemed the same as the -EF 
negative control (Figure 3-28).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-25  Confluency curve for cell lines ANS4, CB660 treated with EGF/FGF (+EF), without EGF/FGF 
(-EF), -EF+TNC, -EF+MDK, -EF+CNTF, -EF+APOE3, -EF+IGFBP3, -EF+IGFBP4, -EF+CSF1 and -
EF+G7 conditioned media (-EF+G7.CM). 
 
 
Figure 3-26  Phase-contrast images of ANS4 cell line at t = 0 and 77 h treated with EGF/FGF (+EF), without 
EGF/FGF (-EF) and -EF+MDK 10 ng/ml.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-27  Phase-contrast images of of ANS4 cell line at t = 144 h treated without EGF/FGF (-EF), -
EF+CNTF, with EGF/FGF (+EF) and +EF+CNTF 10 ng/ml. 
 
 
 
 
 
 
 
 
 
Figure 3-28  Phase-contrast images of CB660 
cell line at  t = 144 h treated without 
EGF/FGF (-EF), -EF+CNTF (10 ng/ml), with 
EGF/FGF (+EF). 
 
 
 
 
 
3.3.20  Treating ANS4 cells with all the seven factors (TNC, MDK, CNTF, APOE3, IGFBP3, 
IGFBP4 and CSF1) simultaneously was similar to the CNTF treatment alone, and treating with 
six factors (TNC, MDK, APOE3, IGFBP3, IGFBP4 and CSF1) did not induce a visible 
difference 
Next, all the above seven factors were added to the media at the same time and the effect on ANS4 
cells was monitored. The results (Figure 3-29) and (Figure 3-30) showed that the seven factors 
resulted in cells similar to when they were treated with the CNTF alone. When only six factors 
excluding CNTF were added to the media, cells did not show an appreciable difference from the -
EF negative control, suggesting that these factors do not have a synergistic effect on ANS4 cells in 
the absence of EGF/FGF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-29  Confluency and cell count for cell line ANS4 treated with EGF/FGF (+EF) alone, without 
EGF/FGF (+EF) and in combination with , 100 ng/ml MDK and 100 ng/ml CNTF. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-30  Phase-contrast images of ANS4 cell line at t = 144 h treated without EGF/FGF (-EF), -EF+all 
factors (TNC, MDK, CNTF, APOE3, IGFBP3, IGFBP4 and CSF1), with EGF/FGF (+EF) and -EF+all 
factors-CNTF (TNC, MDK, APOE3, IGFBP3, IGFBP4 and CSF1). 
 
3.3.21  Some factors might have an effect on ANS4 and IENS cell colony formation 
The effect of the seven factors and conditioned media in the presence of EGF/FGF was also 
investigated by the colony forming assay (Figure 3-31). TNC, MDK and IGFBP4 might enhance 
colony formation of ANS4 cells, whereas IGFBP3 might enhance colony formation of IENS cells. 
Since IGFBP4 was up-regulated in the human GNSs and IGFBP3 was up-regulated in NSs, 
differential use of IGFBP3 and 4 might be associated with tumourigenesis. Notably, CNTF strongly 
inhibited IENS colony formation, further validating that it is a pro-differentiation (i.e., anti-
proliferation) factor. Since the number of replicates is still n=1, drawing any conclusion requires 
more experiments.  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-31  Normalized colony count of ANS4 and IENS cell lines at t = 7-10 days after treated with 
EGF/FGF (+EF) and TNC, MDK, CNTF, APOE3, IGFBP3, IGFBP4 or CSF1 conditioned media. 
3.4  Discussion 
 
To reveal the difference in global protein expression between untransformed, karyotypically normal 
foetal neural stem cells [1] and malignant neural stem cells derived from adult gliomas (GNSs), we 
performed mass spectrometry analyses of both total cell proteome and secreted proteome of these 
cells. This resulted in a total of ~7500 and ~2000 quantified proteins and 446 differentially 
expressed (DE) proteins (152 up-regulation, 294 down-regulation in GNSs) and 167 DE proteins 
(144 up-regulation, 23 down-regulation), respectively. Among the known NS and glioma stem cell 
markers, Galectin-3, Galectin-3-binding protein, L1CAM, GFAP were over-expressed in our GNSs, 
while integrin α6 and ALDH2 were under-expressed. CD133 has been used to isolate brain tumour 
stem cells from different brain tumours [46, 47] but it was identified only in our G166 and G179 
lines, and was not DE when compared to the NSs and not on the mRNA level either [77], 
suggesting that this marker may not be a universal and reliable marker to distinguish GNSs from 
NSs. 
 The gene set enrichment analysis (GSEA) of the 446 DE proteins resulted in chromosome 7 
and 15, which are almost always gained and lost in our GNSs, respectively, suggesting that 
chromosomal aberrations influence not only mRNA- but also protein expressions. In addition, 
several tumour-associated processes were enriched including those related to cell differentiation, 
cell motility, ECM interactions, focal adhesion, structural organization and cell signalling. These 
findings support the notion that cell-matrix and cell-cell adhesion play a crucial role in the 
maintenance of stem cell pools, for instance integrins and other surface proteins mediate signals 
whose disruption may lead to tumourigenesis. Furthermore, the enrichment of categories related to 
blood vessel development is in accordance with the importance of angiogenesis in CSC 
maintenance, as shown in squamous carcinoma [157] and glioma stem cells [158, 159]. Although 
the role of Notch, Wnt and sonic hedgehog (shh) signalling pathways in CSCs have been implicated 
[160, 161], they were not over-represented in our analysis, indicating that these pathways may be 
necessary for regulation of stem-like properties and/or transient proliferation but not for GNS 
tumourigenicity. In fact, to our knowledge no genetic studies have implicated shh pathways being 
activated in GBM and our mouse NS cells could grow without problem in a Notch inhibitor 
(personal communication with S.P.). 
 Since it is speculated that tumourigenesis starts with sustained differentiation and 
subsequent uncontrolled proliferation, we more closely looked at the enriched GO.BP “neuron 
differentiation” category. A network reconstructed only from the DE proteins belonging to this 
category was connected from the ECM to the nucleus, further supporting its relevance to 
tumourigenesis. Some of the DE proteins have been implicated with glioma to varying degrees 
(integrins, tubulins, collagens, kinases, CDK1, EGFR, EPHB2, TNC, etc.) and others were not 
(myosins, CAP1, CAP2, FKBP4, LIMK1, LZTS1, NRXN1, THY1, etc.). The “cell proliferation”-
related processes were not over-represented. This could be because both NS and GNSs were both 
cultured in proliferating conditions.  
 A transcription factor [116] can drive the expression of several hundreds of genes. There 
were 36 DE transcription factors/regulators in our data, 9 of which (FOXO3, TP53, IFI16, NFIC, 
PURA, YAP1, HMGA2 and PRKCB) have been implicated in glioma, while the others do not, 
including LZTS1 found in GO.BP neuron differentiation (Table 3-4). NFIC and IGHMBP2 have 
been shown to be expressed in astrocyte and neuron, respectively, possibly indicating that these 
mature cells could de-differentiate into GNSs and that the expression of these proteins are not 
silenced afterwards. This hypothesis of de-differentiation is not far-fetched, since FoxG1 has been 
shown to be a reprogramming factor from fibroblasts to neural progenitor cells (NPCs) capable of 
differentiation into neurons, astrocytes or oligodendrocytes [137] and since FOXG1 was strongly 
up-regulated in our GNSs on the mRNA level [77] (not identified in our proteomics data).  
 In the transcriptome comparison between NSs and GNSs, novel genes up-regulated in GNSs 
that had not been previously detected by microarray profiling of glioma tumour tissue samples were 
identified [77]. The comparison between this transcriptome data and our proteomics data showed a 
general agreement in expression direction. However, 34 gene/proteins were DE in the same 
direction on both levels, whereas 405 proteins were DE only on the protein level and 207 gene were 
DE only on the mRNA level. It is widely accepted that the expression level of transcripts do not 
always correlate with that of proteins, especially in higher eukaryotes such as human, and this 
relatively poor overlap of DE genes is due partly to posttranscriptional regulation of protein 
expression but perhaps also to a slightly different set of cell lines used in the two experiments. On 
the other hand, those that do agreen on the expression levels of both mRNA and protein are likely to 
have some significance to the cells. 
 In our secreted proteome analysis the majority of DE proteins were up-regulated (144 out of 
167) (Figure 3-11). This trend was also observed in the comparison between cancer and normal 
cells using the AHA method [162]. On the other hand, the distribution of up- and down-regulated, 
secretory proteins in the total cell experiment was more or less equal (Figure 3-11). This 
discrepancy could be because the total cell experiment is capturing secretory proteins inside the cell 
and if they are more rapidly transported outside the cell, the overall abundance of these proteins in 
the cell at a given moment would remain the same. In both experiments the four most abundant 
protein classes by UniProt keywords were receptor / membrane protein, disease mutation, collagen 
and cell adhesion (Figure 3-11). The categories; protease and growth factor / growth factor binding, 
were 6
th
 and 8
th
 most abundant in the secretome experiment, while they were 8
th
 and 11
th
 in the total 
cell experiment, respectively (Figure 3-11), possibly implying that these two classes in the 
secretome could particularly have a significant influence on the cells. Previous secretome studies 
have shown that IGFBP7 is a marker for GBM vessels, and that it was up-regulated in human brain 
endothelial cells upon GBM secretome exposure [163]. CHI3L1 is involved in the regulation of 
malignant transformation and local invasiveness of gliomas [164]. In our current data, both IGFBP7 
and CHI3L1 were strongly expressed in both up and down directions, depending on cell llines. 
Thus, there was a high, inter-individual variability in what has been reported to be GBM-secretome 
signatures and these published results should be taken with caution.  
 After the global proteome characterisation, we aimed to identify surface markers that 
distinguish between NSs and GNSs, since proteins on the plasma membrane can be more 
effectively targeted by drugs than those inside the cell. Markers that are not expressed at all in NSs 
are particularly desirable, as normal NSs should not be killed when GNSs are treated with drugs 
targeting these markers. As glioblastoma stem cells are particularly resistant to radiation, identifying 
new drugs that can kill these cells is likely to be most important [68]. The immunocytochemistry of 
the five candidates (TNC, LAGLS3, THY1, CD9 and TES) revealed THY1 and CD9 being possible 
markers only expressed on GNSs, while TES was specific for NSs. Although THY1 is a marker for 
many stem cells and implicated in GO.BP neuron differentiation, its function in GNS malignancy is 
unclear. Because THY1 is also a marker for neurons, the possibility remains that GNSs arose from 
adult neurons and THY1 expression was just the remnants of it. To rule out this, we need to make 
sure the protein disappears after differentiating GNSs as well as to test more GNS lines.  
 The function of glioblastoma secretome in invasiveness of glioblastoma cells has been 
reported [61] and three TGF-alpha family growth factors, EGF, VEGF and PDGF, have been shown 
to be over-expressed in glioma-conditioned media, which increased proliferation of NSs [67]. It 
remains elusive, however, whether these are the only auto-/paracrine factors mediating the entire 
process of tumourigenesis in vivo. Our conditioned media experiment with ANS4 (mouse NSs) and 
IENS (moues GNSs) revealed that IENS-conditioned media only increased proliferation of IENS 
cells but not that of ANS4 cells (Figure 3-20). This is probably because ANS4 cells are less 
sensitive to the media composition. Indeed, the subsequent experiment showed that ANS4 cells did 
not proliferate at EGF/FGF concentration below 0.1 ng/ml, whereas IENS cells proliferated even 
without EGF/FGF (Figure 3-21). Since proliferation of IENS cells was inhibited in ANS4-
conditioned media (Figure 3-20), ANS4 media may contain pro-differentiation factors at 
concentrations sufficient to suppress IENS proliferation. More experiments are necessary to 
establish this. Our investigation of the effect of seven candidate secreted factors TNC, MDK, 
CNTF, APOE, IGFBP4, CSF1 (over-expressed in GNSs) and IGFBP3 (under-expressed in GNSs) 
on mouse NS and GNS cells revealed that CNTF could induce a morphological change (Figure 3-
27), probably differentiation to astrocytes, as has been shown in NSs [165-167]. It is contradictory 
though that CNTFR was up-regulated in GNSs and Lu et al. [156] reported that CNTFR-alpha is a 
marker for glioma initiating cells and mutations were not common to this protein. Although CNTF 
did not cause any visible change to our IENS cells (data not shown), it has been reported to 
differentiate glioma initiating cells [156] which was supported by our colony-forming assay 
exhibiting a dramatic decrease in IENS colony count but not in ANS4 (Figure 3-31). None of the 
other six factors had any visible effect on confluency, cell count or morphology. However, in the 
colony-forming assay experiment, TNC, MDK and IGFBP4 might have enhanced colony formation 
of ANS4 cells, whereas IGFBP3 might have enhanced colony formation of IENS cells. Since 
IGFBP4 was up-regulated in the human GNSs and IGFBP3 was up-regulated in NSs, differential 
use of IGFBP3 and 4 might be associated with tumourigenesis. Our results also indicate that the 
colony-forming assay could be more sensitive to the media composition and more suitable for the 
current task than the time-lapse imaging. More replicates of the colony-forming assay are necessary 
for drawing a solid conclusion.    
 Conventional cancer cell cultures contain serum, which induces differentiation of CSCs, 
while blocking the cells' capacity to reconstitute the tumour in vivo [3]. In addition, repetitive 
passaging, which is a common practice for non-primary cancer cell lines, results in accumulation of 
de novo mutations of non-primary tumour origin [3]. The serum-free neurosphere culture for CSCs 
can circumvent these problems, however, it contains a heterogeneous mixture of self-renewing and 
differentiating cells. Our cell cultures are advantageous in that primary malignant glioma stem cells 
that can reconstitute the tumour in vivo can be directly compared to the normal, untransformed 
counterparts [4, 56, 58]. By performing both total cell- and secreted proteome analyses using our 
new secretome technique [162], we thus identified many proteins and processes both with and 
without prior associations with glioma biology. Several candidate proteins for surface markers and 
for tumourigenic transformation of NSs were further experimentally tested with some positive 
results. More experiments are, however, necessary to solidify these findings.  
 
Chapter 4 
 
4.  Conclusion 
 
 
In this doctoral study I carried out two projects. The 1
st
 one was about the exploration of the use of 
isotope patterns in MS1 spectra for peptide identification. We demonstrated that the RIA error is 4-
5%, and that this is only modestly influenced by spectral intensity, resolution and the number of 
MS1 scans. The current RIA accuracy has limited discriminatory power at a proteome-wide scale. 
At the same time, the analysis was hampered by the difficulty in calculating FDRs, particularly in 
constructing proper decoy databases that are similar in size as the target database, yet different in 
molecular composition for all peptides considered. Alternative strategies to calculate FDRs will be 
required to address this issue for complex proteomes. Regardless, the utility of RIA may become 
relevant with future instrument developments, considering that even a relatively modest decrease in 
RIA error down to <1% strongly improves discriminatory power. Alternatively, at increased mass 
accuracy even current RIA accuracy levels may be sufficient to fit isotope patterns as a constraint in 
the peptide identification process as a parameter that comes for free in any MS-based proteomic 
experiment.  
 In the 2
nd
 project we conducted comparative proteomics analysis of karyotypically normal, 
untransformed neural stem cells [1] and malignant, adult glioma neural stem cells (GNSs). This 
resulted in a total of ~7500 and ~2000 quantified proteins and 446 differentially expressed (DE) 
proteins (152 up-regulation, 294 down-regulation in GNSs) and 167 DE proteins (144 up-
regulation, 23 down-regulation), respectively. Many proteins and processes without prior 
associations with glioma biology as well as those with known associations were found. After data 
analyses, several candidate proteins for surface markers that could distinguish between NSs and 
GNSs were experimentally validated using immunocytochemistry. Then, candidate GNS-secreted 
factors that might mediate tumourigenic transformation of NSs were evaluated using time-lapse 
imaging and colony-forming assays. Both of these experiments produced some positive results, 
demonstrating the power of proteomics. More experiments are, however, necessary to solidify these 
findings. The next goals would be 1) to find drugs that could specifically kill only GNSs by 
targeting these surface markers, and 2) molecularly characterize the complete process of 
tumourigenesis from NSs to GNSs ex vivo.  
 
 
BIBLIOGRAPHY 
 
1. Taupin, P., et al., FGF-2-responsive neural stem cell proliferation requires CCg, a novel 
autocrine/paracrine cofactor. Neuron, 2000. 28(2): p. 385-97. 
2. Michalski, A., J. Cox, and M. Mann, More than 100,000 detectable peptide species elute in 
single shotgun proteomics runs but the majority is inaccessible to data-dependent LC-
MS/MS. J Proteome Res, 2011. 10(4): p. 1785-93. 
3. Lee, J., et al., Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more 
closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell 
lines. Cancer Cell, 2006. 9(5): p. 391-403. 
4. Pollard, S.M., et al., Glioma stem cell lines expanded in adherent culture have tumor-
specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell, 2009. 
4(6): p. 568-80. 
5. Phillips, H.S., et al., Molecular subclasses of high-grade glioma predict prognosis, delineate 
a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell, 2006. 
9(3): p. 157-73. 
6. Domon, B. and R. Aebersold, Options and considerations when selecting a quantitative 
proteomics strategy. Nat Biotechnol, 2010. 28(7): p. 710-21. 
7. Sadygov, R.G., D. Cociorva, and J.R. Yates, 3rd, Large-scale database searching using 
tandem mass spectra: looking up the answer in the back of the book. Nat Methods, 2004. 
1(3): p. 195-202. 
8. Yates, J.R., 3rd, et al., Method to correlate tandem mass spectra of modified peptides to 
amino acid sequences in the protein database. Anal Chem, 1995. 67(8): p. 1426-36. 
9. Perkins, D.N., et al., Probability-based protein identification by searching sequence 
databases using mass spectrometry data. Electrophoresis, 1999. 20(18): p. 3551-67. 
10. Geer, L.Y., et al., Open mass spectrometry search algorithm. J Proteome Res, 2004. 3(5): p. 
958-64. 
11. Craig, R. and R.C. Beavis, TANDEM: matching proteins with tandem mass spectra. 
Bioinformatics, 2004. 20(9): p. 1466-7. 
12. Cox, J., et al., Andromeda: a peptide search engine integrated into the MaxQuant 
environment. J Proteome Res, 2011. 10(4): p. 1794-805. 
13. Klammer, A.A., et al., Improving tandem mass spectrum identification using peptide 
retention time prediction across diverse chromatography conditions. Anal Chem, 2007. 
79(16): p. 6111-8. 
14. Krokhin, O.V., Sequence-specific retention calculator. Algorithm for peptide retention 
prediction in ion-pair RP-HPLC: application to 300- and 100-A pore size C18 sorbents. 
Anal Chem, 2006. 78(22): p. 7785-95. 
15. Moruz, L., D. Tomazela, and L. Kall, Training, selection, and robust calibration of retention 
time models for targeted proteomics. J Proteome Res, 2010. 9(10): p. 5209-16. 
16. Petritis, K., et al., Improved peptide elution time prediction for reversed-phase liquid 
chromatography-MS by incorporating peptide sequence information. Anal Chem, 2006. 
78(14): p. 5026-39. 
17. Pfeifer, N., et al., Statistical learning of peptide retention behavior in chromatographic 
separations: a new kernel-based approach for computational proteomics. BMC 
Bioinformatics, 2007. 8: p. 468. 
18. Krijgsveld, J., et al., In-gel isoelectric focusing of peptides as a tool for improved protein 
identification. J Proteome Res, 2006. 5(7): p. 1721-30. 
19. Mann, M. and N.L. Kelleher, Precision proteomics: the case for high resolution and high 
mass accuracy. Proc Natl Acad Sci U S A, 2008. 105(47): p. 18132-8. 
20. Senko, M.W., S.C. Beu, and F.W. McLafferty, Automated assignment of charge states from 
resolved isotopic peaks for multiply charged ions. Journal of the American Society for Mass 
Spectrometry, 1995. 6(1): p. 52–56. 
21. Senko, M.W., S.C. Beu, and F.W. McLafferty, Determination of monoisotopic masses and 
ion populations for large biomolecules from resolved isotopic distributions. Journal of the 
American Society for Mass Spectrometry, 1995. 6(4): p. 229–233. 
22. Cox, J. and M. Mann, MaxQuant enables high peptide identification rates, individualized 
p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol, 
2008. 26(12): p. 1367-72. 
23. Zhang, Y., et al., Proteome scale turnover analysis in live animals using stable isotope 
metabolic labeling. Anal Chem, 2011. 83(5): p. 1665-72. 
24. Polacco, B.J., et al., Discovering mercury protein modifications in whole proteomes using 
natural isotope distributions observed in liquid chromatography-tandem mass spectrometry. 
Mol Cell Proteomics, 2011. 10(8): p. M110 004853. 
25. Bocker, S., et al., SIRIUS: decomposing isotope patterns for metabolite identification. 
Bioinformatics, 2009. 25(2): p. 218-24. 
26. Erve, J.C., et al., Spectral accuracy of molecular ions in an LTQ/Orbitrap mass 
spectrometer and implications for elemental composition determination. J Am Soc Mass 
Spectrom, 2009. 20(11): p. 2058-69. 
27. Kind, T. and O. Fiehn, Metabolomic database annotations via query of elemental 
compositions: mass accuracy is insufficient even at less than 1 ppm. BMC Bioinformatics, 
2006. 7: p. 234. 
28. Pluskal, T., T. Uehara, and M. Yanagida, Highly accurate chemical formula prediction tool 
utilizing high-resolution mass spectra, MS/MS fragmentation, heuristic rules, and isotope 
pattern matching. Anal Chem, 2012. 84(10): p. 4396-403. 
29. Weber, R.J., et al., Characterization of isotopic abundance measurements in high resolution 
FT-ICR and Orbitrap mass spectra for improved confidence of metabolite identification. 
Anal Chem, 2011. 83(10): p. 3737-43. 
30. Xu, Y., et al., Evaluation of accurate mass and relative isotopic abundance measurements in 
the LTQ-orbitrap mass spectrometer for further metabolomics database building. Anal 
Chem, 2010. 82(13): p. 5490-501. 
31. Rappsilber, J., M. Mann, and Y. Ishihama, Protocol for micro-purification, enrichment, pre-
fractionation and storage of peptides for proteomics using StageTips. Nat Protoc, 2007. 
2(8): p. 1896-906. 
32. Elias, J.E. and S.P. Gygi, Target-decoy search strategy for increased confidence in large-
scale protein identifications by mass spectrometry. Nat Methods, 2007. 4(3): p. 207-14. 
33. Easterling, M.L., et al., Isotope Beating Effects in the Analysis of Polymer Distributions by 
Fourier Transform Mass Spectrometry. Journal of the American Society for Mass 
Spectrometry 1999. 10(11): p. 1074-1082. 
34. Miura, D., et al., A strategy for the determination of the elemental composition by fourier 
transform ion cyclotron resonance mass spectrometry based on isotopic peak ratios. Anal 
Chem, 2010. 82(13): p. 5887-91. 
35. Shi, S.D., C.L. Hendrickson, and A.G. Marshall, Counting individual sulfur atoms in a 
protein by ultrahigh-resolution Fourier transform ion cyclotron resonance mass 
spectrometry: experimental resolution of isotopic fine structure in proteins. Proc Natl Acad 
Sci U S A, 1998. 95(20): p. 11532-7. 
36. Miladinovic, S.M., et al., On the utility of isotopic fine structure mass spectrometry in 
protein identification. Anal Chem, 2012. 84(9): p. 4042-51. 
37. Knudson, A.G., Jr., Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad 
Sci U S A, 1971. 68(4): p. 820-3. 
38. Feinberg, A.P., R. Ohlsson, and S. Henikoff, The epigenetic progenitor origin of human 
cancer. Nat Rev Genet, 2006. 7(1): p. 21-33. 
39. Teng, I.W., et al., Targeted methylation of two tumor suppressor genes is sufficient to 
transform mesenchymal stem cells into cancer stem/initiating cells. Cancer Res, 2011. 
71(13): p. 4653-63. 
40. Kleihues, P. and L.H. Sobin, World Health Organization classification of tumors. Cancer, 
2000. 88(12): p. 2887. 
41. Stupp, R. and F. Roila, Malignant glioma: ESMO clinical recommendations for diagnosis, 
treatment and follow-up. Ann Oncol, 2009. 20 Suppl 4: p. 126-8. 
42. Furnari, F.B., et al., Malignant astrocytic glioma: genetics, biology, and paths to treatment. 
Genes Dev, 2007. 21(21): p. 2683-710. 
43. Comprehensive genomic characterization defines human glioblastoma genes and core 
pathways. Nature, 2008. 455(7216): p. 1061-8. 
44. Lapidot, T., et al., A cell initiating human acute myeloid leukaemia after transplantation into 
SCID mice. Nature, 1994. 367(6464): p. 645-8. 
45. Hemmati, H.D., et al., Cancerous stem cells can arise from pediatric brain tumors. Proc 
Natl Acad Sci U S A, 2003. 100(25): p. 15178-83. 
46. Singh, S.K., et al., Identification of a cancer stem cell in human brain tumors. Cancer Res, 
2003. 63(18): p. 5821-8. 
47. Singh, S.K., et al., Identification of human brain tumour initiating cells. Nature, 2004. 
432(7015): p. 396-401. 
48. Stiles, C.D. and D.H. Rowitch, Glioma stem cells: a midterm exam. Neuron, 2008. 58(6): p. 
832-46. 
49. Shackleton, M., et al., Heterogeneity in cancer: cancer stem cells versus clonal evolution. 
Cell, 2009. 138(5): p. 822-9. 
50. Galli, R., et al., Isolation and characterization of tumorigenic, stem-like neural precursors 
from human glioblastoma. Cancer Res, 2004. 64(19): p. 7011-21. 
51. Ignatova, T.N., et al., Human cortical glial tumors contain neural stem-like cells expressing 
astroglial and neuronal markers in vitro. Glia, 2002. 39(3): p. 193-206. 
52. Yuan, X., et al., Isolation of cancer stem cells from adult glioblastoma multiforme. 
Oncogene, 2004. 23(58): p. 9392-400. 
53. Suslov, O.N., et al., Neural stem cell heterogeneity demonstrated by molecular phenotyping 
of clonal neurospheres. Proc Natl Acad Sci U S A, 2002. 99(22): p. 14506-11. 
54. Reynolds, B.A. and R.L. Rietze, Neural stem cells and neurospheres--re-evaluating the 
relationship. Nat Methods, 2005. 2(5): p. 333-6. 
55. Singec, I., et al., Defining the actual sensitivity and specificity of the neurosphere assay in 
stem cell biology. Nat Methods, 2006. 3(10): p. 801-6. 
56. Conti, L., et al., Niche-independent symmetrical self-renewal of a mammalian tissue stem 
cell. PLoS Biol, 2005. 3(9): p. e283. 
57. Pollard, S.M., et al., Adherent neural stem (NS) cells from fetal and adult forebrain. Cereb 
Cortex, 2006. 16 Suppl 1: p. i112-20. 
58. Sun, Y., et al., Long-term tripotent differentiation capacity of human neural stem (NS) cells 
in adherent culture. Mol Cell Neurosci, 2008. 38(2): p. 245-58. 
59. Moore, K.A. and I.R. Lemischka, Stem cells and their niches. Science, 2006. 311(5769): p. 
1880-5. 
60. Gilbertson, R.J. and J.N. Rich, Making a tumour's bed: glioblastoma stem cells and the 
vascular niche. Nat Rev Cancer, 2007. 7(10): p. 733-6. 
61. Formolo, C.A., et al., Secretome signature of invasive glioblastoma multiforme. J Proteome 
Res, 2011. 10(7): p. 3149-59. 
62. Plate, K.H., et al., Vascular endothelial growth factor is a potential tumour angiogenesis 
factor in human gliomas in vivo. Nature, 1992. 359(6398): p. 845-8. 
63. Ricci-Vitiani, L., et al., Tumour vascularization via endothelial differentiation of 
glioblastoma stem-like cells. Nature, 2010. 468(7325): p. 824-8. 
64. Wang, Z.H., Y.X. Xue, and Y.H. Liu, The modulation of protein kinase A and heat shock 
protein 70 is involved in the reversible increase of blood-brain tumor barrier permeability 
induced by papaverine. Brain Res Bull, 2010. 83(6): p. 367-73. 
65. Charles, N., et al., Perivascular nitric oxide activates notch signaling and promotes stem-
like character in PDGF-induced glioma cells. Cell Stem Cell, 2010. 6(2): p. 141-52. 
66. Eyler, C.E., et al., Glioma stem cell proliferation and tumor growth are promoted by nitric 
oxide synthase-2. Cell, 2011. 146(1): p. 53-66. 
67. Venugopal, C., et al., GBM secretome induces transient transformation of human neural 
precursor cells. J Neurooncol, 2012. 109(3): p. 457-66. 
68. Bao, S., et al., Glioma stem cells promote radioresistance by preferential activation of the 
DNA damage response. Nature, 2006. 444(7120): p. 756-60. 
69. Boersema, P.J., et al., Multiplex peptide stable isotope dimethyl labeling for quantitative 
proteomics. Nat Protoc, 2009. 4(4): p. 484-94. 
70. Smyth, G.K., Linear models and empirical bayes methods for assessing differential 
expression in microarray experiments. Stat Appl Genet Mol Biol, 2004. 3: p. Article3. 
71. Thomas, P.D., et al., PANTHER: a library of protein families and subfamilies indexed by 
function. Genome Res, 2003. 13(9): p. 2129-41. 
72. Ruepp, A., et al., CORUM: the comprehensive resource of mammalian protein complexes--
2009. Nucleic Acids Res, 2010. 38(Database issue): p. D497-501. 
73. Matthews, L., et al., Reactome knowledgebase of human biological pathways and processes. 
Nucleic Acids Res, 2009. 37(Database issue): p. D619-22. 
74. Ben-Porath, I., et al., An embryonic stem cell-like gene expression signature in poorly 
differentiated aggressive human tumors. Nat Genet, 2008. 40(5): p. 499-507. 
75. Tarca, A.L., et al., A novel signaling pathway impact analysis. Bioinformatics, 2009. 25(1): 
p. 75-82. 
76. Liberzon, A., et al., Molecular signatures database (MSigDB) 3.0. Bioinformatics, 2011. 
27(12): p. 1739-40. 
77. Engstrom, P.G., et al., Digital transcriptome profiling of normal and glioblastoma-derived 
neural stem cells identifies genes associated with patient survival. Genome Med, 2012. 
4(10): p. 76. 
78. Gilbert, C.A. and A.H. Ross, Cancer stem cells: cell culture, markers, and targets for new 
therapies. J Cell Biochem, 2009. 108(5): p. 1031-8. 
79. Visvader, J.E. and G.J. Lindeman, Cancer stem cells: current status and evolving 
complexities. Cell Stem Cell, 2012. 10(6): p. 717-28. 
80. Beckervordersandforth, R., et al., In vivo fate mapping and expression analysis reveals 
molecular hallmarks of prospectively isolated adult neural stem cells. Cell Stem Cell, 2010. 
7(6): p. 744-58. 
81. Fukushi, J., I.T. Makagiansar, and W.B. Stallcup, NG2 proteoglycan promotes endothelial 
cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin. Mol 
Biol Cell, 2004. 15(8): p. 3580-90. 
82. Wei, J., et al., Glioma-associated cancer-initiating cells induce immunosuppression. Clin 
Cancer Res, 2010. 16(2): p. 461-73. 
83. Hellstern, S., et al., Functional studies on recombinant domains of Mac-2-binding protein. J 
Biol Chem, 2002. 277(18): p. 15690-6. 
84. Tinari, N., et al., Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates 
galectin-1-induced cell aggregation. Int J Cancer, 2001. 91(2): p. 167-72. 
85. Cheng, L., et al., L1CAM regulates DNA damage checkpoint response of glioblastoma stem 
cells through NBS1. EMBO J, 2011. 30(5): p. 800-13. 
86. Miraglia, S., et al., A novel five-transmembrane hematopoietic stem cell antigen: isolation, 
characterization, and molecular cloning. Blood, 1997. 90(12): p. 5013-21. 
87. Weigmann, A., et al., Prominin, a novel microvilli-specific polytopic membrane protein of 
the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-
epithelial cells. Proc Natl Acad Sci U S A, 1997. 94(23): p. 12425-30. 
88. Yin, A.H., et al., AC133, a novel marker for human hematopoietic stem and progenitor cells. 
Blood, 1997. 90(12): p. 5002-12. 
89. Corbeil, D., et al., The human AC133 hematopoietic stem cell antigen is also expressed in 
epithelial cells and targeted to plasma membrane protrusions. J Biol Chem, 2000. 275(8): p. 
5512-20. 
90. Uchida, N., et al., Direct isolation of human central nervous system stem cells. Proc Natl 
Acad Sci U S A, 2000. 97(26): p. 14720-5. 
91. Bao, S., et al., Targeting cancer stem cells through L1CAM suppresses glioma growth. 
Cancer Res, 2008. 68(15): p. 6043-8. 
92. Beier, D., et al., CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show 
differential growth characteristics and molecular profiles. Cancer Res, 2007. 67(9): p. 4010-
5. 
93. Fortunel, N.O., et al., Comment on " 'Stemness': transcriptional profiling of embryonic and 
adult stem cells" and "a stem cell molecular signature". Science, 2003. 302(5644): p. 393; 
author reply 393. 
94. Lathia, J.D., et al., Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell, 2010. 
6(5): p. 421-32. 
95. Sladek, N.E., Human aldehyde dehydrogenases: potential pathological, pharmacological, 
and toxicological impact. J Biochem Mol Toxicol, 2003. 17(1): p. 7-23. 
96. Ma, X., et al., The differentiation of hepatocyte-like cells from monkey embryonic stem cells. 
Cloning Stem Cells, 2008. 10(4): p. 485-93. 
97. Ran, D., et al., Aldehyde dehydrogenase activity among primary leukemia cells is associated 
with stem cell features and correlates with adverse clinical outcomes. Exp Hematol, 2009. 
37(12): p. 1423-34. 
98. Jiang, F., et al., Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung 
cancer. Mol Cancer Res, 2009. 7(3): p. 330-8. 
99. Chen, Y.C., et al., Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in 
head and neck squamous cancer. Biochem Biophys Res Commun, 2009. 385(3): p. 307-13. 
100. Rasheed, Z.A., et al., Prognostic significance of tumorigenic cells with mesenchymal 
features in pancreatic adenocarcinoma. J Natl Cancer Inst, 2010. 102(5): p. 340-51. 
101. Silva, I.A., et al., Aldehyde dehydrogenase in combination with CD133 defines angiogenic 
ovarian cancer stem cells that portend poor patient survival. Cancer Res, 2011. 71(11): p. 
3991-4001. 
102. Chute, J.P., et al., Inhibition of aldehyde dehydrogenase and retinoid signaling induces the 
expansion of human hematopoietic stem cells. Proc Natl Acad Sci U S A, 2006. 103(31): p. 
11707-12. 
103. Alison, M.R., et al., Finding cancer stem cells: are aldehyde dehydrogenases fit for 
purpose? J Pathol, 2010. 222(4): p. 335-44. 
104. Hynes, R.O., Integrins: bidirectional, allosteric signaling machines. Cell, 2002. 110(6): p. 
673-87. 
105. Skog, J., et al., Glioblastoma microvesicles transport RNA and proteins that promote tumour 
growth and provide diagnostic biomarkers. Nat Cell Biol, 2008. 10(12): p. 1470-6. 
106. Goel, H.L., et al., Neuropilin-2 regulates alpha6beta1 integrin in the formation of focal 
adhesions and signaling. J Cell Sci, 2012. 125(Pt 2): p. 497-506. 
107. Véronique, M.-S., The Stem Cell Niche: The Black Master of Cancer. Cancer Stem Cells 
Theories and Practice, 2011. 
108. Joester, A. and A. Faissner, The structure and function of tenascins in the nervous system. 
Matrix Biol, 2001. 20(1): p. 13-22. 
109. Garcion, E., et al., Generation of an environmental niche for neural stem cell development 
by the extracellular matrix molecule tenascin C. Development, 2004. 131(14): p. 3423-32. 
110. von Holst, A., Tenascin C in stem cell niches: redundant, permissive or instructive? Cells 
Tissues Organs, 2008. 188(1-2): p. 170-7. 
111. Garcion, E., A. Faissner, and C. ffrench-Constant, Knockout mice reveal a contribution of 
the extracellular matrix molecule tenascin-C to neural precursor proliferation and 
migration. Development, 2001. 128(13): p. 2485-96. 
112. Garwood, J., et al., The extracellular matrix glycoprotein Tenascin-C is expressed by 
oligodendrocyte precursor cells and required for the regulation of maturation rate, survival 
and responsiveness to platelet-derived growth factor. Eur J Neurosci, 2004. 20(10): p. 2524-
40. 
113. Craig, W., et al., Expression of Thy-1 on human hematopoietic progenitor cells. J Exp Med, 
1993. 177(5): p. 1331-42. 
114. Haeryfar, S.M. and D.W. Hoskin, Thy-1: more than a mouse pan-T cell marker. J Immunol, 
2004. 173(6): p. 3581-8. 
115. Dominici, M., et al., Minimal criteria for defining multipotent mesenchymal stromal cells. 
The International Society for Cellular Therapy position statement. Cytotherapy, 2006. 8(4): 
p. 315-7. 
116. Stadtfeld, M., et al., Defining molecular cornerstones during fibroblast to iPS cell 
reprogramming in mouse. Cell Stem Cell, 2008. 2(3): p. 230-40. 
117. Yang, Z.F., et al., Significance of CD90+ cancer stem cells in human liver cancer. Cancer 
Cell, 2008. 13(2): p. 153-66. 
118. Liu, G., et al., Analysis of gene expression and chemoresistance of CD133+ cancer stem 
cells in glioblastoma. Mol Cancer, 2006. 5: p. 67. 
119. Ishii, H., et al., FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates 
mitosis. Proc Natl Acad Sci U S A, 2001. 98(18): p. 10374-9. 
120. Merlos-Suarez, A., et al., The intestinal stem cell signature identifies colorectal cancer stem 
cells and predicts disease relapse. Cell Stem Cell, 2011. 8(5): p. 511-24. 
121. Jeannet, R., et al., Alcam regulates long-term hematopoietic stem cell engraftment and self-
renewal. Stem Cells, 2013. 31(3): p. 560-71. 
122. Tanaka, H., et al., Molecular cloning and expression of a novel adhesion molecule, SC1. 
Neuron, 1991. 7(4): p. 535-45. 
123. DeBernardo, A.P. and S. Chang, Heterophilic interactions of DM-GRASP: GRASP-NgCAM 
interactions involved in neurite extension. J Cell Biol, 1996. 133(3): p. 657-66. 
124. van Kempen, L.C., et al., Molecular basis for the homophilic activated leukocyte cell 
adhesion molecule (ALCAM)-ALCAM interaction. J Biol Chem, 2001. 276(28): p. 25783-
90. 
125. Buhusi, M., et al., ALCAM regulates mediolateral retinotopic mapping in the superior 
colliculus. J Neurosci, 2009. 29(50): p. 15630-41. 
126. Heffron, D.S. and J.A. Golden, DM-GRASP is necessary for nonradial cell migration during 
chick diencephalic development. J Neurosci, 2000. 20(6): p. 2287-94. 
127. Stephan, J.P., et al., Distribution and function of the adhesion molecule BEN during rat 
development. Dev Biol, 1999. 212(2): p. 264-77. 
128. Brunet, A., et al., Akt promotes cell survival by phosphorylating and inhibiting a Forkhead 
transcription factor. Cell, 1999. 96(6): p. 857-68. 
129. Brunet, A., et al., Protein kinase SGK mediates survival signals by phosphorylating the 
forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol, 2001. 21(3): p. 952-65. 
130. Lehtinen, M.K., et al., A conserved MST-FOXO signaling pathway mediates oxidative-stress 
responses and extends life span. Cell, 2006. 125(5): p. 987-1001. 
131. Hagenbuchner, J., et al., FOXO3-induced reactive oxygen species are regulated by BCL2L11 
(Bim) and SESN3. J Cell Sci, 2012. 125(Pt 5): p. 1191-203. 
132. Seoane, J., et al., Integration of Smad and forkhead pathways in the control of 
neuroepithelial and glioblastoma cell proliferation. Cell, 2004. 117(2): p. 211-23. 
133. Renault, V.M., et al., The pro-longevity gene FoxO3 is a direct target of the p53 tumor 
suppressor. Oncogene, 2011. 30(29): p. 3207-21. 
134. Dou, C.L., S. Li, and E. Lai, Dual role of brain factor-1 in regulating growth and patterning 
of the cerebral hemispheres. Cereb Cortex, 1999. 9(6): p. 543-50. 
135. Shen, L., et al., FoxG1 haploinsufficiency results in impaired neurogenesis in the postnatal 
hippocampus and contextual memory deficits. Hippocampus, 2006. 16(10): p. 875-90. 
136. Fasano, C.A., et al., Bmi-1 cooperates with Foxg1 to maintain neural stem cell self-renewal 
in the forebrain. Genes Dev, 2009. 23(5): p. 561-74. 
137. Lujan, E., et al., Direct conversion of mouse fibroblasts to self-renewing, tripotent neural 
precursor cells. Proc Natl Acad Sci U S A, 2012. 109(7): p. 2527-32. 
138. Dobreva, G., J. Dambacher, and R. Grosschedl, SUMO modification of a novel MAR-
binding protein, SATB2, modulates immunoglobulin mu gene expression. Genes Dev, 2003. 
17(24): p. 3048-61. 
139. Akai, T., et al., High mobility group I-C protein in astrocytoma and glioblastoma. Pathol 
Res Pract, 2004. 200(9): p. 619-24. 
140. Liu, Y., et al., Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the 
double-strand break repair pathway predict glioblastoma survival. J Clin Oncol, 2010. 
28(14): p. 2467-74. 
141. Grohmann, M., et al., Characterization of differentiated subcutaneous and visceral adipose 
tissue from children: the influences of TNF-alpha and IGF-I. J Lipid Res, 2005. 46(1): p. 
93-103. 
142. Guenther, U.P., et al., IGHMBP2 is a ribosome-associated helicase inactive in the 
neuromuscular disorder distal SMA type 1 (DSMA1). Hum Mol Genet, 2009. 18(7): p. 1288-
300. 
143. Lin, L., et al., STAT3 signaling pathway is necessary for cell survival and tumorsphere 
forming capacity in ALDH(+)/CD133(+) stem cell-like human colon cancer cells. Biochem 
Biophys Res Commun, 2011. 416(3-4): p. 246-51. 
144. Guryanova, O.A., et al., Nonreceptor tyrosine kinase BMX maintains self-renewal and 
tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell, 2011. 
19(4): p. 498-511. 
145. Thirant, C., et al., Differential proteomic analysis of human glioblastoma and neural stem 
cells reveals HDGF as a novel angiogenic secreted factor. Stem Cells, 2012. 30(5): p. 845-
53. 
146. D'Andrea, F.P., et al., Cancer stem cell overexpression of nicotinamide N-methyltransferase 
enhances cellular radiation resistance. Radiother Oncol, 2011. 99(3): p. 373-8. 
147. Ikeyama, S., et al., Suppression of cell motility and metastasis by transfection with human 
motility-related protein (MRP-1/CD9) DNA. J Exp Med, 1993. 177(5): p. 1231-7. 
148. Prasad, P.D., J.A. Stanton, and S.J. Assinder, Expression of the actin-associated protein 
transgelin (SM22) is decreased in prostate cancer. Cell Tissue Res, 2010. 339(2): p. 337-47. 
149. Hasegawa, A., et al., Regulation of glial development by cystatin C. J Neurochem, 2007. 
100(1): p. 12-22. 
150. Kato, T., et al., A neurosphere-derived factor, cystatin C, supports differentiation of ES cells 
into neural stem cells. Proc Natl Acad Sci U S A, 2006. 103(15): p. 6019-24. 
151. de Azevedo-Pereira, R.L., et al., Cysteine proteases in differentiation of embryonic stem 
cells into neural cells. Stem Cells Dev, 2011. 20(11): p. 1859-72. 
152. Konduri, S.D., et al., Modulation of cystatin C expression impairs the invasive and 
tumorigenic potential of human glioblastoma cells. Oncogene, 2002. 21(57): p. 8705-12. 
153. Nakabayashi, H., M. Hara, and K. Shimuzu, Clinicopathologic significance of cystatin C 
expression in gliomas. Hum Pathol, 2005. 36(9): p. 1008-15. 
154. von Holst, A., et al., Neural stem/progenitor cells express 20 tenascin C isoforms that are 
differentially regulated by Pax6. J Biol Chem, 2007. 282(12): p. 9172-81. 
155. He, J., et al., CD90 is identified as a candidate marker for cancer stem cells in primary 
high-grade gliomas using tissue microarrays. Mol Cell Proteomics, 2012. 11(6): p. M111 
010744. 
156. Lu, J., et al., CNTF receptor subunit alpha as a marker for glioma tumor-initiating cells and 
tumor grade: laboratory investigation. J Neurosurg, 2012. 117(6): p. 1022-31. 
157. Beck, B., et al., A vascular niche and a VEGF-Nrp1 loop regulate the initiation and 
stemness of skin tumours. Nature, 2011. 478(7369): p. 399-403. 
158. Hamerlik, P., et al., Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma 
stem-like cell viability and tumor growth. J Exp Med, 2012. 209(3): p. 507-20. 
159. Yao, X., et al., Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) Plays a Key 
Role in Vasculogenic Mimicry Formation, Neovascularization and Tumor Initiation by 
Glioma Stem-like Cells. PLoS One, 2013. 8(3): p. e57188. 
160. Cerdan, C. and M. Bhatia, Novel roles for Notch, Wnt and Hedgehog in hematopoesis 
derived from human pluripotent stem cells. Int J Dev Biol, 2010. 54(6-7): p. 955-63. 
161. Takebe, N., et al., Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog 
pathways. Nat Rev Clin Oncol, 2011. 8(2): p. 97-106. 
162. Eichelbaum, K., et al., Selective enrichment of newly synthesized proteins for quantitative 
secretome analysis. Nat Biotechnol, 2012. 30(10): p. 984-90. 
163. Pen, A., et al., Glioblastoma-secreted factors induce IGFBP7 and angiogenesis by 
modulating Smad-2-dependent TGF-beta signaling. Oncogene, 2008. 27(54): p. 6834-44. 
164. Ku, B.M., et al., CHI3L1 (YKL-40) is expressed in human gliomas and regulates the 
invasion, growth and survival of glioma cells. Int J Cancer, 2011. 128(6): p. 1316-26. 
165. Hughes, S.M., et al., Ciliary neurotrophic factor induces type-2 astrocyte differentiation in 
culture. Nature, 1988. 335(6185): p. 70-3. 
166. Johe, K.K., et al., Single factors direct the differentiation of stem cells from the fetal and 
adult central nervous system. Genes Dev, 1996. 10(24): p. 3129-40. 
167. Hermanson, O., K. Jepsen, and M.G. Rosenfeld, N-CoR controls differentiation of neural 
stem cells into astrocytes. Nature, 2002. 419(6910): p. 934-9. 
 
 
 
Acknowledgement 
 
I would like to acknowledge all the people who helped me in some way or another during my PhD. 
First and foremost, I would like to thank my supervior Jeroen for hist continuous support 
throughout my study. In the similar line I am thankful for all the current lab members, Chris, 
Daniel, Ita, Jenny, Mandy, Sina, Sophia and Tim, and the former lab members Katrin, Markus, 
Sergey and Sonja. My thank also goes to the EMBL proteomics core facility members, Joanna, 
Kristina and Stefan, and former Gavin's lab member, Jan, and current Gavin's lab member, Marco. I 
have a lot of thank to Bernd Fischer in Wolfgang Huber's lab for his valuable help with statistics 
and R. Outside Heidelberg, Paul Bertone (EBI) helped initiate my 2
nd
 project as well as gave me 
valuable advice during the project. Pär Engström in Bertone's lab also provided me with the 
transcriptome data, scripts for the analyses and some hints for the project direction. I would like to 
thank a lot our principal collaborator for my 2
nd
 project, Steven Pollard (UCL), for giving me 
important biological insights and letting me do experiments in his lab. In the same line, I thank 
Christine Ender in Pollard's lab for performing experiments for me and giving me useful advice. All 
the Pollard's lab members were very nice to me during my stay there. Finally, I would like to 
acknowledge my thesis advisory comittee members, Paul Bertone, Bruce Edgar (DKFZ) and Lars 
Steinmetz.  
 
